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Summary 
Animal African trypanosomosis (AAT) is a complex of parasitic diseases of various domestic 
and wild animal species caused by different species of trypanosomes. Trypanosoma (T.) brucei, T. 
congolense and T. vivax are transmitted by tsetse flies.  
Trypanosoma evansi, but also T. vivax, is mechanically transmitted by other biting flies and T. 
equiperdum is sexually transmitted in Equidae. All these pathogenic trypanosome species occur 
in Ethiopia. In particular, surra caused by T. evansi, is the number one parasitic disease of camel 
that is the main domestic animal species in many pastoral communities and that may become 
increasingly important with the current climate change. AAT entails serious economic losses due 
to mortality, morbidity and reduction in productivity. Compared to tsetse-transmitted AAT, the 
attention given towards control and research on non-tsetse transmitted animal trypanosomoses 
(NTTAT) is negligible. This doctoral study can be seen as a contribution to increase our knowledge 
on NTTAT due to T. evansi and to attract the attention of policy makers and the international 
research community for this disease. 
The study, conducted partly in Ethiopia and partly in Belgium, aimed at 1° defining the 
epidemiological situation of NTTAT in domestic animals in Tigray and Afar regions in Northern 
Ethiopia, 2° isolating trypanosomes from infected animals, 3° improving the molecular and 
serological diagnosis of surra.  
A cross-sectional epidemiological survey was conducted on 754 dromedary camels, 493 
cattle, 264 goats, 181 sheep, 84 donkeys, 25 horses and 10 mules. Overall parasitologically 
confirmed prevalence of NTTAT was 3.8% (68 animals) and was significantly higher in cattle 
(7.3%) than in camels (4.0%), sheep (0.6%) and goats (0.4%). No trypanosomes were detected in 
equines. Buffy coat samples from parasitologically positive animals were cryostabilised in a 
special cryomedium for subsequent isolation. Antibody detection with CATT/T. evansi revealed 
an overall seroprevalence of 19.6% with significantly higher seroprevalence in cattle (37.3%) than 
in camels (13.7%), goats (13.3%), sheep (12.7%) and donkeys (10.7%). These high 
seroprevalences could not be confirmed in the immune trypanolysis test (TL) which is considered 
fully specific for T. evansi. Only part of this discrepancy between both antibody detection tests 
can be attributed to the presence of T. vivax in the studied animals. The latter species was 
detected by the TvPRAC PCR in 3.5% of the camels, 3.0% of the goats, 2.6% of the cattle and 2.2% 
of the sheep but not in equines. Two camels and one goat harboured a mixed infection with T. 
evansi and T. vivax. Overall molecular prevalence of T. evansi type A, assessed with RoTat 1.2 
PCR, was 8.0% and was significantly higher in horses (28.0%), mules (10.0%) and camels (11.7%) 
than in cattle (6.1%), donkeys (6.0%), goats (3.8%) and sheep (2.2%). Four camels, all from Awash 
Fentale district in Afar, were positive in the T. evansi type B specific EVAB PCR thus providing the 
first molecular evidence of T. evansi type B in Northern Ethiopia. All four were negative in 
CATT/T. evansi and TL although one of them was also positive in RoTat 1.2 PCR suggesting a 
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mixed infection. The higher serological prevalence as compared to the molecular prevalence of T. 
evansi, particularly in ruminants, could be explained by the fact that antibody detection tests like 
CATT/T. evansi, cannot distinguish current from cured infection and that during chronic 
infections, parasitaemia can be far below the detection limit of parasitological and molecular 
tests. Also, the CATT/T. evansi can cross-react with other infections. 
Among the 68 parasitologically positive animals, 34 were negative in T. evansi and T. vivax 
specific PCRs and were checked with ITS1-PCR for the possibility of infections with T. theileri and 
T. congolense. Two bovine were positive for T. theileri and no animal was positive for T. 
congolense. 
The isolation of trypanosomes from the 68 parasitologically positive buffy coat samples from 
36 cattle, 30 camels, 1 sheep and 1 goat was conducted in immunosuppressed mice and yielded 
22 T. evansi stocks, all from camels. Not surprisingly, no T. vivax stocks could be isolated in the 
mouse model. Typing by PCR on the original buffy coats revealed 20 T. evansi type A (positive in 
RoTat 1.2 PCR) and 2 T. evansi type B (positive in EVAB PCR). Twelve of the type A stocks and 
both type B stocks were brought to Belgium for further investigation, included adaptation to in 
vitro culture for in vitro drug sensitivity testing. After in vivo expansion, and re-typing, nine stocks 
were confirmed as type A, two as type B and three stocks appeared to be mixed infections with 
both types. One T. evansi type A stock was akinetoplastic, i.e. had lost its mitochondrial DNA 
consisting of concatenated circular DNA densily packed in an organelle called kinetoplast. While 
expansion in mice allowed to propagate the mixed infections, in vitro culture was selective for T. 
evansi type B. Furthermore, multiple in vitro passages induced the loss of the kinetoplast in some 
stocks but infectivity to mice was not affected. In vitro drug sensitivity assays with melarsomine 
dihydrochloride, diminazene diaceturate, isometamidium chloride and suramin revealed no 
resistance against these trypanocidal drugs in the five in vitro adapted stock from Northern 
Ethiopia. In order to address some limitations of the current molecular tests for typing T. evansi, 
the gene of the F1-ATP synthase subunit of eight Northern Ethiopian T. evansi stocks and some 
other reference strains was sequenced. Type-specific single nucleotide polymorphisms (SNPs) 
and deletions observed within this gene, may provide new markers to identify the T. evansi type 
that do not rely on variant surface glycoprotein, genes or kinetoplast DNA. In addition, MORF-2 
REP analysis indicated two distinct allelic profiles in T. evansi type A stocks and that they are 
different from the Indonesian RoTat 1.2 reference strain. The MORF-2 REP allelic profiles showed 
that the Northern Ethiopian T. evansi type B stocks are distinct from the Kenyan T. evansi type B. 
Control of AAT relies on detection of infected animals followed by administration of 
trypanocidal drugs. In routine practice, diagnosis of surra is limited to the observation of 
unspecific clinical signs. If at all applied, parasitological techniques that are commonly used for 
the diagnosis of surra have limited sensitivity and molecular diagnostics are simply not adapted 
for routine diagnosis in developing countries. Therefore, serodiagnosis by means of detection of 
T. evansi-specific antibodies, for example with the Card Agglutination Test for T. evansi (CATT/T. 
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evansi), ELISA or immune trypanolysis (TL), is recommended by the World Organization for 
Animal Health (OIE). Among these test, only CATT/T. evansi can be applied in the field although it 
is still dependent on electricity to run the rotator and to respect the cold chain needed to 
preserve the quality of the antigen. As such, CATT/T. evansi does not fully comply with the 
ASSURED (affordable, sensitive, specific, user-friendly, rapid, equipment-free and delivered) 
criteria of a diagnostic test required in the 21
st
 century. Moreover, it is produced with native 
antigens purified from trypanosomes grown in laboratory animals. Recently, an alternative 
antibody detection test for serodiagnosis of T. evansi infection, the Surra Sero K-SeT, was 
developed by ITM and Coris BioConcept, a Belgian diagnostic company. Surra Sero K-SeT is an 
immunochromatographic test (ICT) where the antigen consists of an N-terminal fragment of 
RoTat 1.2 VSG, recombinantly expressed in Pichia pastoris. In this doctoral study, we compared 
the diagnostic accuracy of Surra Sero K-SeT and CATT/T. evansi with TL as reference test by 
testing sera from 300 camels, 100 water buffaloes, 100 horses, 82 bovines, 88 sheep, 99 dogs and 
37 alpacas. The Surra Sero K-SeT displayed considerably higher sensitivity than CATT/T. evansi 
(98.1% versus 84.4%) but somewhat lower specificity (94.8% versus 98.3%). In particular and for 
unknown reasons, the specificity with the alpaca sera was disappointingly low (83.8%). 
Unfortunately, we were not able to test the Surra Sero K-SeT on sera from camels infected with 
T. evansi type B but we hypothesize that it cannot detect type B infections thus jeopardising its 
diagnostic potential in countries where T. evansi type B is present, like Kenya, Ethiopia and 
possibly Sudan. 
In conclusion, this doctoral study revealed that, in terms of prevalence, NTTAT due to T. 
evansi type A and type B and T. vivax, is an important threat to animal health in Tigray and Afar 
and not only in camel and cattle but also in small ruminants and equines. Control of AAT, in 
Ethiopia and elsewhere, should therefore not only focus on tsetse transmitted trypanosomes and 
should take into consideration the role of small ruminants and equines in the epidemiology of the 
disease. This study allowed us to establish an important new collection of T. evansi stocks from 
Northern Ethiopia, including, two T. evansi type B stocks. Genetic characterization of these stocks 
may eventually lead to an improved genetic marker for type B, based on SNPs in the F1-ATP 
subunit gene. In order to adapt the Surra Sero K-SeT so that it can detect T. evansi type B 
infections, other candidate invariable antigens and other expression systems should be 
investigated. 
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Samenvatting 
Dierlijke Afrikaanse trypanosomosis (AAT) is een verzameling van parasitaire infecties bij 
diverse gedomesticeerde en wilde dieren, veroorzaakt door verschillende soorten trypanosomen. 
Trypanosoma (T.) brucei, T. congolense en T. vivax worden overgebracht door tseetsee vliegen. 
Trypanosoma evansi, maar ook T. vivax, worden mechanisch overgebracht door steekvliegen en 
T. equiperdum is een sexueel overdraagbaar in Equidae. Al deze pathogene trypanosomen komen 
voor in Ethiopië. Vooral surra, veroorzaakt door T. evansi, is de meest voorkomende parasitaire 
aandoening in de dromedaris die een zeer belangrijke gedomisticeerde soort is voor herder 
gemeenschappen en die, in het licht van de huidige klimaatveranderingen, steeds belangrijker 
wordt. AAT is verantwoordelijk voor grote economische verliezen als gevolg van mortaliteit, 
morbiditeit en productiviteitsverlies. Vergeleken met tseetsee-overgedragen AAT wordt weinig 
aandacht besteed aan niet-tseetsee-overgedragen dierlijke trypanosomosis (NTTAT). Met deze 
doctoraatsthesis willen we bijdragen tot de kennis van NTTAT veroorzaakt door T. evansi en 
willen we deze ziekte onder de aandacht brengen van beleidsmakers en de internationale 
wetenschappelijke gemeenschap. 
Deze studie, ten dele uitgevoerd in Ethipië en ten dele in België, beoogde 1° de epidemiologie 
van NTTAT in gedomesticeerde dieren in Tigray en Afar in noordelijk Ethiopië te kennen; 2° 
trypanosomen te isoleren van geïnfecteerde dieren; 3° de moleculaire en serologische diagnose 
van surra te verbeteren. 
Een cross-sectionele epidemiologische survey werd uitgevoerd op 754 dromedarissen, 493 
runderen, 264 geiten, 181 schapen, 84 ezels, 25 paarden en 10 muildieren. De algemene 
parasitologische prevalentie van NTTAT was 3.8% (68 dieren) en was significant hoger in 
runderen (7.3%) dan in dromedarissen (4.0%), schapen (0.6%) en geiten (0.4%). Bij geen enkele 
paardachtige werden trypanosomen gevonden. Buffy coat stalen van parasitologisch positieve 
dieren werden gecryppreserveerd op vloeibare stikstof in een speciaal cryomedium voor de 
isolatie van de trypanosomen achteraf. Antistof detectie met CATT/T. evansi toonde een 
algemene seroprevalentie van 19.6% met significant hogere seroprevalentie in runderen (37.3%) 
dan in dromedarissen (13.7%), geiten (13.3%), schapen (12.7%) en ezels (10.7%). Deze hoge 
prevalenties konden echter niet bevestigd worden in immune trypanolyse (TL) die als absoluut 
specifiek wordt beschouwd voor T. evansi antistoffen. De discrepantie tussen beide antistof 
detectie tests kan slechts gedeeltelijk toegeschreven worden aan infectie met T. vivax in de 
onderzochte dieren. Deze trypanosoom soort werd met behulp van TvPRAC PCR aangetoond in 
3.5% van de dromedarissen, 3.0% geiten, 2.6% runderen and 2.2% schapen maar niet in de 
paardachtigen. Twee dromedarissen en één geit vertoonden menginfecties van T. evansi en T. 
vivax. De algemene moleculaire prevalentie van T. evansi type A, gemeten met de RoTat 1.2 PCR, 
was 8.0% en was significant hoger in paarden (28%), muildieren (10%) en dromedarissen (11.7% 
dan in runderen (6.1%), ezels (6.0%), geiten (3.8%) en schapen (2.2%). Vier dromedarissen, 
allemaal van Awash Fentale disctrict, waren positief voor T. evansi type B in de EVAB PCR. 
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Daarmee toonden we voor de eerste keer via moleculaire diagnose aan dat T. evansi type B ook 
in noordelijk Ethiopië voorkomt. Deze vier dromedarissen waren allen negatief in CATT/T. evansi 
en TL alhoewel één ervan ook positief was voor RoTat 1.2 PCR wat wijst op een menginfectie. De 
hogere seroprevalentie in vergelijking met moleculaire prevalentie van T. evansi, in het bijzonder 
in de runderen, kan verklaard worden door het feit dat antistof tests zoals CATT/T. evansi geen 
onderscheid kunnen maken tussen actieve en genezen infectie en dat in chronische infecties de 
parasitemie ver beneden de detectielimiet van parasitologische en moleculare diagnostische 
tests ligt. Ook is het geweten dat CATT/T. evansi kan kruisreageren met andere infecties. Onder 
de 68 parasitologisch positieve dieren waren er 34 negatief in T. evansi en T. vivax specifieke 
PCRs. Deze werden getest met ITS1-PCR om mogelijke infecties met T. theileri en T. congolense 
aan te tonen. Twee runderen waren positief voor T. theileri terwijl geen enkel dier positief was 
voor T. congolense. 
De isolatie van trypanosomen uit de 68 parasitologisch positieve buffy coat stalen van 36 
runderen, 30 dromedarissen, 1 schaap en 1 geit gebeurde door inoculatie van 
geïmmunosupprimeerde muizen en leverde 22 T. evansi stammen op, enkel van dromedarissen. 
Niet onverwacht werd geen enkele T. vivax stam geïsoleerd in het muismodel. PCR op de 
oorspronkelijke buffy coat stalen toonde twintig T. evansi type A (positief in RoTat 1.2 PCR) en 
twee T. evansi type B (positief in EVAB PCR). Twaalf van de type A stammen en beide type B 
stammen werden naar België gebracht voor verder onderzoek, inbegrepen het aanpassen aan in 
vitro cultuur voor in vitro drug gevoeligheid tests. Na in vivo expansie en hertypering werden 
negen stammen geconfirmeerd als type A, twee als type B en drie stammen bleken gemengde 
infecties te zijn van type A en B. Eén T. evansi type A stam was akinetoplast d.w.z. heeft zijn 
mitochondriaal DNA verloren dat bestaat uit aan elkaar geklonken circulaire DNA strengen die 
dicht opeen gepakt zijn in een organel dat kinetoplast wordt genoemd. Waar expansie in muizen 
de gemengde infecties in stand hield blijken in vitro culturen selectief te zijn voor T. evansi type 
B. Verder blijkt dat herhaaldelijke in vitro passages leidden tot het verlies van de kinetoplast in 
sommige stammen maar niet tot verminderde infectiviteit voor muizen. In vitro drug 
gevoeligheidstests met melarsomine dihydrochloride, diminazene diaceturate, isometamidium 
chloride en suramine konden geen resistentie aantonen tegen deze medicamenten in de vijf 
geteste T. evansi stammen van noordelijk Ethiopië. Om een aantal beperkingen van de bestaande 
moleculaire tests voor T. evansi typering te overkomen werd het F1-ATP synthase Ƴ subunit gen 
van acht T. evansi stammen uit noordelijk Ethiopië en van enkele andere referentie stammen 
gesekweneerd. In dit gen werden type-specifieke "single nucleotide polymorphisms" (SNPs) en 
deleties waargenomen die nieuwe merkers kunnen opleveren om het T. evansi type te 
identificeren, onafhankelijk van variabele oppervlakte eiwit genen of van kinetoplast DNA. 
Bovendien toonde MORF-2 REP analyse het bestaan aan van twee verschillende allelische 
profielen in T. evansi type A stammen die verschillen van de Indonesische RoTat 1.2 referentie 
stam. Deze MORF-2 REP allelische profielen toonden ook aan dat de noord Ethiopische T. evansi 
type B stammen verschillend zijn van de T. evansi type B stam uit Kenia. 
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Controle van AAT berust op detectie van geïnfecteerde dieren gevolgd door behandeling. In 
de routine praktijk blijft diagnose van surra beperkt tot het herkennen van aspecifieke 
symptomen. Parasitologische technieken, als ze al toegepast worden, hebben meestal een 
beperket gevoeligheid en moleculaire diagnostica zijn eenvoudigweg niet geschikt voor routine 
toepassing in endemische landen. Daarom beveelt de Wereld Organisatie voor Dierenwelzijn 
(OIE) serodiagnose aan op basis van het aantonen van T. evansi specifieke antistoffen. 
Voorbeelden zijn de Card Agglutination Test for T. evansi (CATT/T. evansi), ELISA en immuno 
trypanolyse. Van deze tests is enkel de CATT/T. evansi toepasbaar in het veld alhoewel ook die 
nog afhankelijk is van elektriciteit om de rotator aan te drijven en om de koude keten te 
handhaven. Daarme voldoet de CATT/T. evansi niet volledig aan de ASSURED (affordable, 
sensitive, specific, user-friently, rapid, equipment-free and deliverable) criteria, vereist voor 
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 eeuw. Bovendien wordt deze test geproduceerd met natieve antigenen, 
gezuiverd uit trypanosomen die worden opgegroeid in laboratoriumdieren. Recent werd een 
alternatieve antistof detectie test, de Surra Sero K-SeT, ontwikkeld door het ITG en Coris 
BioConcenpt, een Belgische firma. De Surra Sero K-SeT is een immunochromatografische test 
(ICT) waarin het antigeen bestaat uit een N-terminaal fragment van RoTat 1.2 VSG, recombinant 
tot expressie gebracht in Pichia pastoris. In dit doctoraatsonderzoek hebben we de diagnostische 
accuraatheid van de Surra Sero K-SeT vergeleken met CATT/T. evansi en met TL als referentietest. 
Deze vergelijking werd uitgevoerd op serumstalen van 300 dromedarissen, 100 waterbuffels, 100 
paarden, 82 runderen, 88 schapen, 99 honden en 37 alpacas. De Surra Sero K-SeT vertoonde een 
duidelijk hogere gevoeligheid dan de CATT/T. evansi (98.1% versus 84.4%) maar een ietwat lagere 
specificiteit (94.8% versus 98.3%). Om tot nu toe onbekende redenen, was de specificiteit op 
alpacas ontmoedigend laag (83.8%). Spijtig genoeg konden we de Surra Sero K-SeT niet testen op 
dromedarissen geïnfecteerd met T. evansi type B maar we veronderstellen dat deze test geen 
type B infecties kan detecteren wat het diagnostisch potentieel ervan in landen zoals Kenia, 
Ethiopië en mogelijks Soedan, waar T. evansi type B voorkomt, compromiteert. 
We besluiten dat deze doctoraatsstudie aantoont dat, in termen van prevalentie, NTTAT 
veroorzaakt door T. evansi type A en type B en door T. vivax een belangrijke bedreiging vormt 
voor dierengezondheid in Tigray en Afar en dit niet enkel voor dromedarissen en runderen maar 
ook voor kleine herkauwers en paardachtigen. Controle van AAT, in Ethiopië en elders, mag 
daarom niet enkel gericht zijn op tseetsee overdraagbare trypanosomen en moet rekening 
houden met de rol van kleine herkauwers en paardachtigen in de epidemiologie van de ziekte. 
Deze studie liet ons toe een belangrijke nieuwe collectie van T. evansi uit noordelijk Ethiopië uit 
te bouwen waaronder twee T. evansi type B stammen. Genetische karakterisatie van deze 
stammen kan eventueel leiden tot betere genetische merkers voor type B, gebaseerd op SNPs in 
het F1-ATP γ-subunit gen. Voor de aanpassing van de Surra Sero K-SeT zodat ook T. evansi type B 
infecties kunnen opgespoord worden, zal moeten gezocht worden naar kandidaat niet-variabele 
antigenen en een alternatief expressiesysteem voor hun recombinante productie. 
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1. General introduction 
Africa, with the highest population growth rates, faces serious challenges in feeding its 
population. About 233 million (20%) of people in the region are undernourished, with 31% of 
them in eastern Africa (FAO et al. 2015). The continent has about 300 million heads of cattle, 630 
million sheep and goats, 140 million camels and 1.8 billion chicken and birds that play an 
important role in the life of rural and urban communities. The livestock sector contributes to 30 – 
50% of the total agricultural Gross Domestic Product (GDP) in some African countries and plays a 
key role as livelihood asset (Hassane 2013). Half of the estimated 300 million poor people who 
live on less than USD 1.0 per day in sub Saharan Africa (SSA) are highly dependent on livestock. 
The role of livestock in food security and nutrition is through providing meat, milk, draught 
power, manure, fiber etc. Other livestock by-products such as wool, hides and skins add more 
economic value to the sector, which is valued to USD 14 billion per year of which, USD 9 billion is 
in the form of meat, milk and leather while USD 5 billion is in the form of organic fertilizer and 
draft power (AU-IBAR 2010).  
The rapid human population increase, income growth and urbanization in SSA is believed to 
increase the demand for livestock products (Thornton 2010). However, the livestock sector faces 
various challenges that hinder it from meeting these expectations and that limit economic 
growth in this sector. It is principally affected by deficiencies in high productive breeds, food and 
water resources, animal health systems and disease control measures and service delivery, value 
addition, market information and market infrastructure, competitiveness and compliance with 
sanitary and phytosanitary standards. These are coupled with deficiencies in policy, legislative 
and institutional frameworks as well as with inadequate application of available technologies, 
knowledge and skills (AU-IBAR 2014). Among others, African trypanosomosis which affects 
people and livestock, is the major bottle neck of Africa’s struggle against poverty which threatens 
human and livestock health and agricultural production, and, thereby, rural development and 
poverty alleviation in SSA (FAO 2014).  
Tsetse and mechanically transmitted animal African trypanosomosis (AAT) is one of the main 
constraints to sustainable development of livestock farming in SSA, where the impact is 
manifested in disease burden, increased level of poverty, expenditure on controlling the disease, 
restricted access to fertile and cultivable areas, imbalances in land use and exploitation of natural 
resources and compromised growth and diversification of crop-livestock production systems 
(Shaw et al. 2013; Tesfaye et al. 2012; Mattioli et al. 2004). The main pathogenic African 
trypanosomes belong to three subgenera of the Salivaria section, namely, Nannomonas 
(Trypanosoma (T.) congolense), Duttonella (T. vivax), and Trypanozoon. The Glossina (tsetse fly) is 
responsible for tsetse-transmitted trypanosomosis (‘nagana’) due to T. congolense, T. vivax and 
T. brucei in 10 million square kilometers of Africa (Hoare 1972). Non-tsetse transmitted animal 
trypanosomoses (NTTAT) is caused by T. evansi, T. equiprdum and T. vivax infection. NTTAT due 
22 - Chapter 1: Introduction 
to T. evansi and T. vivax is transmitted by biting flies, tabanids and Stomoxys, while T. 
equiperdum is a sexually transmitted disease of equines (Touratier 2000; OIE 2013b).  
Trypanosomosis due to T. evansi (surra) is the number one disease of camels. However, 
horses are also very sensitive to this infection. Infected camels and equines may die within three 
months. Moreover, cattle, buffalo, pigs, goat and sheep suffer from immunosuppression, 
resulting in increased susceptibility to other diseases or vaccination failure (Gutiérrez et al. 
2006a; Holland et al. 2003; Holland et al. 2001). The disease occurs in Africa, Asia, Latin America 
and with sporadic import cases in Europe (Desquesnes et al. 2013b; Gutiérrez et al. 2010).  
Surra control is of great concern in order to protect the worldwide livestock production. 
Vaccination against the disease is unavailable; moreover, the insect vectors and animal reservoirs 
are still abundant. As a result, control programs mostly depend on accurate detection and 
treatment of infected cases (Desquesnes et al. 2013a; Nguyen et al. 2014). Currently, the 
treatments available for AAT are not species specific. However, correct diagnosis is a prerequisite 
for understanding the epidemiology and designing and implementation of sound control 
strategies (Pillay et al. 2013). 
Diagnosis of a T. evansi infection usually starts with clinical symptoms or the detection of 
antibodies to T. evansi. However, conclusive evidence of T. evansi infection relies on detection of 
the parasite in the blood of infected animals. Unfortunately, parasitological techniques cannot 
always detect ongoing infections as the level of parasitaemia is often low and fluctuating, 
particularly during the chronic stage of the disease (Büscher 2014). The most sensitive 
parasitological test for trypanosomes of the Trypanozoon group is the mini-Anion Exchange 
Centrifugation technique (mAECT) with an analytical sensitivity of < 50 parasites per ml (Büscher 
et al. 2009). As an alternative to parasitological tests, a number of DNA detection tests such as 
PCR, Q-PCR and LAMP have been developed. The most sensitive are not T. evansi specific but will 
detect also T. brucei and T. equiperdum. Only few tests are claimed to be specific for T. evansi, 
including the PCR-RoTat 1.2 and Q-PCR RoTat 1.2 (Konnai et al. 2009; Claes et al. 2004). These 
molecular diagnostic tests are highly appreciated for surveillance and research purposes. 
However, since none of them are conceived as point-of-care tests, their value for diagnosis in 
rural settings where surra prevails is jeopardized.  
For the detection of antibodies, the only test that is recommended by the World Animal 
Health Organisation is the CATT/T. evansi (OIE 2012). This test uses a T. evansi specific native 
purified variant surface glycoprotein (VSG) as antigen (in casu RoTat 1.2) (Bajyana Songa & 
Hamers 1988). The same antigen is also used in other test formats like the LATEX/T. evansi and 
ELISA/T. evansi but requires mass culture of T. evansi in rats (Verloo et al. 2000). The use of larger 
protein molecules in antibody detection tests gives rise to a number of false positives due to 
cross-reactivity with non T. evansi specific antibodies resulting in decreased test specificity 
(Büscher 2014). In addition, it has been found that diagnostic tests targeting the RoTat 1.2 VSG 
do not detect infection due to T. evansi type B (Ngaira et al. 2005). To avoid the use of laboratory 
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rodents for the production of native VSG Rode Trypanozoon antigen type 1.2 (RoTat 1.2), a 
recombinant antigen has been developed and used as antigen in ELISA and in latex agglutination 
(Lejon et al. 2005; Rogé et al. 2014; Rogé et al. 2013; Urakawa et al. 2001). None of the above 
mentioned serological test formats complies with the ASSURED criteria of diagnostic tests 
(affordable, sensitive, specific, user-friendly, rapid, equipment-free and delivered) (Mabey et al. 
2004). A way to overcome this is to develop highly specific recombinant antigens that can detect 
infections due to T. evansi type A and B and that eventually will be incorporated into a rapid 
diagnostic test (RDT) for surra, which is designed without the need for host species specific 
conjugates.  
2. Taxonomy of trypanosomes 
Trypanosomes are unicellular flagelatted eukaryotes that belong to the order Kinetoplastida, 
suborder Trypanosomatina and family of Trypanosomatidae. On the basis of their invertebrate 
cycle and preferred host species, mammalian trypanosomes are divided into two major groups, 
the Stercoraria and Salivaria (Hoare 1972). The Stercoraria contain species in which the entire 
development is confined to the gut of the vector and infective metatrypanosomes can be found 
in the faeces of the insect. T. cruzi, the pathogenic trypanosome causing Chagas disease in Latin 
America, and T. theileri, which is a non-pathogenic parasite in bovine and buffaloes, are classical 
examples of stecorarians (Figure 1.1) (Rodrigues et al. 2006; Momen 1999).  
 
Figure 1.1: Schematic representation of the taxonomy of trypanosomes. Adapted from 
Gibson (2003). 
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Except T. evansi and T. equiperdum which do not have insect forms, Salivarian trypanosomes 
complete their cyclical development in the 'anterior station' of the vector and infective stages are 
transmitted to the mammalian host through the bite of an infected fly (Gibson & Bailey 2003). 
3. Morphology and genetic diversity of Trypanosoma evansi 
T. evansi the causative agent of surra, belongs to the genus Trypanosoma, subgenus 
Trypanozoon together with T. brucei (b.) brucei, T. b. rhodesiense and T. b. gambiense and T. 
equiperdum which cause nagana, human African trypanosomiasis (HAT) and the sexually 
transmitted disease of horses (dourine) respectively (Hoare 1972). T. evansi shares some 
characteristics with the other taxa of the subgenus Trypanozoon, such as the nucleic DNA, 
morphology and morphometry of the blood stage parasite. The slender forms are characterized 
by a thin posterior extremity, a large undulating membrane, a free flagellum, a spindle shaped 
cell, a central nucleus and a small subterminal kinetoplast (Figure 1.2 and 1.3) (Desquesnes et al. 
2013b; Lai et al. 2008; Vickerman 1974).  
 
Figure 1.2: Fine structure of T. evansi, as revealed by 
transmission electron microcopy of thin sections (Vickerman 
1974). 
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The kinetoplast corresponds with the DNA (kDNA) of the unique mitochondrion of 
trypanosomatids. This kDNA consists of a huge network of interlocked circular DNA molecules of 
two types: maxicircles and minicircles (Lukes et al. 2005). The maxicircle with a size of ±23-kb in 
20–50 copies, contains a typical set of rRNA and protein-coding genes, most of which encode 
subunits of respiratory chain complexes. The minicircle kDNA comprise a highly diverse set of 
thousands of ±1-kb minicircles, which encode guide RNAs required for posttranscriptional editing 
(Schnaufer et al. 2002; Stuart et al. 1997; Fidalgo & Gille 2011). 
T. equiperdum and T. evansi are dyskinetoplastic (kDNA
-
) since they lack part of the kDNA 
(Claes et al. 2005; Lai et al. 2008; Schnaufer et al. 2002; Carnes et al. 2015). T. equiperdum 
typically has retained maxicircles, in some cases with substantial deletions, but has lost its 
minicircle diversity. T. evansi does not have maxicircles and either shows minicircle homogeneity 
or are akinetoplastic (kDNA°) (Ou et al. 1991; Lun & Vickerman 1991; Ventura et al. 2000; 
Schnaufer et al. 2002). 
T. evansi is biochemically similar to its ancestor T. b. brucei but it is no longer able to undergo 
a cycle in Glossina due to the loss of the maxicircle kinetoplast DNA (kDNA), hence its inability to 
perform oxidative phosphorylation (Hoare 1972; Borst et al. 1987; Lun & Desser 1995; Lai et al. 
Figure 1.3: Morphological features of T. evansi in camel Giemsa 
stained blood smear: large size (25–35 µm), small and subterminal 
kinetoplast (A), thin posterior extremity, large undulating membrance 
(B), central nucleus (C), and free flagellum (D) (Desquesnes et al. 
2013b). 
D 
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2008; Schnaufer et al. 2002). T. evansi and T. equiperdum can only survive as bloodstream forms, 
which produce ATP exclusively through glycolysis (Helfert et al. 2001; Roldán et al. 2011; 
Stephens et al. 2007).  
Based on the restriction enzyme profile on kDNA minicircle, T. evansi are grouped into type A 
(96% sequence identity) and type B that shows >96% identity within the group, and 50–60% 
identity to type A minicircles (Borst et al. 1987; Njiru et al. 2006). Isolates with minicircle type A 
are the most abundant throughout the whole distribution range of T. evansi (Bajyana Songa et al. 
1990; Ou et al. 1991; Lun et al. 1992). On the other hand, type B minicircles have been detected 
only in a few rare T. evansi isolates from camels from Kenya (Borst et al. 1987; Ngaira et al. 
2005). Some T. evansi from South America and China lack both maxicircle and minicircles 
(akinetoplastic) (Masiga & Gibson 1990; Stevens et al. 1989; Ventura et al. 2000; Schnaufer et al. 
2002; Borst et al. 1987; Bajyana Songa et al. 1990; Ou et al. 1991; Lun & Vickerman 1991). 
In addition to the natural loss of the kDNA, it is very fragile and highly sensitive to drugs that 
intercalate into DNA or otherwise interfere with replication giving rise to induced 
dyskinetoplastic (Dk) strains of trypanosomatids (Schnaufer et al. 2002). T. equiperdum strains 
have retained their maxicircles, in some cases with substantial deletions, but have lost their 
minicircle diversity (Lai et al. 2008; Schnaufer et al. 2002). In these dyskinetoplastic strains, in 
addition to its role in ATP production (through oxidative phosphorylation), specific mutations 
(L262P and A273P) in the nuclearly encoded F0F1-ATP synthase gamma () subunit compensate 
for loss of kDNA-encoded gene products in the bloodstream form (BSF) parasite (Dean et al. 
2013). T. evansi and T. equiperdum are morphologically indistinguishable from each other and 
from the long slender bloodstream from T. b. brucei, and their status as independent species has 
been questioned (Brun et al. 1998; Lai et al. 2008; Claes et al. 2005). Recently, sequencing of the 
genome of an akinetoplastic T. evansi strain from China (STIB 805) in comparison with the T. b. 
brucei reference strain (TREU 927/4), showed extensive similarity and the phylogenetic analysis 
indicated that T. evansi/T. equiperdum evolved from within the T. brucei group on at least four 
independent occasions and from genetically distinct T. brucei strains (Carnes et al. 2015). 
Moreover, a phylogenetic analysis based on RNA repeats from various isolates of T. evansi, T. 
equiperdum, T. b. brucei and T. b. gambiense showed no species-specific clusters (Lai et al. 2008). 
In conclusion, there is strong recommendation for re-classification of T. evansi and T. equiperdum 
as T. brucei subspecies, i. e. T. b. evansi and T. b. equiperdum respectively (Carnes et al. 2015; Lai 
et al. 2008; Claes et al. 2003a; Claes et al. 2005).  
To understand the genetic heterogeneity of T. evansi, considerable studies targeting the 
analysis of isoenzymes, restriction fragment length polymorphism (RFLP), microsatellite markers 
and random amplified polymorphic DNA (RAPD) indicated that T. evansi isolates from different 
parts of the globe are genetically homogeneous (Gibson et al. 1983; Stevens et al. 1989; Bajyana 
Songa et al. 1990; Biteau et al. 2000; Lun et al. 2004; Ventura et al. 2002). T. evansi type A is 
believed to exist as a single clonal lineage (Gibson et al. 1983; Njiru et al. 2007; Boid 1988). This 
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low heterogeneity was partly attributed to the use of techniques with low resolution and to the 
absence of recombination caused by the fact that genetic exchange in trypanosomes only occurs 
during their development in the tsetse fly which is not the case for T. evansi (Jenni et al. 1986; 
Njiru et al. 2007). On the other hand, due to extended host pleotropism in diverse geographical 
regions, heterogeneity in virulence and pathogenesis, significant genetic variability is to be 
expected (Reid 2002; Queiroz et al. 2000; De Menezes et al. 2004). Recent studies through AFLP, 
inter-simple sequence repeats (ISSR), microsatellites and ITS region analysis indicated that T. 
evansi type B is genetically divergent from T. evansi type A (Masiga et al. 2006; Njiru et al. 2007; 
Amer et al. 2011).  
4. Variant surface glycoprotein (VSG) and antigenic variation 
The VSGs, anchored to the cell surface through a covalent bond between the C-terminal 
residue and glycosylphosphatidylinositol (GPI) in the cell membrane, with estimated 10
7
 
molecules per cell, form a 12-15 nm monolayer over the entire surface of the BSF trypanosomes 
and is an essential virulence factor (Vickerman 1969; Ferguson et al. 1988). Each VSG molecule 
contains an N-terminal and a C-terminal domain (Johnson & Cross 1979; Carrington et al. 1991). 
The N-terminal domain is exposed to the extracellular environment and shows extreme 
variability in primary sequence of 350-400 residues. The relatively more conserved C-terminal 
domain consits of approximately 50-100 residues, but is inaccessible to antibodies and thus 
unlikely affects antigenic variation (Miller et al. 1984; Schwede et al. 2011). The highly 
immunogenic VSG determines the variable antigen type (VAT) of the individual trypanosome and 
elicits VAT specific protective antibodies with opsonizing, agglutinating and lytic activity (Van 
Meirvenne et al. 1995; Schwede et al. 2015; Schwede et al. 2011). RoTat 1.2 is the predominant 
VAT of most T. evansi strains (Bajyana Songa & Hamers 1988; Verloo et al. 2001). To deal with 
host immune pressure, trypanosomes have evolved a system called antigenic variation (Horn 
2014; Morrison et al. 2009; Pays et al. 2004; Vickerman 1978). Antigenic variation is a periodic 
switch in the VSG expression, whereby the parasites sequentially express and shed a series of 
different VSGs, that enables them to evade the host's protective immune responses (Vickerman 
1978). A single parasite expresses only one type of VSG at a given time, except during switching 
(Barry et al. 2005). During the first ascending wave of parasitaemia, the majority of the parasites 
express the same VSG or the major VAT (Hall et al. 2013; Robinson et al. 1999). Then 
approximately 1% of trypanosome divisions produce a new VAT by expressing a different VSG 
(Robinson et al. 1999; Hall et al. 2013). These new ‘antigenically distinct’ trypanosomes multiply 
and replace the first VAT, giving rise to a subsequent parasitaemia wave which is repeated 
multiple times and results in the development of a chronic infection (Pays et al. 2001; Baral 2010; 
Schwede & Carrington 2010; Hall et al. 2013). The waves of parasitemia in the infected hosts are 
the result of continuous interplay between the immune system and antigenic variation. In 
addition, VSG switching allows the parasites to infect the host that has antibodies against other 
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previously infecting variants (Barry et al. 2005). Each individual growth peak can contain several 
distinct variants (Figure 1.4) (Cnops et al. 2015).  
 
5. Some non-variable surface proteins 
5.1. Invariant surface glycoprotein 75 (ISG75) 
The VSG dimers act as a protective umbrella for underlying surface molecules such as 
invariant surface glycoproteins (ISGs). The bloodstream forms of trypanosomes contain about 5 x 
10
4 
glycosylated ISG75 (ISG75) molecules, with an apparent molecular mass of 75 kDa and 
distributed over the entire cell surface of T.b. brucei (Ziegelbauer & Overath 1992; Ziegelbauer et 
al. 1992; Tran et al. 2008; Overath et al. 1994). The immature ISG75 polypeptide of 523 amino 
acid residues is comprised of four main regions: an N-terminal hydrophobic signal sequence (28 
amino acids) that is cleaved off yielding a mature protein starting at Glu29; a large hydrophilic 
extracellular domain; a stretch of 20 hydrophobic residues close to the C-terminus forming a 
single trans-membrane α-helix; and a small hydrophilic domain (29 amino acids) exposed on the 
cytoplasmic face of the plasma membrane (Ziegelbauer et al. 1995). Multiple copies of ISG75 are 
present in the genome and are transcribed in all species and subspecies of Trypanozoon with 
varying copy number among species, ranging from at least 4 to 16 copies per genome. Based on 
nucleotide similarity, ISG75 is divided into Group I and Group II with 77% and 75% identity 
respectively (Tran et al. 2006).  
 
Figure 1.4: Representation of the concept of antigenic variation during mammalian T. 
brucei infection (Cnops et al. 2015). 
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5.2. Invariant surface glycoprotein 65 (ISG65) 
ISG65 was identified together with ISG75 in the same experiment by surface biotinylation 
(Ziegelbauer & Overath 1992; Ziegelbauer et al. 1992). ISG65, with apparent molecular mass of 
65 kDa, is a BSF specific protein of T. b. brucei but its function remains unknown (Ziegelbauer & 
Overath 1992; Jackson et al. 1993). ISG65 is uniformly spread over the entire cell surface, with an 
estimated 5-7 x 10
4
 molecules per cell (Ziegelbauer & Overath 1992; Ziegelbauer et al. 1992; 
Jackson et al. 1993). The ISG65 gene codes for a polypeptide of 436 amino acid residues with an 
N-terminal cleavable signal sequence, a large hydrophilic extracellular domain, and a 
hydrophobic transmembrane α-helix followed by a small intracellular domain. The gene is 
present in multiple copies, arranged in tandem repeats (Ziegelbauer et al. 1992). ISGs are 
accessible by immunoglobulins but binding is limited and tolerated by the trypanosome 
(Schwede et al. 2015). 
Figure 1.5: A. Schematic representation of a VSG dimer: The N-terminal domain is 
depicted in green, the C-terminal domain in blue and the GPI-anchor in yellow. B. 
Organization of dimeric variant surface glycoprotein molecules anchored in the 
membrane by glycosylphosphatidylinositol (GPI) residues. The hypothetical arrangement 
of an ISG molecule with a membrane spanning helix between the VSG molecules is 
shown. There is only one ISG for approximately 100 VSG molecules. Adapted from 
Overath et al. (1994) and Schwede et al. (2011). 
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5.3. Cytoskeletal tandem repeat protein GM6 
Tandem repeat (TR) proteins of trypanosomatid parasites are often targets of B cell responses 
(Goto et al. 2007). Tandem repeat (TR) protein GM6 is a cytoskeletal protein, located at the 
connection site between the microtubules of the membrane skeleton and the flagellum of the 
parasite (Figure 1.6).  
 
GM6 is equally present in bloodstream and procyclic forms of trypanosomes, and is well 
conserved between different species of salivarian trypanosomes and, though somewhat less, in 
the stercorarians T. rangeli and T. cruzi (Müller et al. 1992; Pillay et al. 2013). GM6 which exerts 
structural roles in the trypanosomal cell consists of repetitive sequence motifs of 60, 11, 9 amino 
acids in T.b. brucei, T. vivax and T. congolense respectively (Pillay et al. 2013; Müller et al. 1992). 
T. congolense GM6 shares 63.8% identity with T.b. brucei GM6 while the T. vivax GM6 repeat 
sequence shares only 51 and 55% identity and 72 and 64% similarity with the homologs of T. b. 
brucei and T. congolense, respectively (Nguyen et al. 2012; Pillay et al. 2013; Nguyen et al. 2014).  
GM6 is recognized by B-cells when parasites are destroyed by the host immune response 
(Müller et al. 1992; Imboden et al. 1995). However, it has been observed that the antibody 
response against GM6 decreases to baseline approximately one month after treatment. In the 
absence of antigenic stimulation, when the parasitaemia drops beneath the necessary parasite 
load, the antibody response is short-lived (Pillay et al. 2013). 
5.4. Drug transporters 
Trypanosomes have two high-affinity adenosine transporters: a P1 type, which transports 
inosine and accounts for 60–70% of the total adenosine uptake; and a P2 type, which transports 
adenine and accounts for 30–40% of the total adenosine uptake into the cell. Diamidines are 
Figure 1.6: Phase contrast and immunofluorescence pictures of a T. vivax trypanosome 
showing partial co-localisation of GM6 and the paraflagellar rod (PFR) proteins by means 
of specific fluorescent antibodies (Pillay et al. 2013). 
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transported via the P2 transporter (Anene et al. 2001). The T. evansi adenosine transporter-1 
gene (TevAT1) (which shares 99.7% homology with TbAT1 gene in T. brucei) encodes a P2-like 
nucleoside transporter required for the uptake and/or action of berenil in T. evansi. TbAT1 is also 
involved in melarsoprol uptake (Burkard et al. 2011). On the other hand, the high-affinity 
pentamidine transporter 1 (HAPT1), today recognized as aquaglyceroporin 2 (aqp2) is responsible 
for most of the P2-independent diminazene uptake in bloodstream trypanosomes and its 
absence generally correlates with high levels of diamidine resistance (Teka et al. 2011; Baker et 
al. 2013). Melaminophenyl arsenicals such as cymelarsan are transported into the trypanosome 
by the P2 adenosine/adenine transporter and additionally by the aquaglyceroporins (aqp2/3) (De 
Koning 2008; Alsford et al. 2012; Carter & Fairlamb 1993). Mutations in aquaglyceroporin 2 
correlate with decreased susceptibility to pentamidine and melarsoprol (Graf et al. 2013). The 
ISG75, acts as a major receptor for suramin (or the serum component to which it is bound) 
delivering the drug into the degradative arm of the endocytic pathway (Alsford et al. 2012; 
Alsford et al. 2013). No transporters are known to exist for isometamidium chloride (ISM). ISM 
freely crosses the plasma membrane, probably by facilitated diffusion, and is subsequently 
actively accumulated into the mitochondria, using the mitochondrial potential as a driving force. 
Resistance to ISM is mostly associated with cross-resistance to homidium (De Koning 2001; 
Peregrine et al. 1997). Recently, innate resistance of T. evansi to ISM has been observed to relate 
with the A281 deletion in the ATP F1  subunit gene (Gould & Schnaufer 2014). Moreover, RNA 
silencing in T.b. brucei revealed that depletion of vacuolar ATPase or adaptin-3 subunits is 
associated with ISM resistance (Baker et al. 2015). 
6. Interactions between the trypanosome and the mammalian host 
In contrast to trypanosomosis due to T. brucei, information on the immunobiological aspects 
and parasite control mechanisms of T. evansi infection is limited (Onah et al. 1998b; Onah et al. 
1998a). Unlike to cyclically transmitted trypanosomes, the mechanically transmitted T. evansi 
parasites complete their entire life cycle in the mammalian host and are under constant immune 
pressure (Baral et al. 2007). Co-evolution has resulted in the development of well-balanced 
growth regulation systems, allowing the parasite to survive sufficiently long without killing its 
mammalian host, ensuring its efficient transmission (Stijlemans et al. 2010). Upon infection with 
African trypanosomes, both arms of the host immune system are activated comprising (i) a 
strong type I cellular immune response, consisting of pro-inflammatory molecules such as tumor 
necrosis factor (TNF), interleukines (IL-1, IL-6) and nitirc oxide (NO) produced mainly by 
“classically” activated macrophages and (ii) a strong humoral anti-trypanosome B-cell response 
(Mansfield & Paulnock 2005; Magez et al. 2008).  
Similar to T. brucei and T. congolense infection, T. evansi infection induces 
immunosuppression at the level of antibody production against heterologous antigens and of the 
proliferative response of peripheral blood lymphocytes (Holland et al. 2001; Holland et al. 2003; 
Onah et al. 1998b; Onah et al. 1996; Onah et al. 1999).  
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IFN- dependent NO production is involved in the suppression of T cell proliferation in T. 
evansi and T. brucei infection (Hertz & Mansfield 1999; Beschin et al. 1998). However, this 
suppression had no measurable effect on parasitemia control or on the life span of T. evansi 
infected mice under laboratory conditions (Baral et al. 2007). The dramatic suppression of the 
immune responses might result in a high susceptibility to opportunistic infections (Darji et al. 
1992; Flynn & Sileghem 1991; Sileghem et al. 1991). Moreover, immunosuppression due to T. 
evansi was shown to cause vaccination failure against classical swine fever and Pasteurella 
multocida (haemorrhagic septicemia) (Holland et al. 2003; Holland et al. 2001). The mechanism 
of immunosuppression in trypanosome infected animal/human is reviewed well by Baral (2010). 
Both macrophages and T cells are involved in initiation of immunosuppression (Tabel et al. 2008). 
The immunosuppression caused by suppressive macrophages is characterized by an inhibition of 
the T cell proliferation due to down regulation of both IL-2 production and expression of IL-2 
receptor (Sileghem et al. 1989; Darji et al. 1992). 
Trypanotolerance is the relative capacity of some livestock breeds to survive, reproduce and 
remain productive under trypanosomosis challenge without the aid of trypanocidal drugs. 
Trypanotolerant cattle such as the N’Dama, the short-horn taurine Baoulé and Lagune, control 
the development of the parasites and limit their pathological effects, the most prominent of 
which is anaemia (D'leteren et al. 1998; Murray & Dexter 1988). Trypanotolerance is under 
genetic control, but its stability can be affected by environmental factors, such as overwork, 
intercurrent disease and repeated bleeding, pregnancy, parturition, suckling, lactation and 
malnutrition (Berthier et al. 2015). The capacity of trypanotolerant cattle to generate sustained 
antibody responses to trypanosome antigens is probably the most prominent immunological 
feature that has been identified so far. Following infection, animals develop a trypanosome-
specific IgM response that is similar in both trypanotolerant and trypanosusceptible cattle 
(Authié et al. 1993; Williams et al. 1996). A distinct population of IgM consists of antibodies of 
low specificity, which react with both trypanosome and non-trypanosome antigens. These 
polyspecific antibodies, which may contain auto-antibodies are likely to mediate pathology rather 
than protection (D'leteren et al. 1998; Williams et al. 1996). A trypanosome-specific IgG response 
(predominantly IgG1) is elicited in infected cattle almost coincidentally with the IgM response. 
Besides having a greater ability to develop specific humoral responses, trypanotolerant cattle 
have been found to maintain higher complement levels during trypanosome infection than 
susceptible zebu cattle (Authié & Pobel 1990). The bone marrow of trypanotolerant breeds has 
higher intrinsic capacity to respond to anaemia (Andrianarivo et al. 1995; Andrianarivo et al. 
1996).  
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7. Epidemiology and economic importance of T. evansi infection 
The epidemiology, pathogenesis and economic significance of surra, due to T. evansi infection 
is descibed well in recent reviews (Figure 1.7) (Desquesnes et al. 2013b; Desquesnes et al. 
2013a). Surra is widely distributed in Afica, Middle East, Latin America, and Asia with sporadic 
import cases in Europe (Hoare 1972; Gutiérrez et al. 2010). Surra is one of the OIE list B multiple 
species diseases (OIE 2016). This multi-host characteristic is attributed to the fact that the 
mechanical vectors such as tabanids do not have strict host preference (Muzari et al. 2010).  
In the non tsetse belt of Africa, surra is principally a disease of camels and horses but cattle 
and goats are also highly susceptible (Gutiérrez et al. 2006b). There is seasonal influence on 
epidemics related to seasonal activity of vectors and other factors such as stress from overwork, 
food shortages, and/or insufficient or poor quality water (Dia et al. 1997a; Desquesnes et al. 
2013a; Zeleke & Bekele 2001). The distribution of T. evansi infection in Ethiopia follows the 
distribution of dromedary camels (Figure 1.8) (Dagnatchew 1982; Abebe 2005). However, due to 
logistic deficiency and lack of accurate diagnostics for the disease, the exact burden and 
economic importance of the disease is not well known. Recent studies in pocket areas of Ethiopia 
indicated parasitological (2%, 12 %) and serological (24%, 25%) prevalence in camels respectively 
from Oromia and Afar regions (Fikru et al. 2015; Hagos et al. 2009).  
Figure 1.7: Geographical distribution of Trypanosoma evansi in the world (Auty et al. 2015). 
T. evansi 
T. evansi inferred 
T. evansi single outbreak 
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In the Middle East and towards Asia, the geographical distribution of T. evansi is also closely 
related to that of dromedaries. Surra is widely distributed principally in bovines, camels, 
buffaloes and equines in large areas of India (Hoare 1972; Ravindran et al. 2008; Singh et al. 
2004; Pathak et al. 1993; Sumbria et al. 2014; Sharma et al. 2013; Kundu et al. 2013; Ul Hassan et 
al. 2006; Shahzad et al. 2010; Tehseen et al. 2015). 
In Latin America, T. evansi is principally a disease of horses and bovine and induces outbreaks 
with very high morbidity and mortality. Other domestic species that are affected by surra are 
buffaloes, cats, pig and dogs (Aquino et al. 2010; John et al. 1992; Aref et al. 2013; Defontis et al. 
2012; Rjeibi et al. 2015; Stevens et al. 1989; Raina et al. 1985). The wild reservoirs in Latin 
America are wild pigs (Tayassu tajacu), white tail deer (Odocoileus virginianus chiriquensis), coati 
(Nasua nasua), brocket deer (Mazama satorii), vampire bats (Desmodus rotundus), capybaras 
(Hydrochoerus hydrochaeris), guinea pig (Cavia porcellus), wild dog (Canis azarae), ocelot (Felis 
pardalis) and llamas (Desquesnes et al. 2013a).  
In Asia, the geographical distribution of T. evansi is spreading steadily in large areas in India, 
China, and Russia (Lun et al. 1993; Singh et al. 2004). Surra usually exhibits an endemic and 
chronic nature, however, an acute outbreaks can occur when the disease is introduced into new 
Figure 1.8: Geographical distribution of Trypanosoma evansi in Ethiopia (white circular dots) 
(Abebe 2005). 
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animal population with no prior exposure (Berlin et al. 2010; Gutiérrez et al. 2005; Adrian et al. 
2010; Desquesnes et al. 2008). 
T. evansi is not present in Australia, but it may spread eastward from Indonesia to Papua New 
Guinea and then Australia (Reid & Copeman 2000). Surra cases in Europe have been ascribed to 
importation of camels from the Canary Islands where the disease was first diagnosed in 1997, in a 
dromedary camel imported from Mauritania (Gutiérrez et al. 2000). Many camels had been 
imported from the Canaries to the European mainland without any previous examination to 
detect T. evansi infection (Gutiérrez et al. 2000; Gutiérrez et al. 2010). This has caused two 
outbreaks of T. evansi infection, in metropolitan France in 2006 on a sheep and camel farm and 
in Spain in 2008 (Desquesnes et al. 2008; Tamarit et al. 2010).  
T. evansi cannot infect human because of its susceptibility to the trypanolytic factor (TLF) in 
normal human serum (NHS), apolipoprotein L-1 (ApoL-1) that provides innate protection of 
humans from infection by African trypanosomes, such as T. evansi, T. b. brucei, and others, with 
the exception of T. b. rhodesiense and T. b. gambiense, which developed resistance mechanisms 
(Vanhollebeke et al. 2008; Pays et al. 2006; Vanhamme et al. 2003). In India, a human case of 
trypanosomosis due to T. evansi occurred in a person with frameshift mutations in both Apo L-1 
alleles that led to an unexpected termination of protein translation by internal stop codons which 
resulted in a total absence of Apo L-1 (World Health Organization (WHO) 2005; Joshi et al. 2005; 
Powar et al. 2006; Vanhollebeke et al. 2006). More recently, a woman in Vietnam, with 
apparently normal blood concentrations of functional Apo L-1 was diagnosed with T. evansi 
infection suggesting that other host parameters may play a role in susceptibility to T. evansi 
infection (Van Vinh et al. 2016). 
T. evansi is mechanically transmitted by blood sucking insects and requires high parasitaemia 
of the “donor host” (Desquesnes et al. 2013a). Of all, mechanical transmission by biting insects 
such as tabanids and Stomoxys is the most important mode of transmission. Besides vector 
transmission and the contamination of a wound, iatrogenic transmission caused by the use of 
nonsterile surgical instruments or needles may be of importance, especially during vaccination 
campaigns and mass treatments. Per-oral transmission through eating infected prey was 
reported in tigers, dogs and rodents (Moloo et al. 1973; Raina et al. 1985; Desquesnes et al. 
2013a). In Latin America, vampire bats (Desmodus rotundus) can act as vector of T. evansi. They 
are infected orally when taking blood from an infected prey. As a host of T. evansi, bats may 
develop clinical symptoms and die during the initial phase of the disease. However, in bats that 
survive, parasites multiply in the blood and are found in the saliva from where they can be 
transmitted to another host during biting (Hoare 1972; Desquesnes 2004). Recently, vertical 
transmission of T. evansi in naturally infected camels and in experimentally in sheep has been 
documented (Narnaware et al. 2016; Campigotto et al. 2015). Clinical signs across host species 
are detailed below in section 9.1. 
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The cumulative effects of the different pathologies due to T. evansi infection cause serous 
economic losses due to its impact high mortality, reduced production (milk and meat), reduced 
reproductive performance, poor carcass quality, decreased draught power and 
immunosuppression in livestock. Furthermore, the financial expenditures for use of 
chemotherapeutic interventions and replacement stocks is quite high (Reid 2002; Pholpark et al. 
1999; Payne et al. 1991; Salah et al. 2015). 
8. Control of African Animal Trypanosomosis 
8.1. Trypanocidal treatment 
Contol of vector borne diseases targets both disease control and vector control. As no vaccine 
against T. evansi infection exists, disease control is mainly based on trypanocidal drugs. Each 
year, 35 million doses of veterinary trypanocidal drugs are administered in Africa, with 
isometamidium chloride (ISM), diminazene aceturate (DA) and ethidium bromide (EtBr) 
representing respectively 40%, 33% and 26% of the total trypanocidal drug market by value 
(Geerts & Holmes 1998). “Curative trypanocidals” have a short term effect, while 
“chemoprophylactic trypanocidals” not only kill parasites but also protect against infection due to 
a sustained curative drug level in the serum of treated animals (Table 1.1) (Desquesnes et al. 
2013a). DA is affordable and easily accessible which often makes it the first-line treatment. DA 
can be used as “premunition treatment” at which the host is clinically cured but remains 
infected, however this could contribute for selection of drug resistant strains. This treatment 
regime could be used in highly enzootic situations, when the infection is not lethal, such as T. 
evansi in bovines while “sterilizing” treatment is used for lethal T. evansi infection in horses and 
dogs (Desquesnes et al. 2013a). ISM, synthesized by coupling homidium with a part of the 
diminazene molecule, has been used in the field for several decades prophylactically or 
therapeutically (Leach & Roberts 1981). ISM is mainly accumulated in the kinetoplast, whereas 
homidium is spread much more diffuse throughout the trypanosome (Boibessot et al. 2002). EtBr 
(or chloride) is a highly toxic, DNA intercalating agent and has mutagenic action (Macgregor & 
Johnson 1977). The mode of action of DA is not clear while for ISM, it cleaves kDNA-
topoisomerase complexes, causing the desegregation of the minicircle network within the 
kinetoplast. However, Kaminsky et al. showed that dyskinetoplastic trypanosomes are equally 
sensitive to ISM as kinetoplastic trypanosomes thus questioning the relevance of the mode of 
action of ISM on the kDNA (Shapiro & Englund 1990; Girgis-Takla & James 1974; Kaminsky et al. 
1997).  
Suramin appeared in 1920 as drug against the early stage of sleeping sickness (HAT) and does 
not cross the blood-brain-barrier (Nok 2003; Sanderson et al. 2007). In addition to the many 
other intracellular effects that suramin may exert on the parasite, it exerts inhibitory activities on 
a wide spectrum of enzymes, e.g. inhibition of the uptake of low density lipoproteins (LDL) 
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(Vansterkenburg et al. 1993; Wang 1995). Suramin has been used to treat surra in Sudan and 
Kenya (El Rayah et al. 1999; Otsyula et al. 1992).  
Quinapyramine was introduced in the 1950s and is used as a therapeutic (antrycide sulphate) 
and prophylactic drug (antrycide prosalt) for T. evansi in camels and T. evansi and T. equiperdum 
in horses. However, due to development of drug resistance, it was withdrawn from the market in 
Africa in the 1970s. The drug has been re-introduced on the market in the mid 1980s under two 
different names. One of the products, tribexin prosalt (quinapyramine sulphate:quinapyramine 
chloride, in the ratio of 3:4; Indian Drugs and Pharmaceuticals Ltd, Hyderabad, India) is 
recommended to treat T. evansi infections in donkeys and camels. Another product, trypacide 
(May and Baker, UK), is available in two forms, trypacide sulphate (subcutaneous, curative) and 
trypacide pro-salt (quinapyramine sulphate:quinapyramine chloride, in the ratio of 3:2, 
prophylactic) (Kinabo 1993).  
Melarsamine hydrochloride (MelCy) is a water-soluble trivalent arsenical agent patented in 
1985 under the trade name cymelarsan (Rhone Merieux, France) (Berger & Fairlamb 1994; 
Otsyula et al. 1992). 
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Table 1.1: Trypanocidal drugs used for treatment of surra in various host species 
 (Desquesnes et al. 2013a; De Koning 2001; Delespaux & De Koning 2007; Kinabo 1993; Röttcher 
et al. 1987). 
 
Trypanocidal 
drug  
Trade name Family Therapeutic/Prophylactic/route 
and dosage 
Host species  
Diminazene 
(di)aceturate 
(DA) 
Veriben, 
Berenil 
aromatic 
diamidines 
therapeutic (7mg/kg bw, IM), 
prophylactic (3.5 mg/kg bw) 
ruminants, 
poor efficacy 
and tolerance 
in horses and 
dogs  
Isometamidium 
(ISM) chloride 
(hydrochloride)  
Samorin, 
Trypamidium, 
Veridium 
phenanthridines therapeutic (0.5mg/kg bw, IM), 
prophylactic (1mg/kg bw) 
ruminants, 
horses have a 
limited 
tolerance  
homidium 
chloride 
(bromide) 
Novidium 
(Ethidium) 
phenanthridines prophylactic (1 mg/kg bw, IM) ruminants, 
horses have a 
limited 
tolerance 
Quinapyramine 
dimethyl-
sulphate 
Antrycide 
sulphate 
aminoquinaldines therapeutic (8 mg/kg bw, SC), 
prophylactic (5mg/kg bw)  
horses and 
camels 
Suramin Naganol ureic, sulfonated 
naphthylamine 
therapeutic (7-10 mg/kg bw, IV 
in horses, and 8-12 mg/kg bw, 
IV in camels), prophylactic (1-2 g 
repeated at 10 days intervals) 
horses and 
camels  
Melarsomine 
dihydrochloride  
Cymelarsan arsenical therapeutic 0.25, 0.25–0.5, 0.5, 
0.75, and 2.5 mg/kg bw, IM 
respectively for each host 
species 
camels, 
horses, cattle; 
buffaloes, 
dogs 
bw: body weight, IM: intramuscular, IV: intravenous, SC: subcutaneous 
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Two injections of cymelarsan (0.5 mg/kg bw), with an interval of 1 month, is recommended to 
control T. evansi outbreaks in non-endemic areas (Gutiérrez et al. 2014). Alternate use of DA and 
ISM constitutes a “sanative pair,” which means that once resistance develops to one of the drugs, 
the other drug is still effective to control the infection. Most trypanocidal drugs cannot effectively 
cure animals with advanced disease, particularly with nervous involvement, when the parasite 
has infiltrated extravascular spaces. This could be due to rapid clearance from the circulation or 
inability to cross the blood-brain-barrier (Desquesnes et al. 2013a).  
Control of AAT is hampered by emergence of drug-resistant trypanosomes (Mäser et al. 2003; 
Geerts et al. 2001). Extensive use of DA, ISM, quinapyramine and suramin has resulted in the 
appearance of resistant strains (Leach & Roberts 1981; Kinabo 1993; Röttcher et al. 1987). Drug 
resistance can be innate (resistant individuals without previous exposure to the particular drug), 
or acquired (due to drug exposure/pressure, cross-resistance or sometimes by mutagenesis) 
(Frommel & Balber 1987; Osman et al. 1992). Resistance to DA and ISM is reported in various 
Trypanosoma species from different parts of Africa, including in Ethiopia (Moti et al. 2012; 
Dagnachew et al. 2015b; Moti et al. 2015; Miruk et al. 2008). Resistance to ISM is mostly 
associated with cross-resistance to homidium, as they are structurally related compounds that 
share the same uptake mechanism (Peregrine et al. 1997). Resistance of T. evansi to suramin has 
been observed experimentally in Sudan and China, and camels in Kenya (El Rayah et al. 1999; 
Zhou et al. 2004; Otsyula et al. 1992). No cross-resistance of suramin with arsenicals, diamidines, 
quinapyramine or isometamidium was observed (El Rayah et al. 1999; Zhou et al. 2004; Ross & 
Barns 1996). So far there are no reports about development of resistance against cymelarsan. 
This drug is not registered in Ethiopia but it has been used to treat horses infected with T. 
equiperdum (Hagos et al. 2010c). However, in the case of nervous infections, high doses (0.5 
mg/kg bw), in horses and dogs (2 mg/kg bw), failed to cure the animals (Desquesnes et al. 2011; 
Berlin et al. 2010; Desquesnes et al. 2013a). Lower doses of cymelarsan failed to treat surra cases 
in buffaloes (0.25 mg/kg to 3 mg/kg), goats (0.3 mg/kg), mice (0.25 mg and 0.5 mg/kg) and cattle 
(0.5 mg/kg) (Lun et al. 1991; Payne et al. 1994a; Hagos et al. 2010c; Zweygarth et al. 1992; 
Syakalima et al. 1995). Clones of T. evansi that developed resistance to cymelarsan in mice 
showed cross resistance to diminazene and pentamidine (Osman et al. 1992; Zweygarth et al. 
1990).  
8.2. Vector control 
In addition to treatment, prevention of infection through vector control is possible. The 
control of mechanical vectors is difficult because of their diversity, high mobility and prolificacy 
(Foil & Hogsette 1994). Control of tabanids is rarely attempted, because it is costly, 
unsatisfactory, unsustainable, and does not provide 100% protection against infection 
(Desquesnes et al. 2013a). Nzi and Vavoua traps are used to study insects and monitor control 
campaigns. The Nzi trap can catch large tabanid species and Stomoxys, while the Vavoua trap 
catches small tabanid species, such as Chrysops (deer flies) and Stomoxys (Mihok 2002). 
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8.3. Vaccination 
Antigenic variation of trypanosomes is a major obstacle in the development of efficient 
vaccines (Magez & Radwanska 2009). Initial vaccination experiments on metacyclic variable 
antigen types (M-VATs) of T.b. brucei and VSG of T. congolense that were reported to provide 
some VSG-specific protection were unsuccessful (Crowe et al. 1984; Crowe et al. 1983; Nantulya 
et al. 1980; Masake et al. 1983). Intracellular trypanosome components, such as β-tubulin, actin, 
microtubule-associated proteins (MAP), purified flagellar pocket fractions, congopain were used 
for vaccination but none of them was able to induce full protection against infection (Balaban et 
al. 1995; Li et al. 2009; Li et al. 2007b; Lubega et al. 2002; Gull 2003; Mkunza et al. 1995; 
Radwanska et al. 2000). Recombinant protein ISG75 has been tried to immunize mice, resulting in 
high titers of ISG75-specific antibodies. However, challenge with trypanosomes showed no 
protection and vaccine-induced anti-ISG75 antibody titers decreased rapidly (Magez & 
Radwanska 2009; Tran et al. 2008). All these failures indicate that vaccination against African 
trypanosomoses might never be feasible (Magez & Radwanska 2009). In addition, all attempts to 
develop an anti-disease vaccine that protects an infected hosts against the development of 
severe disease have eventually failed (Hanotte et al. 2003; Authié et al. 2001; Stijlemans et al. 
2007; Lalmanach et al. 2002; Radwanska et al. 2008). 
9. Diagnosis of T. evansi infection 
Knowing the presence or absence of ongoing infection or exposure is important for providing 
therapy and assessing fit in livestock trade requirements of individual animals and for 
understanding the epidemiology of a disease within a population. Individual diagnosis, 
particularly in developing countries, often depends on non-specific clinical signs and/or 
cumbersome parasitological techniques. It is likely that the diagnosis for individual animals is 
often missed as clinical symptoms are not pathognomonic and the diagnostic sensitivity of 
traditional parasitological techniques is low, particularly in the chronic phase of the disease 
(Büscher 2014; Thrusfield 2007; Jacobson 1998). Each diagnostic test has a number of 
characteristics. The sensitivity is the proportion of infected animals testing positive -or- sensitivity 
=true positives/(true positives + false negatives). The specificity is the proportion of non-infected 
animals testing negative -or- specificity = true negatives/(true negatives + false positives). The 
reproducibility is the ability of a test to produce consistent results when preformed in different 
laboratories and the repeatability is the ability of a test to produce consistent results when the 
test is run on several occasions under identical conditions. Moreover, ease of interpretation, user 
friendliness, rapidity of results and cost are important parameters (Mabey et al. 2004; Jacobson 
1998; Thrusfield 2007). Apart from their intrinsic characteristics, the performance of diagnostic 
tests can be described in terms of positive and negative predictive value (PPV and NPV) that take 
into account the prevalence of the infection or the disease within a given population. The 
formulas are as follows:  
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PPV = sensitivity*prevalence/[sensitivity*prevalence +(1-specificity)*(1-prevalence)] and  
NPV= specificity*(1-prevalence)/[specificity*(1-prevalence) + (1-sensitivity)*prevalence].  
Hence, the prevalence of an infection will define which type of diagnostic test will perform 
best in a given population. In areas with high prevalence of a disease, low sensitive and highly 
specific diagnostics may be adequate if chemoprophylaxis or chemotherapy is administered on a 
herd basis. In areas with low disease prevalence, more sensitive diagnostic tests are required 
(Thrusfield 2007). Diagnostic tests for trypanosomes can be generally grouped into 1° direct tests 
that detect either whole circulating parasites, or, as surrogate of the parasite, its antigens, its 
DNA or RNA and 2° indirect tests that detect the antibody response of the host to the infection 
(Büscher 2014). 
9.1. Clinical signs and symptoms 
The diverse pathologies due to T. evansi infection have been well reviewed in (Desquesnes et 
al. 2013b; Habila et al. 2012). Briefly, the course of the disease runs from subclinical to acute fatal 
cases. Severity is related to the difference in virulence of individual strains, susceptibility of the 
host, local epizootiological conditions and stress factors (Hoare 1972; Desquesnes et al. 2013b). 
In susceptible host species; not the parasite burden itself but immunopathology, including 
anemia and liver pathogenicity cause mortality and morbidity (Magez et al. 2004; Shi et al. 2003; 
Bosschaerts et al. 2009; Stijlemans et al. 2008). Clinical signs and symptoms in African 
trypanosomosis are non-specific or may even be obscure, particularly in trypanotolerant breeds. 
No single symptom is pathognomonic and AAT may simulate many other infections. Therefore, 
clinical diagnosis remains only presumptive and relies upon the combination of several clinical 
signs occurring in a susceptible host in a given epidemiological situation (Büscher 2014). At the 
site where trypanosomes are inoculated by the biting flies, trypanosome multiplication can 
induce swelling of the skin (chancre) followed by intermittent fever (Luckins et al. 1991). Anemia, 
mainly due to extravascular haemolysis is a cardinal sign of AAT (Stijlemans et al. 2008; Rickman 
& Cox 1983). During late infection, AAT is characterized by loss of condition, lassitude, edema of 
the lower parts of the body, urticarial plagues and petechial hemorrhages of the serous 
membranes (OIE 2012; Desquesnes et al. 2013b). Abortions, immunosuppression and infiltration 
and dissemination of T. evansi in the central nervous system (CNS) with fatal clinical symptoms 
are documented (Saleh et al. 2009; Holland et al. 2003; Holland et al. 2001; Seiler et al. 1981; 
Berlin et al. 2009). 
In camels, surra may be acute with high fever (41°C), weakness, loss of appetite and weight, 
abortion, oedema (ventral parts, udder or scrotum, and sheath), anaemia with pale mucous 
membrane, and petechial or ecchymotic haemorrhages and death. It is more often chronic 
(frequently last 2-3 years) than in horses. Sometimes nervous signs such as periodic convulsion 
are observed (Gutiérrez et al. 2006a; Gutiérrez et al. 2005). In horses, the incubation period is 1–
8 weeks, after which fluctuating fever (41.5°C to 44°C) coincides with high peaks of parasitaemia. 
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Other symptoms are weakness, lethargy, anaemia, severe weight loss (often accompanied by 
jaundice and highly coloured urine), transient local or general cutaneous eruption, petechial 
haemorrhages vulvar and vaginal mucosa and on the anterior chamber of the eye and eyelids, 
abortion, staggered locomotion and oedema (submaxillary, legs, briskets, abdomen, testicle and 
sheath or udder) (Silva et al. 1995). Acute signs are often seen in naive populations with high 
mortality rates above 50%. In enzootic areas, horses may exhibit a certain level of resistance with 
chronic or subclinical cases and apparently healthy carriers. Donkeys and mules exhibit the same 
symptoms but milder than those in horses (Silva et al. 1995). 
Surra has been considered as a mild, chronic, or asymptomatic disease in cattle and buffaloes, 
especially in Africa, Venezuela and Latin America, where it is sometimes even difficult to infect 
animals experimentally (García et al. 2006). In India very high mortality rates (>90%) were 
reported. Common clinical signs include fever, anaemia, losses in weight, milk and meat 
production, and losses in draught power, abortion, interruption in oestrous cyclicity. Occasionally 
the evolution may be acute, quickly leading to death (Payne et al. 1993; Desquesnes et al. 
2013b).  
In sheep, natural infection is generally considered as mild or asymptomatic. In some cases, 
experimental infections can even fail, but in others they can lead to clinical signs, mainly fever 
(40°C), lack of appetite, and anaemia. Parasitaemia is generally low (105 parasites/ml) and 
decreases until undetectable for several months; however, under certain circumstances such as 
food restriction or transport stress, parasites can relapse into the blood and clinical signs 
reappear (Desquesnes et al. 2013b). Trypanosomosis including surra in goats may produce acute, 
subacute, chronic, or subclinical forms. Under natural conditions, goats show mild clinical signs 
(Gutiérrez et al. 2006b). In experimental infection, erratic parasitemia, weight loss, and 
significant drop in PCV were observed (Ngeranwa et al. 1991; Ngeranwa et al. 1993).  
Infection in pigs has long been reported as very mild or symptomless (including under 
experimental conditions), however, symptoms such as fever (39°C–41°C), anaemia, weight loss, 
anorexia, low fertility, emaciation, abortion and cutaneous rash, and late nervous evolution, with 
hind leg paralysis can be seen.  
Dogs are highly susceptible for surra, often exhibiting acute cases with strong clinical signs 
leading to death (within a week to a month), especially in stray dogs which are not treated and 
sometimes even despite treatments (Herrera et al. 2004; Singh et al. 1993). Clinical signs are 
intermittent fever (39°C–41°C), oedema (head including larynx, abdominal wall and legs), 
anaemia, weakness, lack of appetite leading to emaciation and, sometimes, paresis of the 
hindquarters and myocarditis, sexual excitement can be seen. Ocular signs with conjunctivitis, 
lachrymation, keratitis, corneal opacity, and/or haemorrhagic signs, fibrin deposits in the anterior 
chamber of the eye; and parasites in ocular aqueous fluid are common (Savani et al. 2005; Aref et 
al. 2013).  
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Confirmed cases of T. evansi infection are documented in tigers. Clinically sick tigers showed 
anorexia, constipation, lethargy and convulsion, rapid respiration, panting, head pressing, rapid 
pulse, fever (Upadhye & Dhoot 2000). An outbreak of T. evansi infection in four tigers, two 
jaguars, and one leopard was characterized by sudden death, respiratory distress, running nose 
and convulsions (Sinha et al. 1971). Very little is known about natural infection in cats, but T. 
evansi experimental infection in cats induced only mild symptoms, such as fever, apathy, 
hyporexia, and vomiting as well as muscular pain, hyperproteinaemia, hyperglobulinaemia, and 
hypoalbuminaemia (Da Silva et al. 2010b; Da Silva et al. 2009).  
9.2. Parasitological techniques 
Parasitological tests are in principle 100% specific and therefore can be used for confirmation 
diagnosis. On the basis of morphological characteristics, microscopy allows tentative 
identification of the trypanosome species. Trypanozoon parasites, including T. evansi are found 
intravascularly as well as extravascularly in different tissues, including the central nervous 
system. Trypanosomes that circulate in the blood are the most accessible for parasitological 
examinations. In the chronic phase of an infection, the parasite load in the blood often remains 
below the detection limit of common microscopic techniques thus making parasite detection 
cumbersome and poorly sensitive (Büscher 2014).  
The wet blood film and stained thin and thick smears are direct blood examination techniques 
without any concentration step. The major disadvantage of these tests is the low sensitivity as 
only parasite levels above 100,000/ml can be detected (Paris et al. 1982). Preparation and 
microscopic examination of the stained slides is time-consuming (10 to 20 min per slide) and 
requires a certain level of expertise to recognize the parasite (Chappuis et al. 2005). The micro 
haematocrit centrifugation technique (mHCT) or Woo test allows the concentration of 
trypanosomes in the blood and therefore is a more sensitive parasite detection method. 
However, identification of the trypanosome species is not obvious although the morphology and 
particularly the characteristic movement of the parasites may be indicative. In this technique, 
blood is drawn into anticoagulant-coated capillary tubes and centrifuged at high speed about 
13,000 g) for 5 minutes to concentrate the trypanosomes in the buffy coat layer (Woo 1970). 
When species identification is desired, the capillary tubes can be broken and the buffy coat 
spread on a microscope slide for examination according to Murray (Murray et al. 1977).  
The mini Anion Exchange Centrifugation Technique (mAECT) separates trypanosomes from 
blood cells on an anion exchange chromatography gel based on their differential surface charge 
in function of pH and ionic strength of the gel equilibration buffer. The buffer negatively charges 
the host blood cells which are subsequently adsorbed onto the anion-exchange column, while 
the neutral or positively charged trypanosomes are eluted, retaining their viability (Lanham & 
Godfrey 1970; Lumsden et al. 1979). Trypanosomes that are eluted from the gel are taken up in a 
clear glass or plastic collector tube that is centrifuged at low speed (about 1,800 g) for 10 minutes 
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to concentrate the parasites at the bottom of the tube where the trypanosomes can be 
microscopically observed under low magnification (10x10). Given that surface charges differ 
between species of Salivarian trypanosomes, and that the negative charge on erythrocytes also 
varies with mammalian species, the mAECT buffer has to be adapted in function of the host and 
the expected trypanosome species (Lanham & Godfrey 1970; Seaman & Uhlenbruck 1963). An 
improved model of mAECT column and collector tube has an analytical sensitivity of <30 
trypanosomes/ml), is robust and avoids the need to mount the collector tube in water for 
microscopic examination (Büscher et al. 2009). mAECT is usually conducted on 0.5 ml of blood 
but prior centrifugation of a larger volume of blood (up to 5 ml) and loading the buffy coat on the 
mAECT column can lower the detection limit to 10 trypanosomes⁄ml (Camara et al. 2010). The 
mAECT is the most sensitive parasite detection technique with an analytical sensitivity that is 
similar or higher than of most molecular diagnostics for African trypanosomiasis but works only 
well on T. brucei, T. evansi and T. equiperdum. It is less performant for T. vivax and T. congolense 
(Büscher 2014).  
9.3. Antigen detection serological tests 
Attempts to develop antigen detection tests for African trypanosomoses have been 
undertaken by many research groups but none has resulted in a diagnostic test (Liu & Pearson 
1987; Nantulya & Lindqvist 1989; Olaho-Mukani et al. 1993; Kashiwazaki et al. 1994; Nantulya 
1994). The major obstacles in the development of antigen detecting tests are: 1° universal VSG 
capturing antibodies are difficult to design, 2° concentrations of circulating parasite antigens are 
too low to be detectable with the current diagnostic test formats and 3° the host immune system 
generates antibodies against most antigens, causing the formation of immune complexes and 
hampering the capturing of these antigens. 
Nanobodies (Nbs) are single-domain heavy chain camel antibodies with a molecular weight of 
15 kDa and have high affinity for their targets and the ability to recognize cryptic epitopes that 
are not easily accessed by classical antibodies. They are expected to bring new insight in 
development of antigen detecting diagnostic tools (Büscher 2014; Magez & Radwanska 2009). 
Anti-VSG Nbs were generated that recognize T. evansi (Saerens et al. 2008) and Nbs developed 
against the paraflagellar rod protein of T. evansi recognized homologues in T. brucei, T. 
congolense and T. vivax, indicating their potential use for the development of a diagnostic tool 
for AAT (Obishakin et al. 2014). 
9.4. Antibody detecting serological tests 
All infections with pathogenic trypanosomes induce high levels of antibodies, both specific 
and non-specific. As a consequence, detection of trypanosome specific antibodies in a host can 
be exploited for diagnostic purposes. Although very useful, serodiagnosis based on antibody 
detection has some shortcomings, for example it cannot differentiate between present and past 
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infection because trypanosome-specific antibodies can remain detectable in the circulation for 
months or even years after cure. Also, antibodies become detectable only after a couple of weeks 
of infection. Furthermore, antibodies due to other infections may cross react with trypanosome 
derived antigens used in a serodiagnostic test (Büscher 2014; Desquesnes et al. 2007; Nguyen et 
al. 2014; Van den Bossche et al. 2000). The most successful antibody detection tests for surra are 
based on a particular VAT of T. evansi, RoTat 1.2. A VAT is defined by very specific epitopes of the 
VSG that are exposed on the surface of a living trypanosome. Some VATs, like RoTat 1.2 are 
expressed early during infection by the majority if not all the different strains within a 
trypanosome taxon and therefore are called predominant (Büscher 2014; Van Meirvenne et al. 
1995). The VAT RoTat 1.2 has been cloned from a T. evansi strain, isolated in 1982 from a water 
buffalo in Indonesia (Bajyana Songa & Hamers 1988). The RoTaT 1.2 VAT is expressed by most T. 
evansi strains collected from over the world, except by T. evansi type B and some T. evansi type A 
strains that do not express the RoTat 1.2 VSG gene (Claes et al. 2004; Ngaira et al. 2005; Ngaira et 
al. 2004; Claes et al. 2003b). Currently, most antibody detection tests make use of native 
antigens but there is an encouraging trend to replace these native antigens by recombinant 
antigens. 
Card Agglutination Test for Trypanosomosis: The CATT/T. evansi is a direct agglutination test 
and is one of the OIE recommended tests for diagnosis of surra. The test makes use of fixed and 
Coomassie stained freeze dried whole trypanosomes of T. evansi VAT RoTat 1.2. Both variable 
and invariable surface antigens take part in the agglutination reaction (Bajyana Songa & Hamers 
1988; OIE 2012). The test kit, which consists of freeze dried antigen, buffer, plastic-test cards, 
spatulas, positive and negative control sera and a rotator, is available from the Applied 
Technology and Production Unit at ITM, Antwerp (Figure 1.9). In its lyophilized form, the antigen 
is stable for at least two years at 2–8°C. The test can be performed on a drop of whole blood or 
on diluted serum or plasma. Specimens are tested by mixing 25 µl of sample with one drop of 
reconstituted antigen on a test zone of the test card. After 5 minutes rotation at 70 rpm, the 
result can be scored. When agglutionation is visible, the test is considered positive. CATT/T. 
evansi is suitable for detection of early as well as late infections with a high positive predictive 
value (OIE 2012). CATT/T. evansi is intended for screening of plain blood or minimally diluted 
plasma or serum and therefore inevitably is prone to false positive results. Its accuracy is best in 
situations with relatively high disease prevalence (high negative predictive value) (Büscher 2014). 
Figure 1.9: CATT/T. evansi kit and agglutination reaction on the plastic card. 
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Enzyme linked immunosorbent assay: ELISA/T.evansi exists in two forms that are 
recommended by OIE. The first uses purified RoTat 1.2 VSG (Verloo et al. 2000). Since ELISA is 
performed on highly diluted plasma or serum and since it uses a purified antigen, its intrinsic 
specificity is higher than CATT/T.evansi. ELISA is restricted to well equipped laboratories with 
regular supply of electricity and pure water and needs host-specific conjugates. For bovines, the 
use of monospecific anti-IgG conjugates is generally recommended. When specific conjugates are 
not available, non-specific proteins able to bind to the Fc fragment of immunoglobulins, such as 
protein A, can be used. Protein A conjugate has been validated for use in camels and works also 
well with horse specimens (OIE 2012; Desquesnes et al. 2009). A second variant of ELISA is based 
on crude water soluble extract of a non-cloned strain of T. evansi. It has the advantage that in 
principle it can detect T. evansi infections with strains that do not express RoTat 1.2. However, it 
has been shown to cross-react with other infections such as T. cruzi and therefore is less specific 
than the ELISA with purified RoTat 1.2 VSG (Desquesnes et al. 2007). 
Indirect immunofluorescent antibody test (IFAT): This test is based on the reaction of 
antibodies in the test specimen (blood, serum, plasma) with intact trypanosome, preferably a 
cloned population of T. evansi RoTat 1.2 grown in mice, that are fixed on a a microscope slide. 
Antibodies that bind to these trypanosomes are detected with a species specific fluorescently 
labeled conjugate (Katende et al. 1987). In general, monospecific anti-IgG (gamma-chain) 
conjugates give the most specific results (OIE 2012). Compared with the CATT, IFAT is more 
sensitive but specificity is lower (Luckins 1992; Dia et al. 1997b). It requires a fluorescence 
microscope and usually, the antigen preparation is not standardized (Nantulya 1990). 
Reproducibility of the test has sometimes been questioned. For these reasons, ELISA is a more 
advisable laboratory technique (Ferenc et al. 1990).  
Latex agglutination test: The LATEX/T. evansi is a rapid indirect agglutination test in which the 
antigen consists of soluble purified RoTat 1.2 VSG covalently coupled to microscopic latex 
particles. The reagent is stabilized by lyophilisation and rehydrated with deionized water before 
use. As for CATT/T.evansi, the test is performed by mixing one drop of antigen with 25 µl of 
diluted plasma or serum on a plastic card and let it react for 5 min on a rotator at 70 rpm (Verloo 
et al. 2000). 
Immunochromatographic test (ICT): ICTs, usually in the form of a lateral flow device, have 
some major advantages over other serological tests formats that make them genuine rapid 
diagnostic tests (RDT) applicable in field conditions without any laboratory facility. RDTs are 
supposed to fulfil the ASSURED criteria: Affordable, Sensitive, Specific, User-friendly (minimal 
manipulations, easy readout), Rapid and Robust (readout within <30 min, stable at ambient 
temperature), Equipment free and Deliverable to the end user (Peeling et al. 2006; Mabey et al. 
2004). Another advantage of lateral flow tests that is of particular importance in AAT, is their 
design that allows to detect antibodies without the need of host species-specific or Ig class-
specific conjugates. Thus, as for direct agglutination and inhibition test formats, the same device 
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can be used for testing bovine, camel, horse, etc. (Büscher 2014). For surra, only one ICT is 
commercialized, the Surra Sero-K-Set (Coris BioConcept, Belgium) (Rogé et al. 2013). A typical 
antibody detection lateral flow ICT contains a sample application pad (made of cellulose and/or 
glass fiber that may or may not function as a filter to retain the blood cells), a conjugate pad (the 
place where labeled antigen-conjugate is dispensed), a nitrocellulose membrane with antigen 
and antibody spotted on respectively the test and control line and an adsorbent pad (works as 
sink at the end of the strip) (Sharma et al. 2015). As an example, the architecture of the Surra 
Sero-K-Set is represented in Figure 1.10.  
Immune trypanolysis test (TL): This test requires the growth of trypanosomes in rodents, is 
costly and is only performed at the OIE Reference Laboratory for Surra at ITM, Antwerp (OIE 
2012). TL makes use of living cloned populations of T. evansi, all expressing the same VAT RoTat 
1.2. When incubated with a specimen that contains RoTat 1.2-specific antibodies and with guinea 
pig serum as complement source, the trypanosomes will be destroyed by antibody-mediated 
complement lysis (Van Meirvenne et al. 1995). The principle of TL is represented in Figure 1.11. A 
serum or plasma sample is considered positive for the presence of anti-RoTat 1.2 antibodies 
when at least 50% of the trypanosomes are lysed after 90 minutes incubation. TL with T. evansi 
RoTat 1.2 is considered 100% specific since the only epitopes at the surface of the living 
trypanosomes that are available for reaction with the host antibodies are the VAT specific 
epitopes. This is contrasting with CATT, LATEX, ICT, ELISA and IFAT where other, cross reacting 
epitopes can react with non-trypanosome specific antibodies in a test sample (Verloo et al. 
2000). The major shortcoming of TL is that it will not detect infections with T. evansi type B since 
this type does not express RoTat 1.2 VSG. 
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POSITIVE TEST 
NEGATIVE TEST 
15 minutes 
Figure 1.10: Surra Sero-K-SeT: architecture, adding blood and chase buffer and readout 
of a positive and negative sample. 
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9.5. Molecular diagnosis 
To overcome the limitations of microscopical analysis, molecular diagnostics have been 
introduced. For reasons of complexity and technical requirements, molecular dignostics are not 
used in routine diagnosis in most AAT endemic countries. The trypanosome genomic material 
consists of nuclear and kinetoplastid DNA (kDNA). The nucleus contains three types of 
chromosomes, (a) megabase chromosomes (1–6 Mb), (b) intermediate chromosomes (200–900 
kb) and (c) minichromosomes (50–150 kb) (El-Sayed et al. 2000). Detection of RNA is the best 
surrogate for detection of living parasites since DNA of dead trypanosomes can remain in the 
circulation for a couple of days. On the other hand, RNA rapidly degrades thus making proper 
specimen processing more delicate. DNA detection tests are based on the amplification of a 
variety of coding and non-coding sequences of genomic or kinetoplast DNA, including highly and 
medium repetitive sequences as well as single copy sequences (Büscher 2014). For sensitivity 
reasons, multicopy genes are preferred over single copy genes (Deborggraeve & Büscher 2012; 
Desquesnes et al. 2001). Non-coding sequences for which PCRs are developed are satellite DNA, 
Figure 1.11: Principle of the immune trypanolysis test. (A) Live cloned T. evansi parasites, all 
expressing RoTat 1.2 VSG, are used as source of antigen; (B) RoTat 1.2VAT-specific IgG 
and/or IgM bind to the N-terminal epitope of the VSG coat; (C) Guinea pig serum 
complement is activated by the Fc part of the antibody in the immune complexes; (D) In the 
absence of VAT specific antibodies, trypanosomes remain intact; (E) Trypanosomes are 
destroyed by antibody–mediated complement lysis. Adapted from Engstler (Engstler et al. 
2007). 
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internal transcribed sequences (ITS1 and ITS2) and repetitive insertion mobile elements (RIME). 
The interest of these non-coding sequences lies in their usually high copy number conferring high 
analytical sensitivity but with the consequence that they are more prone to contamination during 
specimen collection or processing (Desquesnes et al. 2001; Thekisoe et al. 2007). An overview of 
molecular test for diagnosis of T. evansi infection is presented in Table 1.2.  
Ribosomal DNA genes occur in multiple copies in tandem arrays. They are made up of 
transcriptional units (TU) separated by non-transcribed spacers (NTS). The TU consists of an 18S 
ribosomal subunit, an internal transcribed spacer 1 (ITS-1), a 5.8S ribosomal subunit, an ITS-2 and 
a 28S ribosomal subunit (Desquesnes & Dávila 2002). In animal trypanosomosis where mixed 
infections can occur, PCRs that allow discrimination of the trypanosome species in one single run 
and in the same specimen have special interest (Büscher 2014). The ITS1 with a copy number of 
100-200 has a variable length depending on the Kinetoplastida species, but is presumed to be 
constant within a species (Desquesnes et al. 2001). Several variants of PCRs that target the ITS1 
sequence do exist and recently, primers sequences have been modified to improve sensitivity 
(Fikru et al. 2012). Unfortunately, the ITS1 PCR assays are prone to non-specific amplification, 
particularly with bovine blood (Fikru et al. 2014). Therefore, a “Touchdown” PCR approach, which 
employs more stringent primer-template hybridisation temperatures, was introduced (Tran et al. 
2014). In Touchdown PCR, the annealing temperature during the first PCR cycles is well above the 
predicted optimal annealing temperature of the primers thus favouring the amplification of the 
specific target sequence while in the following PCR cycles, the annealing temperature is gradually 
lowered to more permissive temperatures (Don et al. 1991; Korbie & Mattick 2008). The 18S-
PCR-RFLP, a pan-trypanosome PCR followed by cleavage of the amplicons with two restriction 
enzymes (Msp1 and Eco571), generates fragment profiles that are characteristic for T. congolense 
(including sub group differentiation), T. vivax, Trypanozoon and T. theileri (Geysen et al. 2003). 
The TBR1/2 PCR amplifies minichromosome satellite repetitive sequences and is considered the 
gold standard for detection of Trypanozoon DNA and allows detection of as little as 1–5 
trypanosomes/ml of blood (OIE 2012; Masiga et al. 1992).  
With the objective to develop a specific PCR test that would be able to distinguish T. evansi 
from the other members of the Trypanozoon subgenus, a PCR targeting the RoTat 1.2 VSG gene 
was proposed (Urakawa et al. 2001). Extended evaluation on a large collection of Trypanozoon 
taxa with this PCR showed a lower analytical sensitivity of 10 trypanosomes per ml of blood. With 
this PCR, Claes and co-workers were able to show that most T. equiperdum isolates, except BoTat 
1.1 and OVI, are in fact misclassified T. evansi strains (Claes et al. 2004). Since the RoTat 1.2 gene 
is absent T. evansi type B, the RoTat 1.2 specific PCR will not be able to detect infections with this 
taxon (Ngaira et al. 2004; Ngaira et al. 2005; Claes et al. 2004). For diagnosis and identification of 
T. evansi type B infections, primers targeting type B specific minicircle kDNA sequences and JN 
2118Hu VSG have been descried (Njiru et al. 2006; Ngaira et al. 2005). As an alternative to the 
complex PCR tests requiring temperature cycling, the loop-mediated isothermal amplification 
(LAMP) of DNA has been introduced (Njiru 2012). For diagnosis of AAT, LAMP tests targeting VSG 
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RoTat 1.2, VSG JN 2118Hu and RIME have been developed (Njiru et al. 2008; Njiru et al. 2010; 
Thekisoe et al. 2007; Kuboki et al. 2003).  
The diagnostic sensitivity of a PCR is dependent on the initial amount of template DNA and is 
therefore proportional to the parasitaemia in a blood or tissue specimen (OIE 2012). Moreover, 
results obtained in molecular diagnostics are influenced by techniques for specimen collection, 
storage and DNA extraction. To overcome the usual challenges of low parasitaemia in AAT, 
collection of larger volumes of blood (0.2-0.8 ml) or of the buffy coat obtained after 
centrifugation of blood and stored in DNA stabilisation buffers containing guanidinium 
hydrochloride and EDTA, is recommended. These buffers allow to store the specimens for 
months at ambient temperature and are compatible with most of the commercial DNA extraction 
kits (Deborggraeve et al. 2011; De Winne et al. 2014).  
For reference molecular diagnosis, it is necessary to check the quality of the DNA extracted 
from a specimen and the absence of polymerase inhibitors. Therefore, trypanosome specific 
PCRs should be accompanied by a mammalian cytochrome B-specific PCR (Kocher et al. 1989).  
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Table 1.2: Molecular tests for diagnosis of T. evansi infection in animals. 
Specificity  Target  Primers Primer sequence (5’-3’) Amplicon size 
(bp) 
Referenc
e  
Trypanosoma ITS1 Kin 1 
Kin 2 
GCG TTC AAA GAT TGG GCA AT 
CGC CCG AAA GTT CAC C 
Trypanozoon 
(535), T. vivax 
(307), T. 
congolense (671, 
754), T. theileri 
(454), 
(Desques
nes et al. 
2001) 
Trypanosoma ITS1 forward 
reverse 
TGTAGGTGAACCTGCAGCTGGATC 
CCAAGTCATCCATCGCGACACGTT 
Trypanozoon 
(450), T. vivax 
(150), T. 
congolense 
Savannah (650), 
T. theileiri (350) 
(Fikru et 
al. 2012) 
Trypanosoma ITS1 forward 
reverse 
TGT AGG TGA ACC TGC AGC TGGATCT 
CCA AGT CAT CCA TCG CGA CAC GT 
Trypanozoon 
(391-393), T. vivax 
(165), T. 
congolense 
Savanna (612), T. 
theileri (300) 
(Tran et 
al. 2014) 
Trypanosoma Ssu-rDNA 18ST nF2 
18ST nF3 
18ST nR2 
CAACGATGACACCCATGAATTGGGGA 
TGCGCGACCAATAATTGCAATAC 
GTGTCTTGTTCTCACTGACATTGTAGTG 
Restriction 
pattern 
(Geysen 
et al. 
2003) 
Trypanozoon Minichrom
osome 
satellite 
repetitive 
sequence 
TBR1 
TBR2 
GAATATTAAACAATGCGCAG 
CCATTTATTAGCTTTGTTGC 
164 (Masiga 
et al. 
1992) 
T. evansi  
type A 
RoTat 1.2 
VSG 
ILO7957 
ILO8091 
GCC ACC ACG GCG AAA GAC 
TAA TCA GTG TGG TGT GC 
488 (Urakawa 
et al. 
2001) 
T. evansi  
type A 
RoTat 1.2 
VSG 
forward 
reverse 
GCG GGG TGT TTA AAG CAA TA 
ATT AGT GCT GCG TGT GTT CG 
205 (Claes et 
al. 2004) 
T. evansi  
type A 
RoTat 1.2 
VSG 
FIP 
 
BIP 
 
F3 
B3 
TTCGATCGCTGCGAAGTGCGTCTGGAA
GCCATTGTGCG 
AAGCTCTTGATTTACGCGGCGGGCTGC
TAACCCTCTTGCTG 
GCCGCCAATGTAGCTCTT 
CCGCTGCTCGTATGTGTC 
200 (Thekisoe 
et al. 
2007) 
T. evansi  
type B 
minicircle  EVAB1 
EVAB2 
CACAGTCCGAGAGATAGAG 
CTGTACTCTACATCTACCTC 
436 (Njiru et 
al. 2006) 
T. evansi  
type B 
VSG JN 
2118Hu 
forward 
reverse 
TTCTACCAACTGACGGAGCG 
TAGCTCCGGATGCATCGGT 
273 (Ngaira 
et al. 
2005) 
T. evansi  
type B 
VSG JN 
2118Hu 
TeB-F3 
TeB-B3 
TeB-biotin 
FIP 
TeB-BIP 
 
TeB-LF 
TeB-LB 
TeB-FITC 
CCAATCAAAGACGAGCGG 
TGGTTTGTGAGGCCGCAG 
CGGATGCATCGGTGATGCAATCACTAC
TGCATCAAGGGAAGC 
ATCCAGCACCTCGGAACAGCTCTCGGC
AACCAGATCGG 
GTTCACGTGCCTCCGCTTC 
ACGTAGCGGGAAAATACGC 
CTATCCTAAAAGAAGCTGGAG 
171 (Njiru et 
al. 2010) 
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10. Recombinant expression of T. evansi derived antigens for diagnostic 
purposes 
As mentioned above, there is a successful tendency to replace native antigens by 
recombinant antigens in the serological diagnostic tests for surra. Several expression systems can 
be used for the production of recombinant proteins. Selection of the expression system depends 
mainly on considerations of development and running cost, yield, and easiness of downstream 
processing, and necessity of correct glycosylation (Anné et al. 2014). The hosts commonly been 
used for the expression of T. evansi proteins are Escherichia coli, Pichia pastoris, and Spodoptera 
frugiperda (Nguyen et al. 2014; Tran et al. 2009; Rogé et al. 2013; Lejon et al. 2005; Urakawa et 
al. 2001).  
10.1. Escherichia coli (E. coli) 
The main advantages of using E. coli as heterologous protein expression host are its fast 
growth kinetics with easily achievable high cell density cultures, its low requirements for the 
growth median and its fast and easy constituve transformation with exogenous DNA (Rosano & 
Ceccarelli 2014). The Origami E. coli strains (Novagene, USA) have mutations in both the 
thioredoxin reductase (trxB) and glutathione reductase (gor) genes which enhance disulfide bond 
formation. The Rosetta and Rosetta 2 E. coli strains are designed to enhance expression of 
eukaryotic proteins that contain codons rarely used in E. coli. The original Rosetta strain supplies 
tRNAs for the codons AUA, AGG, AGA, CUA, CCC, and GGA on a compatible chloramphenicol-
resistant plasmid, pRARE. The Rosetta 2 strain supplies a seventh rare codon (CGG). The tRNA 
genes are driven by their native promoters (Novagen, USA).  
In most E. coli hosts, heterologous proteins are usually produced in the periplasm, which 
facilitates isolation of the proteins from this compartment and, more importantly, in the oxidizing 
environment of the periplasm the disulfide bond formation (Dsb) system catalyzes the formation 
of disulfide bonds. In order to reach the periplasm, the heterologous proteins are equipped with 
an N-terminal signal sequence that guides them to the Sec-translocon, which is a protein-
conducting channel in the cytoplasmic membrane (Schlegel et al. 2013). Moreover, the pET-
22b(+) expression vector has a signal sequence (pelB leader) for secretion of expressed protein to 
the periplasm; a C-terminal His-Tag sequence for affinity purification; f1 origin of replication and 
confers ampicillin resistance to host cells (Novagen, USA). The main drawbacks of using E. coli as 
expression system are the absence of post-translational modifications, like N-linked glycosylation, 
that may play a role in stability, functionality and antigenicity of eukaryotic proteins. 
Furthermore, the bacteria is enveloped by an outer membrane consisting of lipopolysaccharides 
which is a source of endotoxins and hinders the secretion of proteins into the extracellular 
environment often leading to accumulation of the expressed proteins in the cytoplasm. In these 
insoluble aggregates known as inclusion bodies, proteins are in an inactive conformation and it is 
often difficult to recover them in an active form (Anné et al. 2014). Several T. evansi derived 
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proteins have been successfully expressed in E. coli. For example, the N-terminal extracellular 
domain of ISG75 from LiTat 1.3 T.b. gambiense was expressed in a E. coli Origami strain. The 
recombinant double-tagged (streptavidine and histidine) ISG75 fragment was purified by two-
step affinity chromatography but with low yield (0.5 mg/l). The purified recombinant showed 
definite potential as diagnostic antigen for camels in an ELISA system (Tran et al. 2008; Tran et al. 
2009). Another example is TeGM6-4r that was successfully expressed in a E. coli DH5 strain. The 
purified recombinant protein was tested in ELISA and showed promising diagnostic accuracy 
when tested on T. evansi infected water buffaloes (Nguyen et al. 2014). Also, a VSG fragment, 
expressed in E. coli, showed diagnostic potential in ELISA (Sengupta et al. 2012). 
10.2. Pichia pastoris 
The methylotrophic yeast Pichia (P.) pastoris, is suited to heterologous protein expression of 
either prokaryotic or eukaryotic origins. The advantages of its use are ease of genetic 
manipulation with constitutive expression, high efficiency DNA transformation, high levels of 
protein expression at intra or extracellular level, and the ability to perform eukaryotic protein 
modifications such as glycosylation and disulphide bond formation (Macauley-Patrick et al. 2005). 
However, glycoproteins produced in P. pastoris contain high mannose glycan structures. Those 
structures can hamper downstream processing, might be immunogenic and can cause rapid 
clearance from the circulation (Vervecken et al. 2004). The hypermannosylation can be 
prevented by using the M5 strain of P. pastoris, that has an engineered N-glycosylation pathway 
resulting in homogenous Man5GlcNAc2 N-glycosylation which resembles the predominant Man9-
5GlcNAc2 oligomannose structures in T. brucei (Vervecken et al. 2004; Rogé et al. 2013; Puxbaum 
et al. 2015). The N-terminal part of VSG RoTat 1.2 was recombinantly expressed in the yeast P. 
pastoris with yields up to 20 mg/l of cell culture and high reproducibility and definite diagnostic 
potential in ELISA and ICT format (Rogé et al. 2013). Similarly, the N-terminal fragment of ISG75 
from T. b. gambiense LiTat 1.3 was expressed in a P. pastoris M5 strain. The yield was 10 mg/l cell 
culture. Unfortunately, several shorter degradation products were observed (Rogé et al. 2013). 
This protein degradation didn’t occur when the same gene was recombinantly expressed in E. coli 
(Tran et al. 2008). The recombinant ISG75 fragment purified from P. pastoris showed good 
diagnostic potential in experimentally infected goats but not in naturally infected and control 
camels thus contradicting the results obtained with a similar recombinant ISG75 fragment 
expressed in E. coli (Tran et al. 2008; Tran et al. 2009; Rogé et al. 2013). This example clearly 
illustrates the effect of the expression system on the eventual diagnostic potential of an antigen. 
10.3. Spodoptera frugiperda  
Insect cells like the one from Spodoptera frugiperda, can provide the desired folding and 
disulfide bond formation, as well as oligomerization of a recombinant protein. The disadvantage 
of classical S. frugiperda expression systems is that they are only transiently transfected by a 
virus, in casu a bacculovirus, that contains the gene of interest. The gene of interest is integrated 
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into a nonessential region of the viral genome by homologous recombination, hence large cDNA 
inserts (up to 15 kb) can be accommodated and recombinant virus can be amplified to high titers, 
thereby leading to high-level protein production after infection of insect cells (Ikonomou et al. 
2003). The Spodoptera (S.) frugiperda insect cells have been used for successful production of 
recombinant N-terminal fragments of RoTat 1.2 VSG of T. evansi (Urakawa et al. 2001; Lejon et al. 
2005). With the purified recombinant RoTat 1.2 VSG fragment, an ELISA and a latex agglutination 
test were prepared and both showed acceptable diagnostic accuracy. Unfotunately, the 
expression of the recombinant VSG RoTat 1.2 in S. frugiperda was poorly reproducible and 
attempts to scaling up the production were not successful (Lejon et al. 2005). 
10.4. Leishmania tarentolae 
Recombinant antigens expressed in E. coli are not glycosylated and therefore may miss some 
critical epitopes with diagnostic potential that may be present on glycosylated and correctly 
folded native glycoproteins. In contrast, Leishmania (L.) tarentolae can yield glycosylated 
recombinants that can be engineered to be secreted into the culture medium. L. tarentolae is a 
eukaryotic flagellated unicellular parasite, closely related to T. brucei, and used as a host for 
recombinant protein expression (Breitling et al. 2002). Its ability to produce mammalian like 
complex type N-glycosylation, easy genetic manipulation, straightforward adaptation to large-
scale production, and minimal nutrition requirement makes it an excellent expression host (Basile 
& Peticca 2009; Fritsche et al. 2007). L. tarentolae allows higher levels than other eukaryotes 
(Hacker et al. 2009; Jenkins et al. 2009; Klatt & Konthur 2012). A major advantage of using this 
expression system is that recombinants can either be expressed intracellularly or secreted into 
the culture medium and because L. tarentolae secretes only low levels of endogenous proteins 
and its culture medium. This separation of the heterologous protein from the bulk of cellular 
proteins facilitates purification. Recently, the extracellular domains of ISG65 and VSG LiTat 1.3 
and VSG LiTat 1.5 were successfully expressed in L. tarentolae and showed exceptionally high 
diagnostic accuracy when tested on a panel of reference sera of T.b. gambiense patients and 
endemic controls (Rooney et al. 2015). 
 
  
Objectives and study design 
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1. Background 
In Ethiopia, both cyclically and mechanically transmitted pathogenic Trypanosoma species 
occur. T. evansi infection is widely distributed across the six agro-climatic zones, mainly 
coinciding with the distribution of camels (Dagnatchew 1982; Abebe & Yilma 1996; Abebe 2005). 
In developing countries including Ethiopia, diagnosis of NTTAT makes use of poorly sensitive and 
non-specific diagnostic techniques such as clinical examination and direct microscopic 
examination of blood. Epidemiological studies using T. vivax and T. evansi specific markers have 
only recently been undertaken in Ethiopia (Fikru et al. 2015; Hagos et al. 2009; Hagos et al. 
2010b). Poorly sensitive and specific diagnostics inevitabily lead to underestimation or 
overestimation of the burden of NTTAT and of its impact on livestock production in the country.  
Thus, part of this PhD study is focused on the epidemiology of NTTAT due to T. evansi and T. 
vivax in domestic animals from selected districts of Tigray and Afar regions, both considered as 
tsetse free areas in Ethiopia. 
T. evansi strains from Ethiopia are typically lacking in the cryocollection of the World Animal 
OIE Reference Center for surra at ITM and elsewhere. Furthermore, there are no published 
reports on drug sentivity profiles of T. evansi strains in Ethiopia. 
Thus, part of this PhD study is focused on isolation, phenotypic and genotypic characterization, 
in vitro adaptation and determination of drug sensitivity pattern of T. evansi isolates from 
Ethiopia.  
Accurate diagnosis is crucial for early detection of infections, evaluation of treatment efficacy, 
better understanding of the epidemiology of the disease and for designing appropriate control 
strategies. Conclusive evidence of T. evansi infection relies on detection of the parasite or its DNA 
in the body fluids of infected animals. Unfortunately, parasitological techniques cannot always 
detect ongoing infections as the level of parasitaemia is often low and fluctuating, particularly 
during the chronic stage of the disease. Molecular diagnostic tests are highly appreciated for 
surveillance and research purposes. Sensitive DNA detection tests such as the ITS1 and TBR PCRs 
are not T. evansi specific and will detect also T. brucei and T. equiperdum (Desquesnes et al. 
2001; Masiga & Gibson 1990). T. evansi type A specific RoTat 1.2 PCR and T. evansi type B specific 
kDNA minicircle PCR are available but the latter will not be able to detect akinetoplast T. evansi 
strains that may occur naturally (Claes et al. 2004; Njiru et al. 2006). Moreover, the diagnostic 
sensitivity of molecular diagnostics is also hampered by the often low and fluctuating 
parasitaemia in T. evansi infections. For infection with undetectable parasite loads, suspicion of 
surra can be obtained with antibody detection tests. 
For antibody detection, the most widely used OIE recommended test is the CATT/T. evansi. 
The antigen in this test consists mainly of a T. evansi specific VSG as antigen (in casu RoTat 1.2) 
(OIE 2012). Production of CATT/T. evansi requires mass culture of T. evansi in laboratory rodents. 
The use of whole trypanosomes and complex antigen molecules in the CATT and similar antibody 
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tests gives rise to cross-reactivity with non T. evansi specific antibodies resulting in decreased 
test specificity (Büscher 2014; Desquesnes et al. 2007). To overcome these challenges, ITM and 
Coris BioConcept (Gembloux, Belgium) developed the Surra Sero K-SeT, that makes use of 
recombinant VSG RoTat 1.2 expressed in P. pastoris. 
Thus, part of this study is focused on the diagnostic evaluation of the Surra Sero-K- SeT on 
large serum collections. 
2. General objective 
The general objective was to study the epidemiology, diversity and alternative diagnostics for 
NTTAT in Ethiopia 
3. Specific objectives 
 Assess the epidemiology of NTTAT in domestic animals from Tigray and Afar regions of 
Ethiopia (Chapter 3); 
 Isolate, and phenotypically and genotypically characterize Ethiopian T. evansi stocks 
(Chapter 4); 
 Adapt to in vitro culture and determine in vitro drug senstivity profiles of Ethiopian T. 
evansi stocks (Chapter 4); 
 Evaluate the diagnostic accuracy of Surra Sero-K-SeT, the first RDT for serodiagnosis of 
surra (Chapter 5). 
4. Study design 
This study consists of both field and laboratory based activities that were conducted partly in 
Ethiopia and partly in Belgium. Field activities took place in 4 districts of Tigray region with crop-
livestock mixed agriculture and in 5 districts of Afar region, in one of the main pastoral areas of 
Ethiopia. After ethical clearance of the study protocols, blood specimens were collected from the 
jugular vein of 1811 randomly selected animals (754 dromedary camels, 493 cattle, 264 goats, 
181 sheep, 84 donkeys, 25 horses, and 10 mules). Parasitological examination and PCV recording 
was performed by mHCT of 4 capillary tubes. Animals with detectable trypanosomes were 
treated with appropriate doses of cymelarsan, DA or ISM. The rest of the blood was centrifuged 
to collect plasma for antibody detection with CATT/T. evansi. Part of the plasma was spotted on 
Whatman 4 filter paper for testing in RoTat 1.2 TL, the gold standard test for serodiagnosis of 
surra (Bajyana Songa & Hamers 1988; Verloo et al. 2001; OIE 2012). The corresponding buffy coat 
specimens were preserved in guanidium-EDTA buffer for molecular analysis. Furthermore, of all 
parasitologically positive animals, a copy of the buffy coat was cryopreserved in liquid nitrogen 
for later isolation of the trypanosome strain by inoculation of Swiss albino mice at the College of 
Veterinary Medicine, Mekelle University (Pyana et al. 2011). Stabilate copies were imported to 
ITM in Belgium and expanded in mice for genetic characterisation, in vitro adaptation and drug 
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sensitivity profiling. DNA extraction from the stored buffy coats followed by testing with species-
specific PCRs was also conducted in ITM. RoTat 1.2 PCR, EVAB PCR and TvPRAC PCR were used to 
identify respectively T. evansi type A, T. evansi type B and T. vivax (Claes et al. 2004; Njiru et al. 
2006; Fikru et al. 2014). To addresses some limitations of current molecular markers for T. evansi 
genotyping, the polymorphism within the F1-ATP synthase subunit gene was investigated. For 
the evaluation of the Surra Sero-K-SeT, a large collection of sera originating from diverse 
domestic animal species and from diverse geographical origin was available in the cryobank of 
the OIE Reference Center for Surra at ITM.  
The results of the PhD study are presented as separate chapters corresponding with 
published manuscripts (Chapters 3 to 5), followed by a general discussion and perspectives for 
further research (Chapter 6). 
 
 Epidemiology of Trypanosoma 
evansi and Trypanosoma vivax in 
domestic animals from selected 
districts of Tigray and Afar regions, 
Northern Ethiopia 
Hadush Birhanu, Regassa Fikru, Mussa Said, Weldu Kidane, Tadesse 
Gebrehiwot, Ashenafi Hagos, Tola Alemu, Tesfaye Dawit, Berkvens Dirk, 
Goddeeris Bruno Maria, Büscher Philippe 
Adapted from Parasites and Vectors 2015, 8: 212 DOI: 10.1186/s13071-015-0818-1 
Author contributions: HB and PB conceived this study, generated, analysed and interpreted 
the data and prepared the manuscript. BG and GT contributed for the conception of the study 
and provided technical and infrastructural support to the field and laboratory work in 
Ethiopia. HA, RF, KW and AT participated in the field and part of the laboratory work. DB and 
SM performed the statistical analysis on the data. DT designed the map of the study areas. All 
authors revised and approved the final manuscript. 
Chapter 3: Epidemiology of T. evansi and T. vivax in Northern Ethiopia - 65 
1. Abstract 
African animal trypanosomosis (AAT), transmitted cyclically by tsetse flies or mechanically by 
other biting flies, cause serious inflictions to livestock health. This study investigates the extent of 
non-tsetse transmitted animal trypanosomosis (NTTAT) by Trypanosoma (T.) evansi and T. vivax 
in domestic animals in the tsetse-free regions of Northern Ethiopia, Afar and Tigray.  
A cross sectional study was conducted on 754 dromedary camels, 493 cattle, 264 goats, 181 
sheep, 84 donkeys, 25 horses and 10 mules. Microhaematocrit centrifugation technique was 
used as parasitological test. Plasma was collected for serodiagnosis with CATT/T. evansi and 
RoTat 1.2 immune trypanolysis (TL) while buffy coat specimens were collected for molecular 
diagnosis with T. evansi type A specific RoTat 1.2 PCR, T. evansi type B specific EVAB PCR and T. 
vivax specific TvPRAC PCR. 
The parasitological prevalence was 4.7% in Tigray and 2.7% in Afar and significantly higher 
(z=2.53, p=0.011) in cattle (7.3%) than in the other hosts. Seroprevalence in CATT/T. evansi was 
24.6% in Tigray and 13.9% in Afar and was significantly higher (z=9.39, p<0.001) in cattle (37.3%) 
than in the other hosts. On the other hand, seroprevalence assessed by TL was only 1.9% 
suggesting cross reaction of CATT/T. evansi with T. vivax or other trypanosome infections. 
Molecular prevalence of T. evansi type A was 8.0% in Tigray and in Afar and varied from 28.0% in 
horses to 2.2% in sheep. It was also significantly higher (p<0.001) in camel (11.7 %) than in cattle 
(6.1%), donkey (6%), goat (3.8%), and sheep (2.2%). Four camels were positive for T. evansi type 
B. Molecular prevalence of T. vivax was 3.0% and was similar in Tigray and Afar. It didn't differ 
significantly among the host species except that it was not detected in horses and mules. 
NTTAT caused by T. vivax and T. evansi, is an important threat to animal health in Tigray and 
Afar. For the first time, we confirm the presence of T. evansi type B in Ethiopian camels. 
Unexplained results obtained with the current diagnostic tests in bovines warrant particular 
efforts to isolate and characterise trypanosome strains that circulate in Northern Ethiopia. 
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2. Introduction 
African trypanosomosis is one of the most important animal diseases encountered in all agro-
ecological zones of the country and hinders the efforts made for food self-sufficiency (Abebe 
2005). African trypanosomosis is a general term for infections in many different hosts (man and 
his domestic animals and wild animals) caused by various trypanosome species with 
Trypanosoma (T.) brucei, T. congolense, T. vivax, T. evansi and T. equiperdum as the most 
important ones (Hoare 1972). African animal trypanosomoses (AAT) cause serious inflictions to 
the health of livestock ranging from anaemia, loss of condition and emaciation, abortion, death 
etc. (Da Silva et al. 2011; Van den Bossche 2000; Da Silva et al. 2010; Da Silva et al. 2010; Losos 
1986; Gutiérrez et al. 2005; Löhr et al. 1986). The trypanosomes responsible for AAT in Ethiopia 
are T. vivax, T. congolense, T. brucei, T. evansi and T. equiperdum (Dagnatchew 1982).  
T. congolense and T. brucei are exclusively found in the tsetse-infested areas of Ethiopia while 
T. evansi and T. equiperdum occur in the tsetse-free areas. T. vivax can be found in both tsetse-
infested and tsetse-free areas except in the highlands, which are >2500 meter above sea level 
(Dagnatchew 1982; Abebe & Yilma 1996). 
T. evansi has multiple means of transmission of which mechanical transmission by biting 
insects is the most important in camels and other large animals. Other transmission routes such 
as the bite of vampire bats and oral transmission in carnivores has been documented (Hoare 
1972; Raina et al. 1985; Sinha et al. 1971).  
In Ethiopia, T. evansi is widely distributed across the six agro-climatic zones and mainly 
coincides with the distribution of camels (Langridge 1976). Trypanosomosis due to T. evansi 
(surra) is the number one protozoan disease of camels. Horses are also very susceptible. Infected 
camels and equines may die within 3 months. Moreover, cattle, buffalo, pigs, goat and sheep 
infected with T. evansi suffer from immunosuppression, resulting in increased susceptibility to 
other diseases or in vaccination failure (Desquesnes et al. 2013b; Desquesnes et al. 2013a; 
Gutiérrez et al. 2006b). For example, experimental infections in buffalo and pigs have shown 
reduced cellular and humoral responses after vaccination against classical swine fever and 
Pasteurella multicoda in T. evansi infected animals compared to uninfected animals (Holland et 
al. 2003; Singla et al. 2010; Holland et al. 2001).  
Despite the considerable number of epidemiological studies carried out in Ethiopia on cattle 
and camel trypanosomosis in parts of Southern Nations, Nationalities, and Peoples' Region 
(SNNPR), and in Oromiya and Amhara regions, information from Tigray and pastoral areas of 
Afar, belonging to the tsetse-free areas of Ethiopia, is scanty (Sinshaw et al. 2006; Codjia et al. 
1993; Rowlands et al. 1993; Hagos et al. 2010b; Miruk et al. 2008; Cherenet et al. 2006; Fikru et 
al. 2012; Hagos et al. 2009). In addition, due to limited logistic resources and poor diagnostic 
facilities, the exact burden and socioeconomic impact of AAT is probably underestimated and 
information on prevailing trypanosome species and affected hosts remains inaccurate and 
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fragmented (Aradaib & Majid 2006; Büscher 2001; Fikru et al. 2012). Therefore, this study was 
designed to investigate the distribution of T. evansi and T. vivax in selected districts of Tigray and 
in pastoral areas of Afar.  
Diagnosis of AAT is often based on clinical suspicion. Parasite detection is cumbersome in 
many cases where only low numbers of trypanosomes circulate in the host body fluids (Büscher 
2001). Techniques for concentration of the trypanosomes by centrifugation of a blood specimen 
can be applied. After centrifugation of some blood in a capillary tube, the trypanosomes can be 
detected directly under the microscope at the level of the white blood cell layer (the buffy coat) 
(Woo 1969). Where differential diagnosis is needed, the capillary tube can be broken and the 
buffy coat spread on a microscope slide for examination according to (Murray et al. 1977). A 
more sensitive technique is the mini Anion Exchange Centrifugation Technique (mAECT) but the 
technique works best with T. brucei and T. evansi and has poor diagnostic potential for T. 
congolense and T. vivax (Lanham & Godfrey 1970; Lumsden et al. 1979; Zillmann et al. 1996; 
Büscher et al. 2009).  
As an alternative to parasitological diagnosis, molecular diagnostic tests have been 
developed. For the diagnosis of surra, the PCR RoTat 1.2 and Q-PCR RoTat 1.2 are specific for T. 
evansi type A and PCR EVAB is specific for T. evansi type B (Njiru et al. 2006; Claes et al. 2004; 
Konnai et al. 2009). For the molecular diagnosis of T. vivax, the ITS-1 PCR and proline racemase 
PCR (TvPRAC PCR) can be employed (Desquesnes et al. 2001; Fikru et al. 2014). Neither 
parasitological nor molecular tests are 100% sensitive, due to the often low number of circulating 
parasites.  
Serological tests are able to reveal ongoing or past trypanosome infections based on antibody 
detection. For surra, the most specific antibody detection tests make use of the T. evansi specific 
variant surface glycoprotein (VSG) RoTat 1.2 as antigen. The CATT/T. evansi is such a test in the 
form of a direct agglutination test and is the only rapid diagnostic test for surra that is 
recommended by the World Organization for Animal Health (OIE 2012; Bajyana Songa & Hamers 
1988). By virtue of its format as a direct agglutination test, CATT/T. evansi can be applied on any 
host species. Knowledge about the antigenic repertoires of T. vivax is almost nonexistent. Most 
antibody detection tests for T. vivax make use of more or less purified native antigens leaving 
room for aspecific reactions. In regions where T. vivax and T. brucei or T. evansi occur together in 
the same host species, it is almost impossible to identify the infecting trypanosome species at the 
level of circulating antibodies in the host (Büscher 2001; Camargo et al. 2004; Uzcanga et al. 
2004; Uzcanga et al. 2002). Only recently, recombinant T. vivax specific antigens are being 
investigated for their diagnostic potential (Pillay et al. 2013). 
The present study provides data on the epidemiology of AAT in domestic animals in two 
tsetse-free regions of Ethiopia making use of the diagnostic tests presented in Table 3.1. 
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Table 3.1: Some characteristics of the diagnostic tests used in the epidemiological survey. 
 
3. Materials and methods 
Study areas 
The study was conducted in selected districts (weredas) of Tigray and pastoral areas of Afar, 
representing tsetse-free areas of Ethiopia. Tigray region is located in the northern part of 
Ethiopia between longitudes 36°27’ E and 39°59’ E and latitudes 12°15’ N and 14°57’ N (Figure 
3.1). It shares international boundaries with Eritrea and Sudan and regional boundaries with 
Amhara and Afar regions of Ethiopia. Tigray is divided into four zones and 35 weredas (Tassew 
2000). Selected “tabias” or peasant associations from the districts of Raya-Azebo (southern 
zone), Tselemti (northwestern zone) and Kafta-Humera and Tsegede (western zone), were 
included. Afar region, one of the four major pastoral regions in Ethiopia, occupies an area of 
about 270,000 km
2
 and is situated between longitudes 39°34’ E and 42°28’ E and latitudes 8°49’ 
N and 14°30’ N (CSA 2011). The region shares international boundaries with the State of Eritrea 
and Djibouti, as well as regional boundaries with the regions of Tigray, Amhara, Oromia and 
Somali (Figure 3.1). The Afar region consists of 5 administrative zones (sub-regions) (David & 
Thomas 2013). Taking into account the accessibility to the pastoral communities, “kebeles” or 
sampling stations were selected in the districts of Megale (zone 2), Awash Fentale and Amibara 
(zone 3) and Gulina and Yalo (zone 4). 
 
  
Test Accuracy /lower detection limit Target Reference 
mHCT 500 trypanosomes/ml Trypanosomes (Chappuis et al. 
2005) 
CATT/T. evansi sensitivity (73.8-100%), 
specificity (76.9-100%) 
T. evansi  type A (Rogé et al. 2014) 
TL sensitivity (100%) 
specificity (100%) 
T. evansi  type A (Verloo et al. 2000) 
RoTat 1.2 PCR 10 trypanosomes/ml T. evansi  type A (Claes et al. 2004) 
EVAB PCR 1 trypanosome/ml T. evansi  type B (Njiru et al. 2006) 
TvPRAC PCR 500 trypanosomes/ml T. vivax  (Fikru et al. 2014) 
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Figure 3.1: Map of Ethiopia showing study districts in Tigray and Afar regions and tsetse belt 
areas. 
Ethics statement  
The Animal Experimentation Ethics Committee (AEEC) of the Institute of Tropical Medicine, 
Antwerp, Belgium (ITM) advised on the protocol for collection of blood samples from dromedary 
camels, cattle, equines and small ruminants in Ethiopia (EXT2012-1). The standard ethical 
guidelines were also in line with the national guidelines of the Ethiopian Ministry of Livestock and 
Fishery Development and the Institutional Review Board of the Ministry of Science and 
Technology. 
Study design, study animals and specimen collection 
Considering 95% confidence level and average prevalence of 30% (Fikru et al. 2012), the 
number of specimens to collect was planned according to Thrusfield (2007) as 323= (1.96)
2
 x 
Pexp(1-Pexp)/d
2
; where: n = required sample size, d= absolute precision required (d=0.05), Pexp 
= expected prevalence of the disease. A cross sectional study was conducted from February till 
July 2013 on 1811 domestic animals comprising 754 dromedary camels, 493 cattle, 264 goats, 
181 sheep, 84 donkeys, 25 horses and 10 mules. The animals were sampled at watering and 
grazing points and at veterinary clinics where they were brought for accaricide spraying and 
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vaccination. Individual study subjects from willing owners were randomly selected regardless of 
age, gender and body condition (Thrusfield 2007). From each animal, 9 ml of jugular vein blood 
was collected in a heparinised Venosafe tube (Terumo, Leuven, Belgium), labelled with a unique 
code, placed in a coolbox at 4°C and processed as described below. 
Packed cell volume (PCV) and microhaematocrit centrifugation technique (mHCT)  
The microhaematocrit (mHCT) was performed as described by (Woo 1970). Briefly, four 
microhaematocrit capillary tubes were filled with approximately 50 µl of blood from the 
Venosafe tube and stoppered with sealant. After centrifugation at 11,000 g for 5 min, the PCV 
was recorded and the tubes were mounted in a specially designed viewing chamber and 
examined under the microscope at 10x16 magnification for the presence of motile trypanosomes 
at the level of the buffy coat as described by Fikru et al. (2012). Animals with confirmed presence 
of trypanosomes were treated free of charge with 0.25 mg/kg melarsamine hydrochloride 
(cymelarsan) in the case of camels or with 0.5 mg/kg isometamidium chloride (samorin, 
trypamidium) or 7 mg/kg diminazene aceturate (berenil) in the case of ruminants. 
Preparation of plasma and buffy coat specimens 
The blood collected in the heparinised Venosafe tubes was centrifuged for 10 min at 1,500 g 
and plasma was collected with a single use plastic transfer pipette into 2 ml tubes with screwcaps 
(Sarstedt, Nümbrecht, Germany). Plasma was stored at 4 °C until testing for specific antibodies 
with CATT/T. evansi and subsequently frozen at -20 °C. From the remaining blood specimen, 500 
µL of buffy coat layer were collected by means of a micropipette with a filter tip and mixed with 
an equal volume of guanidium EDTA buffer (GEB; 6M guanidium chloride, 0.2 M EDTA, pH 8.0) 
and stored at ambient temperature until DNA extraction (De Winne et al. 2014). Of those animals 
that were parasitologically positive, part of the buffy coat was collected for cryopreservation in 
liquid nitrogen for later isolation of the parasite according to Pyana et al. 2011 (Pyana et al. 
2011). 
CATT/T. evansi 
Detection of T. evansi specific antibodies was carried out by CATT/T. evansi on plasma that 
was prediluted 1:4 in CATT diluent, according to the instructions of the manufacturer (Institute of 
Tropical Medicine, Antwerp, Belgium).  
Immune trypanolysis test for surra 
From each plasma specimen, 30 µl were spotted on Whatman 4 filter paper (Whatman, 
Maidstone, UK) in Ethiopia and shipped to the Institute of Tropical Medicine, Antwerp, Belgium. 
For elution of plasma and test procedures, the protocol developed by Camara and co-workers, 
with modifications, was employed (Camara et al. 2014). Briefly, from each filter paper, two 6 mm 
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diameter disks were punched and placed in a well of a flat bottom microlon microtitre plate 
(Greiner Bio-One, Wemmel, Belgium). Antibodies were eluted overnight at 4 °C in 40 µl of fetal 
bovine serum (FBS) followed by 1 hour on a plate shaker at ambient temperature. Twenty µl of 
the eluted fraction were transferred into a well of a U-bottom polystyrene microtitre plate 
(Sterilin, Newport, UK). Next, T. evansi RoTat 1.2 trypanosomes, grown in a mouse, were diluted 
in ice-cold guinea pig serum (GPS) and kept on ice to obtain a suspension of 5 trypanosomes per 
microscopic field according to the matching method (Herbert & Lumsden 1976). Twenty µl of this 
suspension were added to each well of the microtiter plate with the eluted specimens and 
incubated at ambient temperature for 1 hour. Antibody mediated complement lysis was assessed 
by dispensing 5 µl of the reaction mixture on a microscope slide, covered by a 18 x 18 mm cover 
slip and examination at 25 x 10 magnification under a phase-contrast microscope. Trypanolysis 
was considered positive when at least 50% of the trypanosomes were lysed (Camara et al. 2014). 
DNA extraction 
DNA extraction was performed with the High Pure PCR Product Purification Kit (Roche 
Diagnostics, Mannheim, Germany). Since unexpected clotting of the buffy coat specimens 
preserved in GEB was observed, 200 µl of tissue lysis buffer and 50 µl of proteinase K (Roche 
Diagnostics, Mannheim, Germany) were added to the 1 ml buffy coat-GEB mixture followed by 
digestion for 90 min at 56 °C under constant shaking at 1,000 rpm. Eventually, DNA was extracted 
from 240 µl of this mixture and stored at -20 °C until use. DNA concentrations were measured in 
the Nanodrop ND-1000 UV-Vis spectrophotometer (NanoDrop Technologies, Wilmington, USA) 
or the Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, USA). 
PCR 
All PCR amplifications were carried out in 200 µl thin-wall PCR tubes (ABgene, Epsom, UK) in a 
T3 thermocycler 48 (Biometra, Göttingen, Germany). Amplified products were visualised under 
UV after electrophoresis in a 2% agarose gel at 135 V for 30 minutes and staining with ethidium 
bromide. To check the quality of DNA, a PCR targeting vertebrate cytochrome b was performed 
(Aref et al. 2013; Kocher et al. 1989). To detect T. evansi type A, the RoTat 1.2 PCR was 
conducted (Claes et al. 2004) while the EVAB PCR was used for the detection of T. evansi type B 
(Njiru et al. 2006). Detection of T. vivax was performed by means of TvPRAC PCR (Fikru et al. 
2014). ITS1-PCR was used to test part of the specimen collection for T. congolense, T. theileri and 
Trypanozoon (Desquesnes et al. 2001). Each PCR assay was done in 25 µl reaction volumes with 
12.5 µl HotStar Taq polymerase master mix (Qiagen,Leipzig, Germany) containing 2.5 units 
HotStar Taq DNA polymerase, 1 x PCR buffer with 1.5 mM MgCl2 and 200 µM of each dNTPs, 0.8 
µM of each primer (Biolegio, Amsterdam, Netherlands), 8 µl accugene water (Lonza, Verviers, 
Belgium) and 2.5 µl of template DNA.  
The target genes, primer names and sequences and expected amplicon lengths are 
represented in Table 3.2. Compared to the references cited in the table, some minor changes 
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were made at the level of the polymerase and master mix, the initial denaturation step and the 
numbers of cycles. Cycling conditions for the different PCRs were as follows. Cytochrome B PCR: 
94 °C for 15 min and 35 cycles of 30 sec at 94 °C, 30 sec at 52 °C, 30 sec at 72 °C and final 
extension for 5 min at 72 °C. RoTat 1.2 PCR: 94 °C for 15 min and 40 cycles of 30 sec at 94 °C, 30 
sec at 59 °C, 30 sec at 72 °C and final extension for 5 min at 72 °C. EVAB PCR: 94 °C for 15 min and 
30 cycles of 30 sec at 94 °C, 30 sec at 60 °C, 60 sec at 72 °C and final extension for 1 min at 72 °C. 
TvPRAC PCR: 94 °C for 15 min and 30 cycles of 30 sec at 94 °C, 30 sec at 63 °C, 30 sec at 72 °C and 
final extension for 5 min at 72 °C. ITS-1 PCR: 94 °C for 15 min and 40 cycles of 30 sec at 94 °C, 30 
sec at 60 °C, 30 sec 72 °C and final extension for 5 min at 72 °C. 
 
Table 3.2: Specifications of the PCR assays used in the study.  
Taxon Target gene Primers Primer sequences Amplicon 
length 
Reference 
Vertebrates Cytochrome b L14841 
H15149 
5'-CCATCCAACATCTCAGCATGATGAAA-3' 
5'-GCCCCTCAGAATGATATTTGTCCTCA-3' 
400 bp Adapted from 
(Kocher et al. 
1989) 
T. evansi  
Type A 
VSG RoTat 1.2 RoTat1.2-F  
RoTat1.2-R 
5’-GCGGGGTGTTTAAAGCAATA-3’ 
5’-ATTAGTGCTGCGTGTGTTCG-3’ 
205 bp Adapted from 
(Claes et al. 2004) 
T. evansi  
Type B 
Minicircle EVAB-1 
EVAB-2 
5’-ACAGTCCGAGAGATAGAG-3’ 
5’-CTGTACTCTACATCTACCTC-3’ 
436 bp Adapted from 
(Njiru et al. 2006) 
T. vivax Proline racemase TvPRAC-F  
TvPRAC-R 
5' CGCAAGTGGACCGTTCGCCT- 3' 
5' ACGCGGGGCGAACAGAAGTG-3' 
239 bp Adapted from 
(Fikru et al. 2014) 
Diverse 
Trypanosoma 
species 
ITS-1 ITS-1 F 
ITS-1 R 
 
5’-TGTAGGTGAACCTGCAGCTGGATC-3’ 
5’-CCAAGTCATCCATCGCGACACGTT- 3’ 
T. vivax 150 bp, T. 
theileri 350 bp, 
Trypanozoon 450 
bp, T. congolense 
650 bp 
(Fikru et al. 2012) 
Data analysis 
All data were recorded in Microsoft Excel. STATA /MP 13.1 (StataCorp. 2013) was used for 
statistical analysis. Pearson’s chi- square was used to check the distribution of the sample sizes of 
the different host species within the two regions. Percentages with 95% confidence interval (CI) 
were used to express prevalence. Logistic regression (using a penalised log likelihood if 
necessary) was applied for assessing differences in prevalence of AAT, in function of the 
diagnostic tests, between domestic animal species (except in equines). Linear regression was 
used to evaluate the effect of infection (test positive) on PCV values (dependent variable). To 
assess agreement between the diagnostic tests, Cohen's kappa coefficient was calculated and 
interpreted according to (Landis & Koch 1977). The Z test (Kappa/standard error) was used to 
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verify whether Kappa values were significant or not. P-values < 0.05 were considered as 
significant. 
4. Results 
In total, 1811 animals were sampled of which 959 (53%) in Tigray and 852 (47%) in Afar. In 
general, there was statistically significant interaction (X
2
 = 330.12, p<0.001) between regions and 
sampled domestic animal species, i.e. more cattle and camels were sampled in Tigray than in 
Afar, while more sheep and goats were sampled in Afar than in Tigray.  
Parasite detection 
In 68 animals, trypanosomes were detected (Table 3.3). Thus, the overall parasitologically 
confirmed prevalence of trypanosomosis was 3.8% (CI 2.9-4.6%) with 4.7% (CI 3.4-6.0%) in Tigray 
and 2.7% (CI 1.6-3.8%) in Afar. No trypanosomes were detected in equines. The parasitological 
prevalence in cattle (7.3%, CI 5.0-9.5%) was significantly higher (z=2.53, p=0.011) than in camels 
(4.0%, CI 2.6-5.4%), sheep (0.6%, CI 0-1.7%) and goats (0.4%, CI 0-1.2%).  
Serology 
With CATT/T. evansi, antibodies were detected in 354 animals (Table 3.3). Thus, the overall 
seroprevalence was 19.6% (CI 17.7-21.4%) with 24.6% (CI 21.9-27.3%) in Tigray and 13.9% (CI 
11.5-16.2%) in Afar. Among the equines, CATT/T. evansi was only positive in donkeys (10.7%, CI 
4.0-17.4%). The overall seroprevalence was significantly higher (z=9.39, p<0.001) in cattle (37.3%, 
CI 33.1-41.6%) than in camels (13.7%, CI 11.2-16.1%), in goats (13.3%, CI 9.2-17.4%), in sheep 
(12.7%, CI 7.8-17.6%) and in donkeys (10.7%, CI 4.1-17.4%). With the TL (Table 3.3), T. evansi-
specific antibodies were detected only in 34 animals (30 camels, 2 goats, 1 sheep and 1 donkey). 
Thus, the seroprevalence in TL was 1.9 % (34/1811, CI 1.3-2.5%). Kappa statistics indicated a poor 
but significant agreement between CATT/T. evansi and TL (p < 0.001, Table 3.4). 
Molecular diagnosis 
The overall molecular prevalence of T. evansi type A assessed with RoTat 1.2 PCR was 
145/1811 or 8.0% (CI 6.8-9.3%) with 8.0% (CI 6.3-9.8%) in Tigray and 8.0% (CI 6.2-9.8%) in Afar 
(Table 3.3). The molecular prevalence of T. evansi type A in camels (11.7 %, CI 9.4-14.0%) was 
significantly higher (p<0.001) than in cattle (6.1%, CI 4.0-8.2%), donkeys (6.0%, CI 0.9-11.0%), 
goats (3.8%, CI 1.5-6.1%), and sheep (2.2%, 0.1-4.4%). The molecular prevalence of T. evansi type 
A was 28.0% (CI 10.4-45.6%) in horse and 10.0 % (CI 7.6-27.6%) in mule. Kappa statistics indicated 
a poor but significant agreement between RoTat 1.2 PCR and the antibody detection tests, TL and 
CATT/T. evansi (p < 0.001, Table 3.4). Among the 145 RoTat 1.2 PCR positives, only 71 were 
positive in CATT/T. evansi and only 18 were positive in TL. Four camels, all from Awash Fentale 
district in Afar, were found positive in EVAB PCR indicating the presence of T. evansi type B. All 
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four were negative in CATT/T. evansi and TL although one of them was also positive in RoTat 1.2 
PCR suggesting a mixed infection. 
The overall molecular prevalence of T. vivax assessed with TvPRAC PCR was 54/1811 or 3.0% 
(CI 2.2-3.8%) with 3.3% (CI 2.2-4.5%) in Tigray and 2.6% (CI 1.5-3.7%) in Afar (Table 3.3). The 
molecular prevalences of T. vivax were 3.5% (CI 2.2-4.8%) in camels, 3.0% in goats (CI 1.0-5.1%), 
2.6% (CI 1.2-4.1%) in cattle and 2.2% (CI 0.1-4.4%) in sheep and were not significantly different 
(p=0.925). All horses and mules were negative in TvPRAC PCR. The molecular prevalence of T. 
vivax in cattle from Tigray was 3.2% (13/411) but was 0% in Afar. Among the 54 TvPRAC PCR 
positives, 10 were also positive in CATT/T. evansi but were negative in RoTat 1.2 PCR. Only two 
camels and one goat were positive in both TvPRAC PCR and RoTat 1.2 PCR.  
Among the 68 parasitologically positive animals, 32 cattle, 1 camel and 1 sheep were negative 
in the RoTat 1.2 PCR, EVAB PCR and TvPRAC PCR. To check for the possibility that mHCT detected 
T. theileri and T. congolense, ITS1-PCR was run on their specimens. Four cattle were positive for 
T. vivax and two cattle specimens were positive for T. theileri. Ten were negative. No single one 
was positive for T. congolense. Eighteen cattle specimens showed a profile with amplicons of 
different lengths that could not be interpreted unequivocally. Among the CATT/T. evansi positive 
animals, 269 (77%) were negative in all PCR tests (165 cattle, 42 camels, 33 goats,22 sheep and 7 
donkeys). 
Packed cell volume (PCV) 
In Table 3.5, the average PCV values and standard deviations (SD) are given according to the 
status of the animals in the mHCT, CATT/T. evansi, RoTat 1.2 PCR and TvPRAC PCR. Camels that 
were found positive in those tests had a significantly lower average PCV than the animals that 
were negative in the different tests. The average PCV in TL positive camels (24.2% ± 3.4%) was 
not significantly different from TL negatives (25.7% ± 3.59%) (p=0.05). In cattle and equines, the 
average PCV value was significantly lower only in CATT/T. evansi positive animals. In sheep and 
goats, no significant differences in average PCV were observed. 
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Table 3.3: Test positives over total number of animals for each host species within each region. 
 
Table 3.4: Degree of agreement between diagnostic tests. 
Cross test Observed (%) Expected by chance (%) Kappa Z p 
CATT/T. evansi and ITL  81.45 79.31 0.10 8.45 <0.001 
CATT/T. evansi and RoTat 
1.2 PCR 
80.29 75.58 0.19 9.31 <0.001 
RoTat 1.2 PCR and ITL 92.10 90.42 0.176 9.75 <0.001 
 
 
  
Diagnostic test Region Host species 
Cattle Camel Goat Sheep Mule Horse Donkey 
mHCT 
 
Tigray 32/411 11/343 1/60 1/64 0/10 0/25 0/46 
Afar 4/82 19/411 0/204 0/117 - - 0/38 
Total 36/493 30/754 1/264 1/181 0/10 0/25 0/84 
CATT/T. evansi 
 
Tigray 169/411 39/343 12/60 14/64 0/10 0/25 2/46 
Afar 15/82 64/411 23/204 9/117 - - 7/38 
Total 184/493 103/754 35/264 23/181 0/10 0/25 9/84 
TL Tigray 0/411 21/343 1/60 1/64 0/10 0/25 0/46 
 Afar 0/82 9/411 1/204 0/117 - - 1/38 
 Total 0/493 30/754 2/264 1/181 0/10 0/25 1/84 
RoTat 1.2 PCR Tigray 23/411 33/343 6/60 4/64 1/10 7/25 3/46 
 Afar 7/82 55/411 4/204 0/117 - - 2/38 
 Total 30/493 88/754 10/264 4/181 1/10 7/25 5/84 
EVAB PCR Tigray 0/411 0/343 0/60 0/64 0/10 0/25 0/46 
Afar 0/82 4/411 0/204 0/117 - - 0/38 
Total 0/493 4/754 0/264 0/181 0/10 0/25 0/84 
TvPRAC PCR Tigray 13/411 16/343 2/60 1/64 0/10 0/25 0/46 
 Afar 0/82 10/411 3/204 3/117 - - 3/38 
 Total 13/493 26/754 8/264 4/181 0/10 0/25 3/84 
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Table 3.5: Average PCV of the animals according to their status in the different diagnostic tests. 
Test  Species % PCV test 
negative  
± SD
a
 
% PCV test 
positive  
± SD
a
 
Regression 
coefficient 
value 
t
b
 P
c
 
mHCT Camels  25.8 ± 3.53 21.5 ± 2.53 -4.23 -6.50 < 0.001* 
Cattle  25.9 ± 5.25 24.9 ± 5.49 -0.97 -1.07 0.287 
CATT/T. 
evansi 
Camels  25.9 ± 3.46 23.8 ± 3.87 -2.09 -5.59 < 0.001* 
Cattle  26.6 ± 5.69 24.6 ± 4.19 -2.02 -4.20 < 0.001* 
Equines 33.6 ± 6.3 27.9 ± 7.9 -5.71 -2.56 0.012* 
Goats  26.7± 5.84 24.9 ± 4.57 -1.79 -1.73 0.084 
Sheep  25.1 ± 5.57 22.9 ± 6.11 -2.12 -1.77 0.088 
RoTat 
1.2 PCR 
Camels  25.0 ± 3.49 23.7 ± 3.81 -2.16 -5.39 < 0.001* 
Cattle  25.8 ± 5.25 26.3 ± 5.56 0.53 0.54 0.591 
Equines 33.2 ± 6.6 33.1 ± 7.1 -0.98 -0.05 0.960 
Goats  26.5 ± 5.68 23.3 ± 5.89 -3.29 -1.79 0.074 
Sheep  24.8 ± 5.71 25.5 ± 3.89 0.74 0.26 0.796 
TvPRAC Camels  25.7 ± 3.57 23.8 ± 3.77 -1.89 -2.65 0.008* 
Cattle  25.9 ± 5.30 23.1 ± 2.91 -2.83 -1.92 0.056 
Equines 33.2 ± 6.6 33.2 ± 5 -0.003 0.00 0.999 
Goats  26.4 ± 5.71 26.9 ± 6.30 0.543 0.26 0.792 
Sheep  24.8 ± 5.70 23.8 ± 4.33 -1.05 -0.36 0.716 
a
 SD: standard deviation; 
b
 t: Student's t distribution value; 
c
 P: probability; * statistically 
significant reduction in PCV 
5. Discussion 
In this cross sectional study, the mHCT, CATT/T. evansi, RoTat 1.2 TL and RoTat 1.2 PCR, EVAB 
PCR and TvPRAC PCR were used to assess the non-tsetse transmitted AAT prevalence in domestic 
animals in two regions of northern Ethiopia, Tigray and Afar. The overall prevalence of AAT as 
assessed with mHCT was 3.75% which was similar to AAT prevalence reported in cattle from 
other tsetse-free areas in Ethiopia (3.2% in Gondar and Bale Lowlands) using the same technique 
(Fikru et al. 2012). This is probably underestimating the real prevalence since mHCT is 
acknowledged to detect <50% of infections with low parasitaemia (Monzón et al. 1990; Murray 
et al. 1977). Although only one goat and one sheep were positive in mHCT, this finding confirms 
the presence of trypanosomosis in small ruminants (Sinshaw et al. 2006; Samson & Frehiwot 
2010; Tadesse & Tsegaye 2010; Kebede et al. 2009). The fact that no single equine was positive in 
mHCT while some of them were positive in the T. evansi specific RoTat 1.2 PCR and the T. vivax 
specific TvPRAC PCR, indicates that in these animals the parasitaemia level remained under the 
lower detection limit of mHCT (about 60 trypanosomes/ml), (OIE 2013b). 
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With RoTat 1.2 PCR, it was confirmed that all domestic animals are susceptible to infection 
with T. evansi type A but that camels and horses are particularly at risk (Desquesnes et al. 2013b; 
Desquesnes et al. 2013a). With EVAB PCR, we report for the first time the presence of T. evansi 
type B in camels in Ethiopia. To date, T. evansi type B has only been isolated from camels in 
Kenya although indirect evidence exists that it also circulates in Sudan (Salim et al. 2011; Boid 
1988; Borst et al. 1987; Ngaira et al. 2005). Furthermore, Hagos et al. suggested the existence of 
non-RoTat 1.2 T. evansi in camels from Bale zone in Ethiopia based on their finding that about 
one third of parasitologically positive camels were negative in CATT/T. evansi (Hagos et al. 2009). 
Also in our study, all four camels with T. evansi type B were negative in CATT/T. evansi. These 
data suggest that T. evansi type B is not confined to Kenya but may occur in more East African 
countries and even beyond, thus calling for the adaptation of serological and molecular 
diagnostic tests, like CATT/T. evansi and RoTat 1.2 PCR, to ensure detection of both types of T. 
evansi without compromising specificity. 
Our study also confirms that T. vivax can infect diverse domestic animal species, including 
donkeys (Hoare 1972). The overall molecular prevalence of T. vivax as assessed with TvPRAC PCR 
was lower than reported in other studies (Fikru et al. 2012; Fikru et al. 2014). The present study 
shows that camels in Ethiopia can be infected with T. vivax and that infection is associated with 
morbidity reflected by a significant reduction in PCV. Co-infections with T. vivax and T. evansi 
were rare (2 camels, 1 goat) but characterised by low PCV (20-22.5%). Mixed infection by both 
parasites was also reported in (Takeet et al. 2013).  
As expected, ITS1 PCR confirmed the absence of T. congolense in the mHCT positive animals 
that were negative in RoTat 1.2 PCR and TvPRAC PCR but revealed four T. vivax infections that 
were not picked up by TvPRAC PCR. Interestingly, ten mHCT positive animals remained negative 
in all PCRs. In the single sheep, the presence of the non-pathogenic T. melophagium cannot be 
ruled out but the other nine negatives remain unexplained (Gibson et al. 2010; Büscher & 
Friedhoff 1984). Also unexplained remain the 18 cattle specimens showing a complex amplicon 
profile in ITS1 PCR, including a putative T. vivax specific 150 bp amplicon (see figure 3.2 for an 
example). In a previous study, which led to the development of the TvPRAC PCR, we observed 
that the ITS1 PCR can generate non-specific amplicons in the presence of cattle DNA rendering 
unequivocal interpretation of the results impossible (Fikru et al. 2012). Given the complexity of 
the profile, we didn't undertake sequencing of the undefined amplicons. Although the analytical 
sensitivity of TvPRAC is lower than of ITS1 PCR, it is still higher than of mHCT (Fikru et al. 2014). 
Therefore, mHCT positive and TvPRAC negative but ITS1 T. vivax positive specimens may be due 
to particular T. vivax strains not detectable in TvPRAC. To further investigate these unexplained 
results, it will be necessary to isolate the trypanosomes detected in the mHCT, which will be 
particularly challenging in case of T. vivax. Indeed, T. vivax is notoriously difficult to grow in 
laboratory rodents and/or in culture (Gathuo et al. 1987; D'Archivio et al. 2011). 
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Seroprevalence, as assessed with CATT/T. evansi was much higher than molecular prevalence 
which is not unexpected for several reasons. First, CATT/T. evansi cannot distinguish current from 
cured infection as detectable level of antibodies can persist for 2.3–22.6 month after 
trypanocidal treatment (Hilali et al. 2004; Monzón et al. 2003). Secondly, in particular in chronic 
infections, parasitaemia can be well below the detection limit of parasitological and even 
molecular diagnostic tests, a phenomenon well known in human African trypanosomosis but less 
studied in AAT (Büscher 2014; Deborggraeve & Büscher 2012). Finally, as CATT/T. evansi is not 
100% specific, false positive cases do occur (Verloo et al. 1998).  
Still, the poor agreement between CATT/T. evansi and TL is puzzling. Both serological tests 
detect antibodies against the VSG RoTat 1.2 that is considered specific for T. evansi type A. 
Although a limited loss in sensitivity of TL when performed on filter paper eluates may be 
expected other factors may cause this discrepancy (Camara et al. 2014; Holland et al. 2002). 
While TL detects exclusively variant specific antibodies, CATT/T. evansi detects also antibodies 
directed against non-variant specific epitopes of VSG RoTAt 1.2 and other surface exposed 
antigens. Thus, infection with other trypanosomes, e.g. T. vivax, may lead to a positive result in 
CATT/T. evansi as was suggested in a study on bovine trypanosomosis in Suriname (Van 
Vlaenderen 1996; Uzcanga et al. 2004; Büscher 2001). This cross-reactivity caused by T. vivax 
infection may explain why all CATT/T. evansi positive cattle specimens remained negative in TL. 
However, it provides no explanation why the 30 cattle specimens that were positive in RoTat 1.2 
PCR remained negative in TL and why from the 145 RoTat 1.2 PCR positives, only 71 were also 
positive in CATT/T. evansi. Is it possible that the target sequence of RoTat 1.2 PCR is also present 
150 bp 
M       1        2           3        4          5          6        7           8          9      10      M 
Figure 3.2. Agarose gel showing non-specific ITS1 PCR amplicons on mHCT positive 
buffy coat samples of cattle (lanes 1-10). M= 100 bp marker; the T. vivax specific 
amplicon is 150 bp long. 
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in some particular T. vivax strains circulating in Afar and Tigray but that the gene containing that 
sequence is a pseudogene or a gene that is not expressed during an infection? As we were not 
able to isolate T. vivax strains during this study, a conclusive answer to this question cannot be 
given. 
If one considers a low PCV as a morbidity marker, it is striking that mainly camels are 
susceptible to AAT as disease. Indeed, camels that were positive in mHCT, CATT/T. evansi, RoTat 
1.2 PCR and TvPRAC PCR had a significantly lower PCV than camels that were negative in all these 
tests. Among the other host species, only cattle and equines that were positive in CATT/T. evansi 
had a significantly lower PCV than CATT/T. evansi negative animals again suggesting that most 
CATT/T. evansi positive animals were actually infected, whether with T. evansi or T. vivax. 
Among the parasitologically positive animals, three quarter presented without or with only 
mild symptoms. As in the study region, it is common to treat only sick camels and bovines with 
trypanocidal drugs such as diminazine and isometamidum, asymptomatic infections remain 
without treatment and constitute an uncontrolled reservoir for the disease. 
Our study has some limitations. Although intended, it was not possible to compare the AAT 
prevalence between Tigray and Afar since the number of examined individuals per animal species 
was considerably different between two study regions. Also, the number of examined small 
ruminants and equines was below the intended number of 323. In small ruminants, we observed 
13% seroprevalences and 2-4% molecular prevalences. Hence, the 264 goats and 181 sheep that 
were examined are sufficiently high to obtain statistically significant prevalence data. Finally, no 
stained blood preparations were prepared that would have allowed morphological 
characterisation of those parasites that were detected in the mHCT but that remained negative in 
the species-specific PCRs. 
In the next chapter, we will describe how we isolated and characterized T. evansi stocks from 
the cryopreserved blood of animals that were found parasitologically positive in this 
epidemiological survey.  
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1. Abstract 
Trypanosoma (T.) evansi is a dyskinetoplastic variant of T. brucei that has gained the ability to 
be transmitted by all sorts of biting flies. T. evansi can be divided into type A, which is the most 
abundant and found in Africa, Asia and Latin America and type B, which has so far been isolated 
only from Kenyan dromedary camels. This study aimed at the isolation and the genetic and 
phenotypic characterisation of type A and B T. evansi stocks from camels in Northern Ethiopia.  
T. evansi was isolated in mice by inoculation with the cryopreserved buffy coat of 
parasitologically confirmed animals. Fourteen stocks were thus isolated and subject to 
genotyping with PCRs targeting type-specific variant surface glycoprotein genes, mitochondrial 
minicircles and maxicircles, minisatellite markers and the F1-ATP synthase subunit gene. Nine 
stocks corresponded to type A, two stocks were type B and three stocks represented mixed 
infections between A and B, but not hybrids. One T. evansi type A stock was completely 
akinetoplastic. Five stocks were adapted to in vitro culture and subjected to a drug sensitivity 
assay with melarsomine dihydrochloride, diminazene diaceturate, isometamidium chloride and 
suramin. In vitro adaptation induced some loss of kinetoplasts within 60 days. No correlation 
between drug sensitivity and absence of the kinetoplast was observed. Sequencing the full 
coding sequence of the F1-ATP synthase subunit revealed new type-specific single nucleotide 
polymorphisms and deletions. 
This study addresses some limitations of current molecular markers for T. evansi genotyping. 
Polymorphism within the F1-ATP synthase subunit gene may provide new markers to identify 
the T. evansi type that do not rely on variant surface glycoprotein genes or kinetoplast DNA. 
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2. Introduction 
Trypanosomes are characterised by the presence of a structure called kinetoplast that 
corresponds with the DNA (kDNA) of their unique mitochondrion. T. brucei kDNA contains 20-50 
copies of maxicircles (about 23 kb) and a highly diverse set of thousands of minicircles (about 1 
kb). Maxicircles contain rRNA coding regions and genes coding for subunits of the respiratory 
chain complexes while minicircles code for guide RNAs required for editing (Schnaufer et al. 
2002).  
T. equiperdum and T. evansi are dyskinetoplastic (kDNA
-
) since they lack part of the kDNA 
(Claes et al. 2005; Lai et al. 2008; Schnaufer et al. 2002; Carnes et al. 2015). T. equiperdum 
typically has retained maxicircles, in some cases with substantial deletions, but has lost its 
minicircle diversity. T. evansi does not have maxicircles and either shows minicircle homogeneity 
or are akinetoplastic (kDNA°) (Ou et al. 1991; Lun & Vickerman 1991; Ventura et al. 2000; 
Schnaufer et al. 2002). Based on their minicircle restriction digestion profile, T. evansi can be 
divided into type A and type B (Njiru et al. 2006; Borst et al. 1987).  
T. evansi type A is the most abundant and is found in Africa, South America and Asia. It is 
characterised by the presence of the gene for the variant surface glycoprotein (VSG) RoTat 1.2. 
This RoTat 1.2 VSG is expressed early during infections resulting in the detectability of anti-RoTat 
1.2 antibodies in animals infected with T. evansi type A (Verloo et al. 2001; Bajyana Songa & 
Hamers 1988). In contrast, T. evansi type B is far less common and has so far been isolated only 
from camels in Kenya (Borst et al. 1987; Ngaira et al. 2005). More recently, serological and 
molecular evidence for the presence of T. evansi type B in Sudan, Ethiopia and Chad was 
published (Birhanu et al. 2015a; Hagos et al. 2009; Salim et al. 2011; Boid 1988; Sánchez et al. 
2015). T. evansi type B lacks the RoTat 1.2 gene and as a consequence, infections with this type 
are not detected with serological and molecular tests based on RoTat 1.2 VSG, such as the 
CATT/T. evansi and RoTat 1.2 PCR (Njiru et al. 2006; Bajyana Songa & Hamers 1988; Claes et al. 
2004; Ngaira et al. 2005). So far, three molecular tests have been developed for the identification 
of T. evansi type B: the EVAB PCR, targeting a type B-specific minicircle DNA sequence, and a PCR 
and a LAMP targeting a type B-specific VSG JN 2118Hu (Njiru et al. 2006; Ngaira et al. 2005; Njiru 
et al. 2010). T. equiperdum is the least known parasite of the Trypanozoon group, with very few 
isolates available for research, albeit new stocks were isolated from Ethiopian and Venezuelan 
horses recently (Hagos et al. 2010c; Sánchez et al. 2015).  
Unlike T. brucei, T. evansi and T. equiperdum cannot develop in tsetse flies due to their 
inability to transform into the procyclic life stage. They can only survive in a mammalian host 
where they produce ATP exclusively through glycolysis. In contrast to bloodstream forms, ATP 
production in procyclic trypanosomes relies on oxidative phosphorylation and, therefore, on the 
capacity to express the full set of corresponding mitochondrial genes, including some which are 
encoded by the kDNA (Dean et al. 2013; Schnaufer et al. 2002). Bloodstream forms of T. evansi, 
Chapter 4: New Trypanosoma evansi type B isolates from Ethiopia - 85 
 
T. equiperdum and laboratory-generated T. brucei strains that have lost all or critical parts of 
their kDNA, can survive without kDNA due to specific single amino acid mutations in the gamma 
() subunit of the mitochondrial F1-ATP synthase (Dean et al. 2013). Interestingly, the specific 
mutations/deletions in the C-terminal region of F1-ATP  subunit enable differentiation among 
the Trypanozoon strains (Lai et al. 2008). Furthermore, when the F1-ATP  subunits of T. evansi 
type A (A281del), T. equiperdum (A273P) and the laboratory-generated T. brucei (L262P) strains 
are overexpressed in a T. brucei  subunit knock out strain, the latter can survive after loss of its 
kinetoplast after treatment with DNA intercalating drugs such as acriflavin or ethidium bromide 
(Schnaufer 2010; Dean et al. 2013). Once the genetically modified T. brucei are independent from 
kDNA maintenance and expression, they become multidrug resistant to the diamidine and 
phenanthridine class of drugs (Gould & Schnaufer 2014).  
In T. evansi, drug resistance has been reported in several type A strains originating from 
Africa, Asia and Latin America (El Rayah et al. 1999; Payne et al. 1994a; Boid et al. 1989; Zhou et 
al. 2004). Some Chinese strains appear to be innately resistant to the phenanthridine class of 
drugs (Brun & Lun 1994). In contrast, nothing is known on the drug susceptibly of the T. evansi 
type B strains. In Chapter 3, we reported that T. evansi infections are very common in camels, 
equines, cattle and small ruminants in Tigray and Afar provinces in Northern Ethiopia (Birhanu et 
al. 2015a). We also provided molecular and serological evidence that both T. evansi type A and 
type B occur in these provinces. As described in Chapter 3, of those dromedary camels that were 
parasitologically positive, buffy coat samples were collected and cryopreserved in liquid nitrogen 
for later isolation of the parasite. We here report on the isolation, adaptation to in vitro culture, 
genetic and phenotypic characterisation and in vitro drug sensitivity of T. evansi type A and B 
from Northern Ethiopia. 
3. Materials and methods 
Ethics statement 
The Animal Experimentation Ethics Committee (AEEC) of the Institute of Tropical Medicine 
(ITM) advised on the protocol for collection of blood samples from dromedary camels (EXT2012-
1) and for the isolation of trypanosomes via inoculation of mice (EXT2012-2) at the College of 
Veterinary Medicine, Mekelle University. The study protocol for in vivo expansion of 
trypanosomes at ITM was approved by the AEEC (BM2013-1). Collecting blood from camels and 
experiments on mice were conducted according to the national guidelines of the Ethiopian 
Ministry of Livestock and Fishery Development and the Institutional Review Board of the Ministry 
of Science and Technology.  
In vivo isolation of parasites from cryopreserved buffy coat in mice 
Details on the collection and cryopreservation of buffy coat samples from dromedary camels 
that were parasitologically confirmed in the micro haematocrit centrifugation technique have 
been fully described in Chapter 3. Two hundred µl of thawed buffy coat were inoculated 
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intraperitoneally (IP) in two 25–30 g Swiss albino mice that were immunosuppressed with 0.16 µg 
kg
-1
 body weight dexamethasone (Shanghai Central Pharmaceutical, China) one day prior to 
inoculation (Sultana 1996). Parasitaemia was checked in 5 µl of tail blood using the matching 
method (Herbert & Lumsden 1976), starting from day 7 post-infection and subsequently on every 
third day. As soon as trypanosomes were detected in at least one mouse, the animal was 
anaesthetised (the other kept as a backup), its blood was collected on heparin by heart puncture, 
diluted in an equal volume of phosphate buffered saline glucose (PSG; 7.5 g/l Na2HPO42H2O, 0.34 
g/l NaH2 PO4H2O, 2.12 g/l NaCl, 10 g/l D-glucose, pH 8) and subinoculated into four naïve mice 
(200 µl each) which were monitored for parasitaemia as described above. Mice used as backup 
were euthanised when the newly infected mice became positive. When parasitemia reached 
about ± 10
7.8
 cells ml
−1
 of blood, two of these parasitaemic mice were euthanised (the other two 
were kept as back up) and blood was taken for subinoculation into four other naïve mice. This 
protocol was repeated until the parasitaemia reached about 10
8.4
 cells ml
−1
. At this stage the 
stock was considered in vivo adapted. All four mice were anaesthetised and exsanguinated by 
heart puncture in an equal volume of Triladyl-egg yolk-phosphate buffered saline glucose (TEP) 
cryomedium (Pyana et al. 2011) for cryopreservation in 1 ml aliquots.  
In vivo expansion and purification of parasite populations 
Cryostabilates were thawed in a water bath at 37 °C and diluted in PSG to 1 trypanosome per 
field (± 10
5.7
 cells ml
−1
). Two-hundred µl volumes were injected IP in two naïve 20–30 g female 
OF-1 mice (Charles River, Belgium). Starting from three days post infection (DPI), parasitaemia 
was monitored daily and harvested at first peak parasitemia, typically at day 4 to 5 post-infection, 
as described above. Volumes of 0.5 ml of the blood were run over a mini Anion Exchange 
Centrifugation Technique (mAECT) column to separate the trypanosomes from the blood 
(Büscher et al. 2009). The trypanosomes eluted from the column were washed twice with 5 ml 
ice-cold PSG by centrifugation at 1500 g for 15 min. After the last centrifugation, the supernatant 
PSG was discarded and the trypanosome sediment was re-suspended in 100 µl of PSG. Part of 
this suspension was used for in vitro culture adaptation. The remainder was centrifuged at 1500 g 
for 5 min and the sediment was frozen at -80°C until DNA extraction. The isolates used for in vivo 
isolation and expansion and the corresponding T. evansi type A and B specific PCR result on their 
corresponding buffy coat DNA are indicated in Table 4.1. 
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Table 4.1: List of Ethiopian T. evansi isolates with data on origin and results in RoTat 1.2 PCR 
and EVAB PCR performed on DNA extracted from the buffy coat specimens from the infected 
camels. pos: positive, neg: negative. 
Stabilate code Region District Station RoTat 
1.2 
PCR 
EVAB 
PCR 
In vivo 
subpassages 
before first 
cryostabilate 
In vivo 
expansion 
at ITM 
MCAM/ET/2013/MU/01 Afar Megalle Adahara pos neg 3 yes 
MCAM/ET/2013/MU/02 Tigray Raya-
Azebo 
Chercher pos neg 5 yes 
MCAM/ET/2013/MU/03 Tigray Raya-
Azebo 
Kukufto pos neg 5 no 
MCAM/ET/2013/MU/04 Tigray Raya-
Azebo 
Chercher pos neg 3 yes 
MCAM/ET/2013/MU/05 Tigray Raya-
Azebo 
Balla pos neg 4 yes 
MCAM/ET/2013/MU/06 Tigray Raya-
Azebo 
Balla pos neg 3 yes 
MCAM/ET/2013/MU/07 Afar Yallo Gubidera  pos neg 2 yes 
MCAM/ET/2013/MU/08 Afar Golina Ullel-ella pos neg 2 yes 
MCAM/ET/2013/MU/09 Tigray Raya-
Azebo 
Kukufto pos neg 3 yes 
MCAM/ET/2013/MU/10 Afar Awash 
Fentale 
Alibete neg pos 2 yes 
MCAM/ET/2013/MU/11 Afar Megalle Adahara pos neg 3 yes 
MCAM/ET/2013/MU/12 Afar Yallo Gubidera pos neg 3 no 
MCAM/ET/2013/MU/13 Afar Golina Ullel-ella pos neg 3 yes 
MCAM/ET/2013/MU/14 Afar Awash 
Fentale 
Alibete neg pos 3 yes 
MCAM/ET/2013/MU/15 Afar Awash 
Fentale 
Dihoon pos neg 2 yes 
MCAM/ET/2013/MU/16 Afar Golina Ullel-ella pos neg 2 no 
MCAM/ET/2013/MU/17 Afar Awash 
Fentale 
Dihoon pos neg 2 yes 
MCAM/ET/2013/MU/18 Afar Megalle Adahara pos neg 2 no 
MCAM/ET/2013/MU/19 Afar Megalle Adahara pos neg 3 no 
MCAM/ET/2013/MU/20 Afar Golina Ullel-ella pos neg 2 no 
MCAM/ET/2013/MU/21 Afar Megalle Adahara pos neg 3 no 
MCAM/ET/2013/MU/22 Afar Megalle Adahara pos neg 3 no 
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In vitro adaptation in HMI-9 medium with horse serum 
The highly concentrated trypanosome suspension in PSG was diluted to 2 x 10
5
 cells ml
−1
 in 
Hirumi’s modified Iscove’s medium 9 (HMI-9), complemented with 15% (v/v) heat-inactivated 
foetal bovine serum (Gibco, Belgium) and 5% (v/v) heat-inactivated horse serum (Gibco, Belgium) 
(abbreviated as HMI-9 (HS)) (Van Reet et al. 2011; Hirumi & Hirumi 1989). Parasites were seeded 
at 2 x 10
4
, 2 x 10
3
 and 2 x 10
2
 cells ml
−1
, in a total volume of 500 µl in a 48-well plate (Nunc, 
Denmark) and incubated at 37 °C and 5% CO2. After 72 hours, a well, where trypanosome density 
had increased above 2 x 10
5
 cells ml
−1
, was used for further subpassage in 500 µl of HMI-9 (HS). 
The well with the highest density of viable parasites was then further maintained in HMI-9 
without horse serum (Van Reet et al. 2011). When possible, log phase growing in vitro cultures 
were scaled up in flasks (Nunc, Denmark) to obtain larger numbers of parasites for 
cryostabilisation, DNA extraction and in vitro drug sensitivity testing (Van Reet et al. 2014). The in 
vitro growth curves of the different stocks were generated by seeding cells at 1 x 10
4
 cells ml
−1
 in 
500 µl of HMI-9 in three replicate wells that were counted every 24 hours. The doubling times 
(Td) were calculated from the exponential part of the curve using non-linear regression fitted with 
an exponential equation in GraphPad Prism 6 (GraphPad, version 6, USA). 
Molecular characterisation of parasite populations 
DNA extraction of trypanosome sediments prepared from the in vivo expanded and the in 
vitro adapted populations was performed with DNA Isolation Kit (Roche Diagnostics, Germany) 
following the protocol recommended for isolation of DNA from mammalian tissue. From T.b. 
brucei AnTat 1.1
E
, T.b. gambiense LiTat 1.3, T.b. gambiense type II ABBA and T. equiperdum 
Dodola 940, DNA was extracted using the Maxwell 16 Tissue DNA Purification kit on a Maxwell 16 
instrument according to the manufacturer's instructions (Promega, Belgium). DNA concentrations 
were measured using the Nanodrop ND-1000 UV-Vis spectrophotometer (NanoDrop 
Technologies, USA) and adjusted to 10 ng µl
-1
. A set of PCRs targeting VSG genes (RoTat 1.2 and 
JN 2118Hu), maxicircle genes (ND4, ND5, ND7 and A6), class A minicircles (miniA PCR) and class B 
minicircles (EVAB PCR), minisatellites (MORF-2REP), P2 adenosine transporter (AT1) and the F1-
ATP -subunit were adopted to characterise the studied parasite populations (Urakawa et al. 
2001; Ngaira et al. 2005; Domingo et al. 2003; Dean et al. 2013; Njiru et al. 2006; Biteau et al. 
2000; Graf et al. 2013). Where applicable, the published PCR protocols were adjusted to the 
requirements of the HotStarTaq Plus DNA polymerase (Qiagen, Germany). Primer sequences, 
reaction mixture contents, cycling conditions and expected amplicon size are described and 
referenced in Table 4.2. All PCR amplifications were carried out in 200 µl thin-wall PCR tubes 
(ABgene, UK) in a T3 thermocycler 48 (Biometra, Germany). Ten µl of amplified products were 
electrophoresed in 1 to 2% agarose gel at 135 V for 30 min and afterwards stained with ethidium 
bromide for visualization under UV light. For direct sequencing, PCR was performed in 50 – 100 µl 
volumes and amplicons were cleaned up and concentrated using a PCR cleanup kit (QIAquick PCR 
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Purification Kit, Qiagen, Germany) and sent out for bidirectional Sanger sequencing at the 
Genetic Sequencing Facility (VIB, Belgium) using the described PCR primers.  
The full length sequence of the F1-ATP -subunit was cloned into a BamHI and HindIII double 
digested pHD309 vector using the In-Fusion Cloning kit (Clontech, Japan). Primers contained a F1-
ATP -subunit specific sequence based on the T. evansi sequence of STIB 810 (EU185797) and a 5′ 
extension of 15 bp specific to the place of integration in pHD309, containing the restriction sites 
and sequence overlap with the vector, as required for the In-Fusion Cloning reaction. 
Proofreading-PCR was performed using the Clone-Amp HiFi PCR premix (Clontech, Japan). 
Amplicons were cleaned up (QIAquick PCR Purification Kit, Qiagen, Germany) before use in the 
In-Fusion protocol. The reaction products were transformed in Stellar competent cells according 
to the manufacturer's recommendations (Clontech, Japan). Transformant clones were checked 
for the presence of insert using colony PCR, cultured in LB medium, plasmid purified (QIAprep 
Spin Miniprep Kit, Qiagen, Germany) and at least 7 to 12 clones per transformation were 
bidirectionally sequenced at the Genetic Sequencing Facility (VIB, Belgium) using primers binding 
to pHD309. 
In vitro drug sensitivity testing 
Melarsomine dihydrochloride (Cymelarsan, Sanofi Aventis, France) and isometamidium 
hydrochloride (Veridium, Ceva Santé Animale, Belgium) were prepared as 10 mg ml
−1
 stock 
solutions in distilled water. Dophanil powder (Dophanil, Docpharma, Belgium), containing 445 mg 
diminazene diaceturate and 555 mg antipyrine per gram, was concentrated to a 10 mg ml
−1
 
diminazene diaceturate solution in DMSO (Sigma, Belgium). Suramin (Germanin, Bayer, Germany) 
was prepared as a 100 mg ml
−1 
in DMSO. A method to measure the IC50 values of compounds in 
96-well plates was performed as described elsewhere (Gillingwater et al. 2007). Briefly, 2 × 10
4
 
cells ml
−1
 from in vitro adapted stocks, each in four replicates, were exposed to seven threefold 
drug dilutions, ranging from 5000 to 7 ng ml
−1
 for suramin, 500 to 0.7 ng ml
−1
 for diminazene 
diaceturate and from 250 to 0.35 ng ml
−1
 for melarsomine dihydrochloride and isometamidium 
hydrochloride, in a total volume of 200 µl of HMI-9 medium. Next, the plate was incubated for 72 
hours at 37°C with 5% CO2 followed by addition of 20 µl of resazurin (Sigma, Belgium; 12.5 mg in 
100 ml PBS) for measuring trypanosomes viability. After a further 24 h incubation at 37°C and 5% 
CO2, fluorescence was measured (excitation λ = 560 nm; emission λ = 590 nm) with a VictorX3 
multimodal plate reader using top reading (Perkin Elmer, Belgium) (Van Reet et al. 2014). The 
results were expressed as the percent reduction in parasite viability compared to the parasite 
viability in control wells without drugs. The 50% inhibitory concentration (IC50) was calculated 
using non-linear regression fitted with a (log) inhibitor versus normalised response (variable 
slope) equation (GraphPad, version 6, USA). The IC50 values obtained from day 30 and day 60 in 
vitro cultures were compared using t-tests corrected for multiple testing according to the Holm-
Sidak method ( = 0.05) (GraphPad, version 6, USA). 
.
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Table 4.2: PCRs used in the present study with target sequence, primer name and sequences, length of expected amplicon, reaction mixtures 
and cycling conditions. Reaction mixture 1: 25 µl containing 25 ng DNA, 1X CoralLoad buffer, 1.5 mM of MgCl2, 200 µM of dNTPs, 0.5 µM of each 
primer, 0.5 U of HotStar TaqPlus. Reaction mixture 2: 25 µl containing 25 ng DNA, 1X CoralLoad buffer, 1.5 mM of MgCl2, 200 µM of dNTPs, 1 
µM of each primer, 0.5 U of HotStar TaqPlus. Reaction mixture 3: 25 µl containing 25 ng DNA, 1X CloneAmp HiFi PCR premix and 0.25 µM of 
each primer. bp: base pair, P: Plus DNA strand, M= Minus DNA strand. 
Target 
sequence 
Primers Primer sequences Amplicon 
length 
Reaction 
mixture 
Cycling conditions Adapted from  
VSG RoTat 
1.2 
ILO7957 5′-GCC ACC ACG GCG AAA GAC-3′ 488 bp 1 95 °C for 5 min and 35 cycles of 
30 sec at 94 °C, 30 sec at 58 °C, 
30 sec at 72 °C and final 
extension for 5 min at 72 °C 
(Urakawa et al. 
2001) 
 ILO8091 5′-TAA TCA GTG TGG TGT GC-3′ 
VSG JN 
2118Hu 
Forward 5′-TTCTACCAACTGACGGAGCG-3′ 273 bp 1 95 °C for 5 min and 35 cycles of 
30 sec at 94 °C, 30 sec at 55 °C, 
30 sec at 72 °C and final 
extension for 5 min at 72 °C 
(Ngaira et al. 
2005) 
 Reverse 5′-TAGCTCCGGATGCATCGGT-3′ 
Maxicircle 
A6 
Forward 5′-AAAAATAAGTATTTTGATATTATTAAAG-3′ 381 bp 2 95 °C for 5 min and 30 cycles of 
94 °C for 1 min, 54 °C for 1 min, 
and 72 °C for 30 s followed by a 
final elongation step at 72 °C for 
8 min 
(Domingo et al. 
2003) 
 Reverse 5′-TATTATTAACTTATTTGATC-3′ 
Maxicircle 
ND4 
Forward 5′-TGTGTGACTACCAGAGAT-3′ 256 bp 2 Idem as above (Domingo et al. 
2003) 
 Reverse 5′-ATCCTATACCCGTGTGTA-3′ 
Maxicircle 
ND5 
Forward 5′-TGGGTTTATATCAGGTTCATTTATG-3 
 
400 bp 2 Idem as above (Dean et al. 2013) 
 Reverse 5′-CCCTAATAATCTCATCCGCAGTACG-3′ 
Maxicircle 
ND7 
Forward 5′-ATGACTACATGATAAGTA-3 
 
167 bp 2 Idem as above (Domingo et al. 
2003) 
 Reverse 5′-CGGAAGACATTGTTCTACAC-3′ 
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Minicircle 
class A 
MiniA 5′-GGGTTTTTTAGGTCCGAG-3′ 1000 bp 1 95 °C for 5 min and 35 cycles of 
30 sec at 94 °C, 30 sec at 58 °C, 
30 sec at 72 °C and final 
extension for 5 min at 72 °C 
(Njiru et al. 2006) 
 Reverse 
MiniB 
5′-CCGAAAATAGCACGTG-3’ 
Minicircle 
class B 
EVAB1 5’-CACAGTCCGAGAGATAGAG-3’ 436 bp 1 95 °C for 5 min and 30 cycles of 
30 sec at 94 °C, 30 sec at 60 °C, 
60 sec at 72 °C and final 
extension for 10 min at 72 °C 
(Njiru et al. 2006) 
 EVAB2 5’-CTGTACTCTACATCTACCTC-3’ 
Minisatellite 
MORF2-REP 
P 5’TGCATGGCAATAGCGATGGGC-3’ repeated 
102 bp 
sequence 
1 95°C for 5 min fand 30 cycles of 
denaturing at 94°C for 30 s, 
annealing at 60°C for 30 sec and 
extension at 72°C for 3 min. 
Elongation was continued for 
72°C for 5 min 
(Biteau et al. 
2000) 
 M 5’ATCGTCACCTGGTGTACTTCTC-3’ 
TeAT1 TbAT1-F 5’-GAAATCCCCGTCTTTTCTCAC-3’ 1600 bp 1 95 °C for 5 min, 24 cycles of 1 min 
at 95°C followed by 1 min at 56 
°C and 2 min at 72 °C, and final 
extension at 72 °C for 5 min 
(Graf et al. 2013) 
 TbAT1-R- 5’-ATGTGCTGAGCCTTTTTCCTT-3’ 
F1-ATP 
synthase Ƴ 
subunit 
F1-ATP-F 5’-
AACTGCAACGAAGCTTATGTCGGGCAAGCTT
CGTC-3’ 
918 bp 3 98 °C for 30 sand 35 cycles of 98 
°C for 15 s, 59.4 °C for 15 s , 72° C 
for 20 s and 72 °C for 5 min 
followed by cool down to 4 °C 
 
 F1-ATP-R 5’-
TAAATGGGCAGGATCCCTACTTGGTTACTGC
CCCTTC-3’ 
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Microscopic examination for presence of a kinetoplast in trypanosomes 
Trypanosome populations at different stages of in vivo and in vitro expansion were examined 
for the presence of the kinetoplast using 4',6-diamidino-2-phenylindole (DAPI) staining. Briefly, 
live trypanosomes in PSG or in vitro culture medium were washed in PBS by centrifugation, 
deposited onto microscope slides, air dried and fixed with methanol for 30 min. Subsequently, 
the slides were rehydrated in PBS and mounted in 87% glycerol containing 1 μg ml
-1
 DAPI (Sigma, 
Belgium) (Dean et al. 2013). Images were captured with an epifluorescence microscope (Olympus 
BX41, Olympus, Japan) equipped with a NU fluorescent cube (excitation: 360-370 nm and 
emission > 420 nm)) and Cell
˄
D software (Olympus, Japan). DAPI stained trypanosomes were 
grouped according to the number of kinetoplasts (K) and nuclei (N) present within each cell. The 
percentage of kinetoplastic cells in a DAPI stained slide was calculated on the basis of on average 
300 examined trypanosomes, by dividing the sum of 1K1N + 2K1N + 2K2N cells by the sum of 
1K1N + 2K1N + 2K2N + 0K1N + 0K2N cells. A two-tailed Spearman correlation matrix (using a 
confidence interval of 95%) was used to find the correlation between the percentage of 
kinetoplastic cells at day 30 and day 60 of in vitro culture and the respective IC50 value for a 
particular drug (GraphPad, version 6, USA).
 
In vivo infectivity check 
To check the in vivo infectivity of trypanosome populations that were cryostabilised after 
continuous propagation in vitro for 60 days, 5 x 10
6
 cells in 300 µl were inoculated in a single OF-1 
mouse where after parasitaemia was checked as described above.  
4. Results 
Isolation of Ethiopian T. evansi stocks 
Thirty cryopreserved buffy coat specimens from parasitologically positive dromedary camels 
were inoculated in immunosuppressed Swiss albino mice. In total, 22 parasite stocks originating 
from 22 different animals could be isolated and cryopreserved after 2 to 5 subpassages in mice. 
They were labelled as MCAM/ET/2013/MU/01 to MCAM/ET/2013/MU/22. Based on positivity in 
RoTat 1.2 PCR and EVAB PCR of the corresponding cryopreserved buffy coats, 20 of these stocks 
are T. evansi type A and 2 are T. evansi type B (Table 4.1) (Birhanu et al. 2015a). Copy cryovials of 
these primary isolates were brought to ITM, Antwerp and 14 were selected for further expansion 
in mice. The selection was based on their geographical origin and subtype: 12 type A stocks 
originated from different sampling stations in Afar and Tigray (MCAM/ET/2013/MU/01, 02, 04, 
05, 06, 07, 08, 09, 11, 13, 15, 17) and two type B stocks (MCAM/ET/2013/MU/10 and 14) were 
from Awash Fentale in Afar. At peak parasitaemia, between 4 to 7 DPI, parasites were harvested, 
purified from blood using a mAECT column, washed with PSG and pelleted for DNA extraction 
and for in vitro culture adaptation.  
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Molecular typing based on specific VSG sequences of in vivo expanded stocks 
DNA extracts of in vivo expanded stocks were subjected to RoTat 1.2 PCR and JN 2118Hu PCR 
to identify the T. evansi type based on type-specific VSG sequences. In addition, the specificity of 
these PCRs was tested on DNA of other Trypanozoon strains (T.b. brucei AnTat 1.1
E
, T.b. 
gambiense LiTat 1.3, T.b. gambiense type II ABBA, T. evansi type A RoTat 1.2, T. evansi type B 
KETRI 2479 and T. equiperdum Dodola 940). Results are represented in Table 4.3. All the in vivo 
expanded stocks that originated from RoTat 1.2 PCR positive buffy coats, were also positive in 
RoTat 1.2 PCR (MCAM/ET/2013/MU/01, 02, 04, 05, 06, 07, 08, 09, 11, 13, 15 and 17). Direct 
sequencing of the 488 bp amplicons from these putative T. evansi type A stocks and the T. evansi 
RoTat 1.2 strain revealed 100% identity (in a 350 bp sequenced fragment) with the published 
RoTat 1.2 VSG sequence (AF317914), thus identifying them as T. evansi type A. Only one 
synonymous polymorphism (C699A) was found in MCAM/2013/ET/MU/04. The gel with the 
RoTat 1.2 PCR products from the purified trypanosomes showed a faint band of about 400 bp 
amplified in T. evansi KETRI 2479 and in MCAM/ET/2013/MU/10 and 14. Direct sequencing of 
these 400 bp amplicons failed, probably due to the low concentrations of the amplicons. The PCR 
targeting the T. evansi type B specific VSG JN 2118Hu generated the expected amplicon in T. 
evansi type B KETRI 2479 and in MCAM/ET/2013/MU/10 and 14. Additionally, an amplicon was 
generated from MCAM/ET/2013/MU/15. Also for T.b. brucei AnTat 1.1
E
 and T.b. gambiense type 
II ABBA, amplicons of 273 bp were produced in the JN 2118Hu PCR. Direct sequencing of these 
amplicons revealed that the Ethiopian T. evansi type B MCAM/ET/2013/MU/10 and 14, T. evansi 
type B KETRI 2479 and T.b. brucei AnTat 1.1
E
 were 100% identical (in a 190 bp sequenced 
fragment) to the corresponding sequence of JN 2118Hu VSG (AJ870486). In T.b. gambiense type II 
ABBA, one synonymous mutation (G300A) was found. 
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Table 4.3. Genetic characteristics of the trypanosome populations studied. pos = positive, neg = negative, seq = sequence identity, n.a. = not 
applicable, n.d. = not done, (f) = faint, * amplification failed may be due to restricted elongation time in PCR protocol or probably high number 
of repeats present. 
 RoTat 1.2 JN 2118Hu Maxicircle PCR Minicircle class 
Fraction of 
kinetoplast
ic cells in 
vivo 
Minisatellit
e profile 
Trypanosome stock or strain PCR  seq PCR seq ND4 ND5 ND7 A6 A B % MORF2-REP 
T.b. brucei AnTat 1.1
E
 neg n.a. pos identical pos pos pos pos pos (f) neg n.d. neg*. 
T.b. gambiense LiTat 1.3 neg n.a. neg n.a. pos pos pos pos neg neg n.d. 7,11 (f) 
T. b. gambiense ABBA neg n.a. pos G300A pos pos pos pos neg neg n.d. 3 
T. evansi RoTat 1.2 pos identical neg n.a. neg neg neg neg pos neg 97 4,6 
T. evansi KETRI 2479 neg n.a. pos identical neg neg neg neg neg pos 98 3,5 
T. equiperdum Dodola 940 neg n.a. neg n.a. pos pos pos pos neg neg n.d. 11(f) 
MCAM/ET/2013/MU/001 pos  identical neg n.a. neg neg neg neg pos neg 97 7 
MCAM/ET/2013/MU/002 pos  identical neg n.a. neg neg neg neg pos neg 98 6,7 
MCAM/ET/2013/MU/004 pos  C699A neg n.a. neg neg neg neg pos neg 99 6,7 
MCAM/ET/2013/MU/005 pos  identical neg n.a. neg neg neg neg pos neg 98 6,7 
MCAM/ET/2013/MU/006 pos  identical neg n.a. neg neg neg neg pos neg 99 6,7 
MCAM/ET/2013/MU/007 pos  identical neg n.a. neg neg neg neg pos neg 100 6,7 
MCAM/ET/2013/MU/008 pos  identical neg n.a. neg neg neg neg pos neg 98 6,7 
MCAM/ET/2013/MU/009 pos  identical neg n.a. neg neg neg neg neg neg 0% 6,7 
MCAM/ET/2013/MU/010 neg n.a. pos identical neg neg neg neg neg pos 98 3,4 
MCAM/ET/2013/MU/011 pos  identical neg n.a. neg neg neg neg pos  pos (f) 98 7 
MCAM/ET/2013/MU/013 pos  identical neg n.a. neg neg neg neg pos neg 99 6,7 
MCAM/ET/2013/MU/014 neg n.a. pos identical neg neg neg neg neg pos 99 3,4 
MCAM/ET/2013/MU/015 pos  n.d. pos n.d. neg neg neg neg pos pos 98 3,4,6,7 
MCAM/ET/2013/MU/017 pos  identical neg n.a. neg neg neg neg pos pos (f) 99 6,7 
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Morphological and genotypic kDNA status of the in vivo expanded stocks 
Four PCRs that target maxicircle DNAs, of which three NADH-dehydrogenase subunits (ND4, 
ND5, ND7) and the ATPase subunit 6 (A6), and two PCRs that target class-specific minicircle 
sequences (miniA PCR and EVAB PCR) were run on DNA extracts of the purified trypanosomes 
(Table 4.3). All Ethiopian T. evansi stocks and T. evansi type A RoTat 1.2 and T. evansi type B 
KETRI 2479 were negative for all four maxicircle genes, while T.b. brucei AnTat 1.1
E
, T.b. 
gambiense LiTat 1.3, T.b. gambiense type II ABBA and T. equiperdum Dodola 940 were positive 
for all four maxicircle genes.  
All stocks that contain RoTat 1.2 VSG, except MCAM/ET/2013/MU/09, were positive in miniA 
PCR. Additionally, weak amplification was seen in T.b. brucei AnTat 1.1
E
. MCAM/ET/2013/MU/10 
and 14 were positive in EVAB PCR, confirming their identification as T. evansi type B as observed 
on their corresponding buffy coat specimens (Table 4.1). Additionally, EVAB PCR amplicons were 
detected in 3 stocks that were also positive for RoTat 1.2 VSG PCR suggesting a mixed infection 
with type A and B: a strong amplification was present in MCAM/ET/2013/MU/15, while a weak 
amplification was visible in MCAM/ET/2013/MU/11 and 17. The presence of kinetoplasts in the 
trypanosome cells was demonstrated using fluorescence microscopy with DAPI staining on ex 
vivo isolated trypanosomes (Table 4.3). T. evansi RoTat 1.2, T. evansi KETRI 2479 and all but one 
Ethiopian T. evansi stocks show a kinetoplast in > 96% of the cells. Stock MCAM/ET/2013/MU/09 
was found to be akinetoplastic since only the nucleus of the trypanosomes was visible with DAPI. 
MORF2-REP minisatellite profile of the in vivo expanded stocks 
In T. evansi RoTat 1.2, the MORF2-REP locus consists of 4 and 6 repeats, while in T. evansi 
KETRI 2479, 3 and 5 repeats were found (Table 4.3). In vivo expanded Ethiopian stocks of type A 
had either 1 allele (7 repeats) or 2 alleles (6 and 7 repeats), thus displaying a different pattern 
than T. evansi type A RoTat 1.2. The Ethiopian type B stocks MCAM/ET/2013/MU/10 and 14 
contain 3 and 4 repeats, and thus have a pattern different from T. evansi type B KETRI 2479. 
MCAM/ET/2013/MU/15 showed a clear pattern of the Ethiopian type B (3 and 4 repeats), and 
double allele pattern of the Ethiopian type A (6 and 7 repeats). The other presumed mixed type A 
and type B stocks MCAM/ET/2013/MU/11 and 17 showed only the Ethiopian type A T. evansi 
pattern (Fig 4.1). DNA extracted from the buffy coats revealed similar MORF2-REP patterns as the 
in vivo expanded trypanosomes except for the buffy coat of MCAM/ET/2013/MU/15 that 
revealed only the Ethiopian type A MORF2-REP pattern. The other Trypanozoon strains showed 
the following patterns: T. b. gambiense LiTat 1.3 had 7 and 11 repeats, T.b. gambiense type II 
ABBA had 3 repeats, T. equiperdum Dodola 940 had 11 repeats, while no amplicons were 
generated from T.b. brucei AnTat 1.1
E
 under the giving PCR conditions.  
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F1-ATP synthase subunit genotyping 
Sequence analysis of in total 136 clones of the full length F1-ATP synthase  subunit, amplified 
from DNA of the in vivo expanded Ethiopian stocks MCAM/ET/2013/MU/04, 06, 09, 10, 11, 13, 
14, 15 and of T.b. brucei AnTat 1.1
E
, T.b. gambiense LiTat 1.3, T. evansi RoTat 1.2, T. evansi KETRI 
2479, T. b. gambiense type II ABBA and T. equiperdum Dodola 940 revealed diverse homozygous 
and heterozygous nucleotide polymorphisms spread over the entire coding sequence (Table 4.4). 
The F1-ATP synthase  subunit of T.b. gambiense LiTat 1.3 (KT934830) appeared homozygous 
and identical to the T.b. gambiense DAL972 sequence (Tbg972.10.90). T.b. gambiense type II 
ABBA (KT934831) appeared homozygous and differed in only two SNPs (G801T and A882G) from 
the T.b. gambiense sequence. T. evansi RoTat 1.2 and the Ethiopian stocks 
MCAM/ET/2013/MU/04, 06, 09,11 and 13 were heterozygous and revealed in one allele 
(KT934833), identical to the published full length T. evansi STIB 810 (EU185798) sequence, the 
deletion of nucleotides A841-843del. The second allele contained a C142T polymorphism 
(KT934832), that is not present in the wild-type T. evansi STIB 810 sequence (EU185797), but that 
could be identified in the genome sequence of the Chinese akinetoplastic T. evansi STIB 805 
strain (Carnes et al. 2015). For T. evansi KETRI 2479 and the Ethiopian stocks 
MCAM/ET/2013/MU/10 and 14 we obtained heterozygous alleles, different from the partial 
sequence of T. evansi KETRI 2479 (EU185794). The first allele had the unique A844T 
polymorphism (KT934835), and differed from the second allele in 3 additional SNPs (T321C, 
Figure 4.1. MORF2-REP profiles of Ethiopian T. evansi stocks and T. evansi and T. brucei 
reference strains. 1.5 % agarose gel showing MORF2-REP minisatellite PCR amplicons. 
Lane M: 100 bp plus marker, lanes 1 to 14: Ethiopian T. evansi stocks 
MCAM/ET/2013/MU/01-02-04-05-06-07-08-09-10-11-13-14-15-17, lane 15: T.b. 
gambiense LiTat 1.3, lane 16: T.b. brucei AnTat 1.1
E
 lane 17: T. evansi type A (RoTat 1.2), 
lane 18: T. evansi type B (KETRI 2479), lane 19: T. equiperdum Dodola 940, lane 20: T. b. 
gambiense ABBA, lane N: negative control. 
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T807C, T867G) that were also found in some T.b. brucei and T. equiperdum. Interestingly, the in 
vivo expanded stock of MCAM/ET/2013/MU/15 revealed alleles that belonged to T. evansi type A 
and type B. In contrast, when the original buffy coat of this stock was tested, only alleles of T. 
evansi type A were found. Finally, T. equiperdum Dodola 940 (KT934836) appeared homozygous 
and its single allele was identical to one of the two alleles found in T.b. brucei AnTat 1.1
E 
( 
KT934837), but differed in 5 SNPs with the sequence from T. equiperdum BoTat 1.1 (EU185793) 
and in 6 SNPs with T. equiperdum STIB 841 (EU185792). However, for the T. equiperdum STIB 841 
strain, 5 of the 6 SNPs were ambiguous polymorphisms that do not rule out similarity to T. 
equiperdum Dodola 940.  
 In vitro adaptation of Ethiopian T. evansi stocks 
Fourteen Ethiopian T. evansi stocks, T. evansi RoTat 1.2 and T. evansi KETRI 2479 were 
expanded in mice and purified from blood at peak parasitaemia to initiate primary in vitro 
cultures in HMI-9 (HS) medium. After 96 hours, the initial 2x10
4
 cells ml
−1
 inoculum reached 
concentrations above 2x10
5
 cells ml
−1
 for all the different stocks. These cells were used for 
further in vitro propagation by subpassage in fresh medium. Over the next 72 hours, only 
MCAM/ET/2013/MU/09, 14 and 15, and T. evansi RoTat 1.2 and T. evansi KETRI 2479 showed 
proliferation. In contrast, slightly increased cell densities were observed for 
MCAM/ET/2013/MU/01, 04, 06 and 10. For all other strains not a single inoculum proliferated 
and longer incubation led to growth cessation. 
Because the HMI-9 (HS) medium did not support sufficient in vitro culture growth for most of 
the Ethiopian T. evansi stocks, it was abandoned and replaced with HMI-9 without horse serum. 
In vitro adapted strains of T.b. brucei AnTat 1.1
E
 and T.b. gambiense LiTat 1.3 were cultured in 
HMI-9 in parallel. In vitro cultures were only considered adapted to HMI-9 medium when it was 
possible to maintain the parasites in continuous proliferation. To this extent, dense parasite 
cultures, containing 2 – 5 x 10
5
 cells ml
−1
, were subpassaged into new wells using serial fivefold 
dilutions in fresh medium. When these subpassages reached densities above 2 x 10
5
 cells ml
−1
 
within a 48 - 96 hours period, the stock was considered adapted. The five stocks that already 
grew well in the HMI-9 (HS) medium continued proliferating when inoculated from the dense 
cultures at serial fivefold dilutions in HMI-9. These five stocks were considered to be in vitro 
adapted after 15 days of in vitro culture. Out of the four remaining stocks, only 
MCAM/ET/2013/MU/04 and 10 slowly regained the ability to proliferate in HMI-9 at a reduced 
subpassaging scheme using serial twofold dilutions. MCAM/ET/2013/MU/04 required 25 days to 
adapt, while MCAM/ET/2013/MU/10 was only fully adapted after day 35 of in vitro culture. 
Gradually increasing the culture volume allowed to obtain sufficient parasites from the adapted 
cultures for in vitro drug testing, DNA extraction, and cryostabilisation at day 30 (all, except 
MCAM/ET/2013/MU/10) and at day 60 of in vitro culture (all stocks).  
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Table 4.4: F1-ATP synthase  subunit single nucleotide polymorphism (SNP) observed within the studied trypanosome stocks and strains or 
retrieved from GenBank. Some SNPs were only present in T.b. b. TREU927 (G6A, C9T,C572G), T.b.b 29-13 (C149G, A168C, C866T) and T.b.b. STIB 
920 (G738C) and are not represented in the table. del=deletion, GAN: GenBank accession number, * identical to all Ethiopian T. evansi type A 
stocks, ** identical to all Ethiopian T. evansi type B stocks. Blank spaces indicate no change and – indicates missing sequence information. 
 
Stock/strain 
 
A93G C142T C194T A198G G294A T321C A356T T654C T663C G801T T807C G817C 841-843 
GCT 
A844T T867G A882G T892C GAN 
T.b.g. DAL972 G   G      T      G  Tbg972.10.90 
T.b.g. LiTat 1.3 G   G      T      G  KT934830 
T.b.g. ABBA G   G              KT934831 
T. ev. RoTat 1.2*  T T               KT934832 
T. ev. RoTat 1.2*   T          del     KT934833 
T. ev. STIB 810   T               EU185797 
T. ev. STIB 810   T          del     EU185798 
T. ev. KETRI 2479**      C     C    G   KT934834 
T. ev. KETRI 2479**      
 
    
 
  T 
 
  KT934835 
T. ev. KETRI 2479 - - - - - - - - -  C   T G   EU185794 
T. eq BoTat 1.1      C     C C      EU185793 
T. eq. STIB 841   Y  R C W Y Y      G  C EU185792 
T. eq. Dodola 940   T   C   C      G   KT934836 
T.b.b. AnTat 1.1
E
   T   C   C      G   KT934837 
T.b.b. AnTat 1.1
E
     A    C         KT934838 
T.b.b. STIB 920      C   C  C    G   EU185791 
T.b.b. 29-13 -  T   C   C      G  C EU185790 
T.b.b. TREU927 G    A C T C          Tb927.10.180 
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DNA of the in vitro adapted stocks was subjected to RoTat 1.2 PCR, EVAB PCR and MORF2-REP 
PCR. All in vitro stocks had similar molecular profiles as their corresponding in vivo expanded 
parental stocks, except MCAM/ET/2013/MU/15. While the in vivo expanded stock of the latter 
was identified as a mixed infection of T. evansi type A and type B, the in vitro adapted stock (at 
day 30 and day 60 in vitro culture) was identified as pure T. evansi type B with the above 
mentioned PCRs and confirmed by cloning and sequencing of the F1-ATP synthase subunit. 
Thus, beside T. evansi RoTat 1.2 and T. evansi KETRI 2479, we achieved the in vitro adaptation of 
2 Ethiopian type A stocks, 2 Ethiopian type B stocks and additionally ended up with a pure T. 
evansi type B in vitro adapted stock originating from a mixed type A and type B in vivo adapted 
stock. Growth curves were generated for T.b. brucei AnTat 1.1
E
 and all seven in vitro adapted 
stocks (Fig.4.2). T.b. brucei AnTat 1.1
E
 and T. evansi RoTat 1.2 had the shortest Td, 7.5 ± 0.3 h
-1
 
and 7.7 ± 0.2 h
-1
 respectively, and reached the highest maximum population density (MPD) of ± 3 
– 4 x 10
6
 cells ml
-1
, while T. evansi KETRI 2479 had a longer Td, 10.8 ± 0.2 h
-1
, and a lower MPD of 
± 1 x 10
6
 cells ml
-1
. The Ethiopian type A stocks MCAM/ET/2013/MU04 and MU09 had a Td of 11.2 
± 0.4 and 11.3 ± 0.4 respectively, and a MPD of ± 1 x 10
6
 cells ml
-1
. Similarly, the Ethiopian type B 
stocks MCAM/ET/2013/MU10, 14 and 15 had a Td of 12.9 ± 0.5, 11.3 0.5 and 12.1 ± 0.6 
respectively, and a MPD of ± 0.7 – 1 x 10
6
 cells ml
-1 
(Fig 4.2). 
  
Figure 4.2: In vitro growth curve of trypanosome stocks and strains. T.b.b. = T.b. brucei, T.e. 
= T. evansi, MU = MCAM/ET/2013/MU. 
100 -Chapter 4: New Trypanosoma evansi type B isolates from Ethiopia 
In vitro drug sensitivity and relation to kDNA 
After day 30 and 60 of in vitro culture, IC50 values were determined for melarsomine 
dihydrochloride (Cymelarsan) (Figure 4.3A), isometamidium hydrochloride (Veridium) (Figure 
4.3B), diminazene diaceturate (Dophanil) (Figure 4.3C) and suramin (Germanin) (Figure 4.3D). In 
general, non-significant differences (p > 0.05) were found between IC50 values recorded at day 30 
and day 60 of in vitro culture, except for the melarsomine dihydrochloride IC50 values of T. evansi 
RoTat 1.2 and T. evansi MCAM/ET/2013/MU/14 and for the isometamidium hydrochloride IC50 
values of T. evansi KETRI 2479 and T. evansi MCAM/ET/2013/MU/09 (p < 0.05). For comparison 
between the different stocks, the IC50 values of day 30 and day 60 of in vitro cultures were 
averaged. All Ethiopian T. evansi stocks had IC50 values for melarsomine dihydrochloride (IC50 1.9 
– 3.3 ng ml
-1
) that were similar to those of T.b. gambiense LiTat 1.3 (IC50 4.3 ng ml
-1
), T.b. brucei 
AnTat 1.1
E
 (IC50 6.8 ng ml
-1
), T. evansi RoTat 1.2 (IC50 3.0 ng ml
-1
) and T. evansi KETRI 2479 (IC50 4.1 
ng ml
-1
). For isometamidium hydrochloride, the IC50 values of the Ethiopian T. evansi (IC50 0.6 – 
6.2 ng ml
-1
) fall within the range of T.b. gambiense LiTat 1.3 (IC50 0.1 ng ml
-1
), T.b. brucei AnTat 
1.1
E
 (IC50 7.3 ng ml
-1
), T. evansi RoTat 1.2 (IC50 7.1 ng ml
-1
) and T. evansi KETRI 2479 (IC50 5.5 ng ml
-
1
). However, the two Ethiopian T. evansi type A stocks (IC50 4.3 – 6.2 ng ml
-1
) appear to be 
threefold less sensitive that the three type B stocks (IC50 0.6 – 1.9 ng ml
-1
). For suramin, large 
differences in IC50 values were found among the Ethiopian T. evansi (IC50 15.9 – 261.5 ng ml
-1
) 
stocks and among the other strains: T.b. brucei AnTat 1.1
E
 (IC50 39.5 ng ml
-1
) and T. evansi RoTat 
1.2 (IC50 35.8 ng ml
-1
) appear highly susceptible, while T.b. gambiense LiTat 1.3 (IC50 134.0 ng ml
-1
) 
and T. evansi KETRI 2479 (IC50 222.4 ng ml
-1
) are less susceptible. 
The two Ethiopian T. evansi type A (IC50 153.5 – 261.5 ng ml
-1
) appear to be tenfold less 
sensitive than the three type B (IC50 15.9 – 27.6 ng ml
-1
). For diminazene diaceturate, the IC50 
values of all Ethiopian T. evansi (IC50 17.5 – 48.5 ng ml
-1
) are higher than those of T.b. gambiense 
LiTat 1.3 (IC50 5.2 ng ml
-1
) and T. evansi RoTat 1.2 (IC50 13.8 ng ml
-1
), but similar to T.b. brucei 
AnTat 1.1
E
 (IC50 39.6 ng ml
-1
) and T. evansi KETRI 2479 (IC50 24.0 ng ml
-1
). The two Ethiopian T. 
evansi type A (IC50 37.4 – 48.5 ng ml
-1
) appear to be twofold less sensitive than the three type B 
(IC50 17.5 – 25.9 ng ml
-1
). Direct sequencing of the full length TeAT1 PCR amplicons of 
MCAM/ET/2013/MU/04, 09, 10, 14, and 15, T. evansi type A RoTat 1.2 and T. evansi Type B KETRI 
2479 revealed no polmorphisms to the wild-type TeAT1 sequence (AB124588). 
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DAPI staining was performed on in vivo and in vitro propagated stocks (Figure 4.4). In vitro 
culture did not change the percentage of kinetoplastic cells in T.b. gambiense LiTat 1.3 (99%), T.b. 
brucei AnTat 1.1
E
 (99%) and MCAM/ET/2013/MU/09 (0%) (Figure 4.5). On the other hand, 
already after 30 days in vitro culture a decrease in the percentage of kinetoplastic cells was 
Figure 4.4: Percentage of kinetoplastic cells within T. evansi populations. Percentage of 
kinetoplastic cells visualised after DAPI staining and fluorescence microscopy within 
populations after 30 (black bars) and 60 days (grey bars) in vitro propagation. T.b.g. = T.b. 
gambiense, T.b.b. = T.b. brucei, T.e= T. evansi, MU = MCAM/ET/2013/MU. 
Figure 4.3: In vitro drug sensitivity of T. evansi. IC50 values for different drugs, with standard 
error bars, obtained with different Trypanosoma sp. stocks and strains after 30 (black bars) 
and 60 days (grey bars) in vitro culture. Significant differences between IC50 values of 30 and 
60 days in vitro cultures are indicated by an asterisk. T.b.g. = T.b. gambiense, T.b.b. = T.b. 
brucei, T.e. = T. evansi, MU = MCAM/ET/2013/MU. Panel A: IC50 values for melarsomine 
dihydrochloride. Panel B: IC50 values for isometamidium hydrochloride. Panel C. IC50 values 
for suramin and Panel D: IC50 values for diminazene diaceturate. 
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observed in T. evansi RoTat 1.2 (89%), T. evansi KETRI 2479 (81%), MCAM/ET/2013/MU/04 (97%), 
14 (93%) and 15 (94%) compared to non-in vitro adapted trypanosomes. After 60 days of in vitro 
culture, the percentage of kinetoplastic cells dropped even further for T. evansi KETRI 2479 
(64%), MCAM/ET/2013/MU/04 (89%) and 10 (35%). No significant correlation was observed 
between the percentage of kinetoplastid cells of all in vitro adapted T. evansi stocks (including 
day 30 and day 60) and their IC50 values for melarsomine dihydrochloride ( = -0.13, p = 0. 67), 
isometamidium hydrochloride ( = -0.324, p = 0.278), suramin ( = -0.097, p = 0.752) and 
diminazene diacetureate ( = -0.355, p = 0.233). These data suggest that among the in vitro 
adapted Ethiopian T. evansi stocks there is no relation between the drug sensitivity and the 
presence of kinetoplast DNA. Furthermore, their loss of kDNA does not seem to influence rodent 
infectivity since all cryostabilates made from day 60 in vitro cultures remained infective for mice 
with detectable parasitaemia at 4-5 DPI. 
  
Figure 4.4. Percentage of kinetoplastic cells within T. evansi populations. Percentage of 
kinetoplastic cells visualised after DAPI staining and fluorescence microscopy within 
populations after 30 (black bars) and 60 days (grey bars) in vitro propagation. T.b.g. = T.b. 
gambiense, T.b.b. = T.b. brucei, T.e= T. evansi, MU = MCAM/ET/2013/MU. 
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5. Discussion  
Previous molecular and serological studies revealed that trypanosome infections in camels 
from Northern Ethiopia are caused by either RoTat 1.2 PCR or EVAB PCR positive parasites. In 
some instances amplicons of both PCRs were detected within the same buffy coat extract, 
suggesting the occurrence of mixed infections (Chapter 3, (Birhanu et al. 2015a)). The present 
study was undertaken to isolate the trypanosomes from camels carrying apparent single 
infections through inoculation of their buffy coats in immunosuppressed mice. The in vivo 
inoculation led to the successful isolation of 22 stocks, out of which 14 were selected on the basis 
of their geographical origins for further investigations (5 stocks from Tigray and 9 stocks from 
Afar). Next, we performed an in-depth comparative molecular analysis on DNA extracts from the 
isolated parasite stocks using diverse PCRs. Furthermore, we analysed the specificity of each of 
these PCRs on a collection of Trypanozoon strains.  
The RoTat 1.2 VSG sequence can be used to characterise T. evansi type A (Urakawa et al. 
2001; Claes et al. 2004). In our collection, all buffy coats positive in RoTat 1.2 PCR yielded in vivo 
isolated stocks that were RoTat 1.2 PCR positive but that were negative in the maxicircle gene 
Figure 4.5: DAPI staining and confocal microscopy on T. evansi 
MCAM/ET/2013/MU/09 showing only the nucleus but no 
kinetoplast. 
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targeting PCRs. Furthermore, with the exception of the akinetoplastic stock 
MCAM/ET/2013/MU/09, all these strains had type A minicircles. MCAM/ET/2013/MU/09 may be 
naturally akinetoplastic since the DNA extracted from the original buffy coat was negative in all 
PCRs targeting kinetoplast DNA. The occurrence of naturally akinetoplastic strains was previously 
documented in Latin America and China (Stevens et al. 1989; Ventura et al. 2000; Ou et al. 1991; 
Lun & Vickerman 1991). One stock (MCAM/ET/2013/MU/04) contained a SNP in its RoTat 1.2 
VSG PCR amplicon. SNPs in RoTat 1.2 amplicons were previously reported in Egypt but do not 
necessarily lead to a negative result in RoTat 1.2 based antibody detection tests. This was also the 
case for the camel from which MCAM/ET/2013/MU/04 was isolated (Elhaig et al. 2013; Amer et 
al. 2011). 
Initially defined by minicircle class B, identification of T. evansi type B is possible with EVAB 
PCR that amplifies a fragment of this minicircle (Njiru et al. 2006). Additionally, it was proposed 
that the VSG JN 2118Hu, first described in a Kenyan T. evansi strain, is a specific marker for T. 
evansi type B (Ngaira et al. 2005).  
In our collection, two buffy coat extracts that were positive in EVAB PCR yielded in vivo 
isolated stocks that were EVAB PCR positive as well. Interestingly, an EVAB PCR amplicon was also 
detected in three additional in vivo expanded stocks that were RoTat 1.2 PCR positive but for 
which the corresponding buffy coats were EVAB PCR negative. These three stocks might be mixed 
infections. JN 2118Hu VSG PCR appeared to be less sensitive because it detected only 3 out of 5 
EVAB PCR positive isolated stocks. Furthermore, the JN 2118Hu VSG PCR appeared to be less 
specific since T.b. brucei AnTat 1.1
E
 and T.b. gambiense type II ABBA were also positive in this 
PCR. None of the EVAB PCR positive isolated stocks contained maxicircle DNA and they were all 
negative in miniA PCR, except for the three mixed infections. Therefore, we conclude that we 
isolated at least two “pure” T. evansi type B stocks from Ethiopian camels, decades after the 
initial isolation of T. evansi type B from camels in Kenya (Njiru et al. 2006). 
We used the minisatellite locus MORF2-REP to verify whether both putative mixed stocks, 
that were positive in RoTat 1.2 PCR and EVAB PCR, were real mixed infections or hybrids between 
T. evansi type A and B. The Ethiopian isolates clustered in two classes of T. evansi type A, of 
which one with a previously described heterozygous profile (6 and 7 repeats) and one with a 
homozygous profile (7 repeats). The Ethiopian T. evansi type B stocks had a heterozygous profile 
(3 and 4 repeats) differing from the only known profile described for Kenyan type B isolates (3 
and 5 repeats) (Masiga et al. 2006). In one of the mixed infections we observed a profile that can 
be interpreted as a mixture of Ethiopian type A and type B, while the others only revealed the 
Ethiopian type A pattern. These results prove that we are dealing with mixed infections and not 
with hybrids between T. evansi type A and type B. To exclude that these apparent mixed 
infections represent cross-contamination with genetic material, we attempted in vitro cultivation 
of the in vivo expanded stocks. 
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Previously we have shown that addition of 1,1% methylcellulose to HMI-9 greatly helps the in 
vitro adaptation of Trypanozoon strains, including T.b. gambiense and T. evansi RoTat 1.2 (Van 
Reet et al. 2011). However, to avoid the use of this highly viscous medium we preferred the use 
of horse serum to adapt T. evansi stocks, as suggested in previous reports (Hirumi et al. 1997; 
Kaminsky & Brun 1998; Zweygarth & Röttcher 1986). While this approach proved to be successful 
for all type B stocks, only two out of nine Ethiopian T. evansi type A could be adapted. 
Interestingly, in the case of mixed stock MCAM/ET/2013/MU/15, this medium selected T. evansi 
type B out of the mixed population. While only the type A infection was detected in the buffy 
coat DNA extract, both types could be detected in the in vivo expanded stock DNA, but eventually 
only type B was detected in the in vitro adapted stock.  
Gillingwater and colleagues reported on the drug sensitivity profiles of a panel of T. evansi 
and T. equiperdum strains where they considered T. evansi STIB 806K to be a reference sensitive 
strain for suramin (IC50 70.4 ng ml
-1
), diminazene diaceturate (IC50 4.5 ng ml
-1
) and melarsomine 
dihydrochloride (IC50 1.4 ng ml
-1
). They reported drug resistance in two T. evansi stocks with an 
IC50 for suramin > 10000 ng ml
-1
 (STIB 780 and STIB 781), and in the T. equiperdum OVI strain, 
with an IC50 for diminazene diaceturate of 302 ng ml
-1
 and an IC50 for melarsomine 
dihydrochloride of 17.6 ng ml
-1
 (Gillingwater et al. 2007). The only strain that is shared between 
their panel and our collection is T. evansi RoTat 1.2, which despite different approaches in the 
experimental testing, yielded corresponding IC50 values, especially for diminazene diaceturate 
and melarsomine dihydrochloride, thus facilitating comparison between both studies. In our 
Ethiopian T. evansi collection, no resistance against melarsomine dihydrochloride was found. 
However, some stocks appeared to have raised IC50 values for suramin (> 200 ng ml
-1
) and 
diminazene diaceturate (> 50 ng ml
-1
). The IC50 values that we observe for T.b. gambiense LiTat 
1.3 and the Ethiopian T. evansi type B are similar to the in vitro IC50 value of 0.82 ng ml
-1
 found by 
Sahin and coworkers for T. congolense IL3000 which is sensitive to isometamidium (Veridium) in 
vivo (Sahin et al. 2014). In the same study, an in vitro IC50 of 11.06 ng ml
-1
 is reported for T.b. 
brucei AnTat 1.1 strain, which is slightly higher than the value that we obtained in experiments 
with our T.b. brucei AnTat 1.1 strain and the other T. evansi stocks (Sahin et al. 2014). 
Nevertheless, defining our T. evansi stocks as either sensitive or resistant based solely on the in 
vitro drug sensitivity results may be too audacious, given the fact that IC50 values were 
determined in only one assay, the resazurin viability assay (Kaminsky et al. 1997; Räz et al. 1997; 
Van Reet et al. 2013). Therefore, an in vivo drug sensitivity profile of all our Trypanozoon strains 
against the commonly used trypanocides remains to be elucidated. Interestingly, both Ethiopian 
T. evansi type A stocks appear to be less susceptible to suramin, diminazene diaceturate and 
isometamidium hydrochloride than the three type B stocks. In T.b. brucei, resistance against 
suramin and isometamidum hydrochloride has been linked to several proteins (Alsford et al. 
2012; Baker et al. 2015), while resistance to diamidine and melaminophenyl classes of drugs is 
attributed to the transporter protein TbAT1 and the aquaporin AQP2 (Munday et al. 2015a; 
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Munday et al. 2015b; Munday et al. 2014). The lower sensitivity to diminazene diaceturate was 
not caused by mutations in the T. evansi TeAT1 (Witola et al. 2004).  
Interestingly, DAPI staining of the trypanosomes indicated slight to severe loss of the kDNA in 
all in vitro adapted T. evansi stocks, when compared to in vivo adapted stocks. The loss of kDNA 
in in vitro cultured T. evansi is a phenomenon that has been known for a long time (Schnaufer et 
al. 2002; Njiru et al. 2006; Zweygarth et al. 1990; Kaminsky et al. 1997). Non-vital loss of the 
kinetoplast is made possible by mutations in the F1-ATP  subunit of T. evansi allowing to 
uncouple from the Fo subunit and effectively circumventing the requirement for mitochondrial 
gene expression (Schnaufer et al. 2005). Furthermore, it has been shown that the expression of 
certain T. evansi F1-ATP  subunit coding sequences in T. brucei allows this species to survive loss 
of its kDNA after chemical treatment (Dean et al. 2013). Moreover, in such genetically modified T. 
brucei, independence of kDNA maintenance and expression is associated with multidrug 
resistance (Gould & Schnaufer 2014). In our collection of T. evansi stocks we did not observe 
differences in drug sensitivity between populations that were partially or completely akinetoplast 
confirming earlier evidence that the presence or absence of kDNA is irrelevant within this context 
(Gould & Schnaufer 2014; Kaminsky et al. 1997). 
Recently, Carnes et al. showed that SNPs in the F1- ATP subunit could be used to 
genotypically support the multiple origins of at least four dyskinetoplastic T. evansi/T. 
equiperdum lineages: one major group of RoTat 1.2 VSG positive T. evansi/T. equiperdum type A, 
and three very small groups each represented by only a single strain: T. evansi type B KETRI 2479, 
T. equiperdum BoTat and T. equiperdum OVI (Carnes et al. 2015). All Ethiopian T. evansi type A 
had the corresponding mutation of the type A group. The Ethiopian type B T. evansi shared a 
similar profile as KETRI 2479. Finally, the Ethiopian T. equiperdum strain Dodola, which had some 
maxicircle genes but was negative for both type A and type B markers revealed an F1-ATP 
synthase sequence similar to T.b. brucei AnTat 1.1
E 
 strain, thus likely belongs to the same 
dyskinetoplastic group as T. equiperdum OVI (Dean et al. 2013; Carnes et al. 2015). 
Summarizing, our study shows that the apparent T. evansi type that is detected in a buffy coat 
of an infected camel does not necessarily represent the full diversity that is present in the 
infected animal. Moreover, the fact that 5 out of 22 new T. evansi isolates from camel in Ethiopia 
contain T. evansi type B may be an indication that is more widespread than currently known. The 
inoculation of the trypanosomes in immunosuppressed mice may allow the propagation of mixed 
populations. In contrast, in vitro cultivation seems to reduce the diversity by selecting for only 
one particular type, in our study T. evansi type B. Secondly, our study addresses some drawbacks 
of current molecular markers for T. evansi genotyping. To rely solely on VSG markers or kDNA 
markers for the molecular identification of T. evansi may be misleading due to possible 
recombinations occurring in VSG genes and to the presence of akinetoplastic T. evansi stocks. In 
this regard, we confirm that the F1-ATP -subunit gene, that is not related to the VSG repertoire 
nor to the presence of kDNA, may become an interesting target for genotyping T. evansi stocks in 
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areas where both types overlap and where mixed infections can occur. Nevertheless, it is not 
possible to separate the Ethiopian T. equiperdum from T. brucei on the basis of this target gene. 
Thirdly, no evidence of in vitro drug resistance was found in our collection of T. evansi type A and 
type B stocks. The presence or partial absence of kDNA in the in vitro adapted T. evansi stocks did 
not correspond with the drug sensitivity phenotype.  
From the above, we conclude that the presence of T. evansi type B in Ethiopian camels must 
be taken into account when proposing control measures against surra. For serological as well as 
for molecular screening, tests or test combinations that are able to detect both T. evansi type A 
and B should be used. The present data on in vitro drug sensitivity of both types do not suggest 
that it is necessary to differentiate type A from type B in order to choose the drug for treating 
infected animals. 
In the epidemiological survey described in Chapter 3, we used the CATT/T. evansi for 
serological screening. In the meantime, the first immunochromatography test for T. evansi had 
been developed, the Surra Sero K-SeT. The major advantages of this test are its long term 
thermostability and its individual test format. In Chapter 5, we describe the diagnostic evaluation 
of the Surra Sero K-SeT on archived sera as a first step in the process of its further development 
and eventual implementation. 
 .
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1. Abstract 
Trypanosoma evansi, the causative agent of surra, infects different domestic and wild animals 
and has a wide geographical distribution. It is mechanically transmitted mainly by 
haematophagous flies. Parasitological techniques are commonly used for the diagnosis of surra 
but have limited sensitivity. Therefore, serodiagnosis based on the detection of T. evansi specific 
antibodies is recommended by the World Organisation for Animal Health (OIE). Recently, we 
developed a new antibody detection test for the serodiagnosis of T. evansi infection, the Surra 
Sero K-SeT. Surra Sero K-SeT is an immunochromatographic test (ICT) that makes use of 
recombinant variant surface glycoprotein rVSG RoTat 1.2, produced in the yeast Pichia pastoris. 
In this study, we compared the diagnostic accuracy of the Surra Sero K-SeT and the Card 
Agglutination Test for T. evansi Trypanosomososis (CATT/T. evansi) with immune trypanolysis (TL) 
as reference test on a total of 806 sera from camels, water buffaloes, horses, bovines, sheep, 
dogs and alpacas. Test agreement was highest between Surra Sero K-SeT and TL (κ=0.91, 95% CI 
0.841-0.979) and somewhat lower between CATT/T. evansi and TL (κ=0.85, 95% CI 0.785-0.922) 
and Surra Sero K-SeT and CATT/T. evansi (κ=0.81, 95% CI 0.742-0.878). The Surra Sero K-SeT 
displayed a somewhat lower overall specificity than CATT/T. evansi (94.8% versus 98.3%, χ
2
 
=13.37, p<0.001) but a considerably higher sensitivity (98.1% versus 84.4%, χ
2
 =33.39, p<0.001). 
We conclude that the Surra Sero K-SeT may become an alternative for the CATT/T. evansi for 
sensitive detection of antibodies against T. evansi in domestic animals.  
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2. Introduction 
Parasitological techniques such as Giemsa stained thin smears or thick drops and the 
microhaematocrit centrifugation technique (mHCT), are commonly used for the diagnosis of 
surra but their sensitivity is low due to the fluctuating and often low parasitaemia, particularly 
during the chronic stage of the disease (Büscher 2014). Therefore, serodiagnosis based on the 
detection of T. evansi specific antibodies is recommended by the World Organisation for Animal 
Health (Organisation Internationale des Epizooties, OIE) (OIE 2012). Within the mammalian host, 
the cell membrane of the trypanosome is covered by a monolayer of variant surface glycoprotein 
(VSG). This VSG coat is highly immunogenic and induces a strong antibody response in the host. 
As a result, trypanosomes that are recognised by VSG-specific antibodies are destroyed (Pays et 
al. 2004; Horn 2014). The VSG conferring the variant antigen type RoTat 1.2 is shared among 
most T. evansi strains, except in some rare T. evansi strains isolated from dromedary camels in 
Kenya (Verloo et al. 2001; Ngaira et al. 2005) and Ethiopia (Chapters 3 and 4). Several antibody 
detection tests have been developed that are based on the native VSG RoTat 1.2 including the 
Card Agglutination Test for Trypanosomosis (CATT/T. evansi), enzyme linked immunosorbent 
assay (ELISA/T. evansi) and immune trypanolysis (TL) (Bajyana Songa & Hamers 1988; Verloo et 
al. 1998; Lejon et al. 2005). To avoid the use of laboratory rodents for the production of native 
VSG RoTat 1.2, the N-terminal domain of VSG RoTat 1.2 has been expressed as recombinant 
protein in Spodoptera frugiperda insect cells and in Pichia pastoris yeast cells and used as antigen 
in ELISA and in latex agglutination (Urakawa et al. 2001; Lejon et al. 2005; Rogé et al. 2014). None 
of the above mentioned serological test formats complies with the ASSURED criteria (affordable, 
sensitive, specific, user-friendly, rapid, equipment-free and delivered) (Mabey et al. 2004). 
Therefore, the development of an ASSURED serodiagnostic test for surra remains necessary 
(Büscher 2014). 
Following the development of the HAT Sero K-SeT for sleeping sickness caused by T. brucei 
gambiense, we developed a similar test for the serodiagnosis of infection with T. evansi, the Surra 
Sero K-SeT (Büscher et al. 2013; Büscher et al. 2014). This test (Coris BioConcept, Gembloux, 
Belgium) is a lateral flow immunochromatographic test (ICT) for detection of RoTat 1.2- specific 
antibodies in blood, serum or plasma of any mammalian species. The test uses a fragment of VSG 
RoTat 1.2, produced as recombinant antigen in Pichia pastoris (Rogé et al. 2013). In the present 
study, we report on the diagnostic accuracy of the Surra Sero K-SeT on sera from various 
domestic animal species from different parts of the world in comparison with CATT/T. evansi and 
TL as reference test. 
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3. Materials and methods  
Ethics statement 
For the in vivo culture of trypanosomes in mice, ethical approval was obtained from the 
Veterinary Ethics Committee of the Institute of Tropical Medicine, Antwerp,Belgium under 
protocol BM2013-7. 
Sera 
A total of 806 sera from dromedary camels, water buffaloes, bovines, sheep, horses, dogs and 
alpacas were analysed (Table 5.1). These sera belong to the archived collection from the Institute 
of Tropical Medicine, Antwerp, Belgium. 
Table 5.1: Host species, origin, year of collection, number and status in immune trypanolysis (TL) 
of all serum samples used in this study. TL pos: immune trypanolysis positive; TL neg: immune 
trypanolysis negative. 
Species Origin Year Number TL pos TL neg Reference 
Camel Morocco 1997-1998 100 64 36 (Atarhouch et al. 2003) 
Camel Mali 1989-1991 97 34 63 (Diall et al. 1994) 
Camel  Niger 1995 77 70 7 (Verloo et al. 1998) 
Camel  
Spain (Gran 
Canaria) 1997-1999 26 13 13 (Gutiérrez et al. 2000) 
Water 
buffalo Philippines 1995 100 82 18 ** 
Bovine Suriname 1992-1993 82 0 82 ** 
Sheep  France 2007 81 0 81 
(Desquesnes et al. 
2008) 
Sheep*  UK (Scotland) 1994 7 7 0 (Onah et al. 1996) 
Horse Diverse 2010-2012 50 0 50 ** 
Horse 
Spain (Gran 
Canaria) 2009 50 0 50 (Gutiérrez et al. 2010) 
Dog  Diverse 2013 74 0 74 ** 
Dog Belgium 1988 25 0 25 ** 
Alpaca 
The 
Netherlands 2012-2014 19 0 19 ** 
Alpaca UK 2012-2014 18 0 18 ** 
Total   806 270 536  
* Experimentally infected 
** Left-over specimens from reference diagnostic activities within the framework of the OIE 
Reference Laboratory for Surra at the Institute of Tropical Medicine, Antwerp, Belgium  
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Immune trypanolysis 
TL was used as reference test for T. evansi specific antibodies since it is considered 100 % 
specific and has a high analytical sensitivity (Verloo et al., 2000). TL makes use of a cloned T. 
evansi population of live trypanosomes all expressing the VSG RoTat 1.2. In the presence of anti-
RoTat 1.2 antibodies and of guinea pig complement, these trypanosomes will be killed by 
antibody-mediated complement lysis (Verloo et al. 2000; Van Meirvenne et al. 1995). TL was 
performed with a suspension of about 10
7
 trypanosomes per milliliter as estimated by the 
Matching Method (Herbert and Lumsden, 1976). This suspension was freshly prepared by diluting 
the blood from a mouse infected with T. evansi RoTat 1.2 with guinea pig serum (GPS, Harlan, 
Horst, The Netherlands). Twenty five µl of the test serum were mixed with 25 µl of GPS in wells of 
U-bottom polystyrene microtitre plates (Sterilin, Newport, UK) and incubated at ambient 
temperature for 30 min. To this mixture, 50 µl of the trypanosome suspension were added. After 
90 min at ambient temperature, antibody mediated lysis was assessed by phase-contrast 
microscopy at 25x10 magnification. When 50% or more of the trypanosomes were lysed, the 
specimen was considered positive for the presence of anti-RoTat 1.2 antibodies, indicating 
current or past infection with T. evansi. 
CATT/T. evansi 
CATT/T. evansi was used as one of the index tests. It is one of the OIE recommended tests for 
T. evansi-specific antibody detection CATT/T. evansi was carried out according to the instructions 
of the manufacturer with serum diluted 1:4 in CATT diluent. 
Surra Sero K-SeT 
Surra Sero K-SeT was the second index test of which the diagnostic accuracy was assessed in 
this study. The antigen in the Surra Sero K-SeT consists of recombinant rVSG RoTat 1.2, produced 
in Pichia pastoris (Rogé et al. 2013). Surra Sero K-SeT was performed according to the 
instructions of the manufacturer. Briefly, 15 µl of serum was dispensed in the sample application 
window of the cassette, followed by 85 µl of the migration buffer. After 15 min, the test result 
was read as positive if both the control and the test line were visible (even if very faint), negative 
if only the control line was visible and invalid if the control line was not visible (Figure 5.1). 
Statistical analysis 
All data were recorded in Microsoft Excel (Microsoft, Version 2010). Sensitivities and 
specificities with 95% confidence intervals (CI) were calculated using STATA /MP 13.1 (StataCorp. 
2013) with TL as reference test. McNemar χ
2
 was calculated to test differences in sensitivity and 
specificity between the two index tests, Surra Sero K-SeT and CATT/T. evansi. The level of 
agreement between the diagnostic tests was determined using Cohen’s kappa coefficient (Landis 
& Koch 1977; Viera & Garrett 2005). Probability (p) values < 0.05 were considered as significant. 
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4. Results 
The results obtained with the 806 sera and the three diagnostic tests are represented in a 
contingency table (Table 5.2). All diagnostic tests showed almost perfect agreement (κ > 0.8). The 
test agreement was highest between Surra Sero K-SeT and TL (κ=0.91, 95% CI 0.841-0.979) and 
somewhat lower between CATT/T. evansi and TL (κ=0.85, 95% CI 0.785-0.922) and between 
CATT/T. evansi and Surra Sero K-SeT (κ=0.81, 95% CI 0.742-0.878). 
Table 5.2: Contingency table with results of all sera tested in the immune trypanolysis (TL), the 
Card Agglutination Test for T. evansi Trypanosomosis (CATT/T. evansi) and the Surra Sero K-SeT. 
 CATT Sero K-SeT   Sero K-SeT 
TL pos neg pos neg  CATT pos neg 
pos 228 42 265 5  pos 231 6 
neg 9 527 28 508  neg 62 507 
 
The sensitivities and specificities of CATT/T. evansi and Surra Sero K-SeT using TL as the 
reference test, both overall and for each host species, are shown in Table5. 3. Since all sera from 
bovines, horses, dogs and alpacas were negative in TL, sensitivities of the index tests could not be 
calculated. Overall, as well as separately for camels and water buffaloes, the sensitivity of the 
Surra Sero K-SeT was significantly higher (p < 0.001) than the sensitivity of the CATT/T. evansi 
(Table 5.3). All seven experimentally infected sheep sera tested positive in both index tests. On 
the other hand, the overall specificity of Surra Sero K-SeT was significantly lower than that of 
CATT/T. evansi (p < 0.05) as was the specificity of Surra Sero K-SeT for bovines, dogs and, in 
particular, alpacas. Of this latter species, 6 out of 37 sera, all from UK, were false positive in the 
Figure 5.1: Surra Sero K-SeT Kit. Fifteen µl of blood or plasma are applied in the specimen 
window, followed by 85 µl of chase buffer. After 15 min, the reaction is read as positive (red 
test line and red control line), negative (red control line only) or invalid (no visible control line). 
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Surra Sero K-SeT while all were negative in CATT/T. evansi. Of all 806 sera tested, four bovines 
and one sheep were false positive in both CATT/T. evansi and Surra Sero K-SeT. No invalid results 
were obtained with Surra Sero K-SeT. 
Table 5.3: Sensitivity (Se) and specificity (Sp) with 95% confidence interval (CI) of the Card 
Agglutination Test for T. evansi Trypanosomosis (CATT/T. evansi) and the Surra Sero K-SeT 
according to the host species and with immune trypanolysis (TL) as reference test. na = not 
applicable, p = probability.  
Host 
species 
Sensitivity (95% CI) Specificity (95% CI) 
CATT/T. evansi Surra Sero K-SeT Chi square, p CATT/T. evansi Surra Sero K-SeT Chi square, p 
Camel 87.3  
(81.7-91.4) 
97.8  
(94.5-99.1) 
15.70  
< 0.001* 
99.2  
(95.4-99.9%) 
95.8  
(90.5-98.2) 
2.67  
0.103 
Water 
buffalo 
76.8  
(66.6-84.6) 
98.8  
(93.4-99.8) 
18.00  
< 0.001* 
100 
 (82.4-100) 
94.4  
(74.3-99.0) 
1.00 
0.317 
Bovine na na na 95.1  
(88.0-98.7) 
89.0 
(80.4-94.1) 
5.00 
0.025* 
Sheep 100  
(64.6-100) 
100  
(64.6-100) 
na 96.3  
(89.7-98.7) 
96.3  
(89.7-98.7) 
0.00 
1.000 
Horse na na na 99.0  
(94.6-99.8) 
100  
(96.3-100) 
1.00 
0.317 
Dog na na na 100  
(96.3-100) 
96.0  
(90.0-98.4) 
4.00 
0.046* 
Alpaca na na na 100  
(90.6-100) 
83.8  
(68.9-92.4) 
6.00 
0.014* 
Overall 84.4  
(79.6-88.3) 
98.1  
(95.7-99.2) 
33.39  
< 0.001* 
98.3  
(96.8-99.1) 
94.8  
(92.6-96.4) 
13.37 
< 0.001* 
* statistically significant 
5. Discussion 
In this study, we evaluated the diagnostic accuracy of Surra Sero K-SeT, a newly developed 
immunochromatographic serodiagnostic test, in comparison with CATT/T. evansi, the latter being 
one of the antibody detection tests recommended by OIE (OIE 2012). Cohen's kappa analysis 
showed an almost perfect agreement between both tests (κ > 0.8). Surra Sero K-SeT was 
significantly more sensitive than CATT/T. evansi but its specificity was lower, particularly in 
bovines and alpacas. The higher sensitivity may be explained by the fact that undiluted serum is 
tested in the Surra Sero K-SeT while in the CATT/T. evansi, the test serum is diluted (1:4). The 
lower specificity in bovines may be explained by the detection of antibodies generated by other 
infections that cross react with the recombinant RoTat 1.2 VSG. For example, the bovine sera 
originated from Suriname where, at the time of collection, no T. evansi was reported but where 
Chapter 5: Surra Sero K-SeT, a new immunochromatographic test for T. evansi - 117 
 
false positive reactions in CATT/T. evansi were attributed to the presence of T. vivax (Van 
Vlaenderen 1996; Dávila & Silva 2000). Similar cross reactions caused by T. vivax and T. cruzi 
infections were previously observed in an ELISA where the antigen consisted of a crude lysate of 
T. evansi trypomastigotes (Desquesnes et al. 2007). Although not tested in this study, we do not 
expect the recombinant RoTat 1.2 antigen to cross react with antibodies raised against non-
pathogenic trypanosomes such as T. theileri or T. melophagium since in that case, the specificity 
of the Surra Sero K-SeT in bovine, buffalo and sheep would be much lower. The 16% alpaca sera 
that were false positive in Surra Sero K-SeT while true negative in CATT/T. evansi are more 
puzzling since all the animals originated from a country that is non-endemic for pathogenic 
trypanosomes (UK). As a consequence, we cannot recommend Surra Sero K-SeT for testing of 
alpaca. It would be interesting to investigate whether the sub-optimal specificity of the Surra 
Sero K-SeT can be overcome by the use of alternative recombinant VSG RoTat 1.2 expressed in 
Escherichia coli or in Spodoptera frugiperda (Sengupta et al. 2012; Urakawa et al. 2001).  
We were not able to include sera from animals infected with T. evansi type B, which we 
consider a limitation of our study. Although Surra Sero K-SeT showed high sensitivity when tested 
on different host species in the current study, it may not detect infections with T. evansi type B, 
known not to express RoTat 1.2 VSG (Ngaira et al. 2005; Ngaira et al. 2003; Ngaira et al. 2004; 
Njiru et al. 2004). This rare trypanosome type was isolated for the first time from camels in Kenya 
and may also occur in Sudan and Ethiopia (Borst et al. 1987; Hagos et al. 2009; Salim et al. 2011). 
Therefore, it might be of interest to combine different antigens in the Surra Sero K-SeT, thus 
broadening the spectrum of antibodies that can be detected, including antibodies detectable in 
early T. evansi type A infections before the apparition of anti-RoTat 1.2 antibodies. Examples of 
antigens that might be combined with the recombinant RoTat 1.2 VSG in the Surra Sero K-SeT are 
recombinantly expressed fragments of invariant surface glycoprotein 75 (ISG75) and tandem 
repeat cytoskeleton protein GM6 that have been shown to bear diagnostic potential in camel, 
goat and water buffalo (Tran et al. 2009; Rogé et al. 2013; Nguyen et al. 2012; Müller et al. 1992). 
Of particular interest is GM6 of which a 4 repeat fragment derived from T. evansi (TeGM6-4r) has 
been expressed in E. coli and incorporated in a lateral flow ICT (Nguyen et al. 2015). When tested 
on naturally infected sheep, goat and cattle in KwaZulu-Natal, South Africa, it showed moderate 
diagnostic potential (Nguyen et al. 2015) that may be exploited in combination with the 
recombinant RoTat 1.2 VSG used in the Surra Sero K-SeT. Increasing the sensitivity of a diagnostic 
test for surra, even with the risk of decreasing its specificity is particularly of interest in situations 
where it is important to detect all infected animals. For instance when moving susceptible 
animals from an endemic to a non-endemic country or when disease control measures include 
the identification and treatment of reservoir hosts. 
As mentioned earlier, ICTs have several advantages over other test formats such as ELISA, TL 
or card agglutination tests. ICTs come as individually packed tests, can be performed with whole 
blood, are equipment-free and thermostable and therefore are perfectly fit for use in the field or 
in a rudimentary laboratory environment. Thus, the Surra Sero K-SeT is applicable in rural 
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veterinary clinics where herdsmen come with their animals for vaccination, acaricide spraying 
and treatment for common diseases. Also, laboratories where diagnosis of surra is performed 
irregularly and on a small number of animals, may benefit from the individual test format of the 
Surra Sero K-SeT. Taken together, the management of surra, that till today is primarily based on 
treatment of clinical cases only, may drastically change when rapid diagnostic tests, like the Surra 
Sero K-SeT, become available. 
We conclude that the Surra Sero K-SeT may become an ASSURED alternative for the CATT/T. 
evansi for sensitive detection of antibodies against T. evansi in domestic animals depending on 
the epidemiological situation. In regions where the prevalence is high, like we observed in the 
epdimiological part of our study, the higher sensitivity of the Surra Sero K-SeT compared to 
CATT/T. evansi (if confirmed with whole blood in stead of plasma), is advantageous since the 
Surra Sero K-SeT will have a higher negative predictive value, even when the specificity is lower 
than of CATT/T. evansi. On the other hand, in regions where the prevalence is low, it would be 
more efficient to use the CATT/T. evansi that is more specific, since its positive predictive value 
will be higher than of the Surra K-SeT. When prevalences are close to zero, a diagnostic test with 
a specificity near 100% is needed to reach an acceptably high positive predictive value. In that 
case, neither Surra Sero K-SeT nor CATT/T. evansi fulfil the requirements and rather should 
immune trypanolysis be preferred to screen animals in a population at risk or to confirm a 
positive result obtained with CATT/T. evansi or Surra Sero K-SeT. When it is not possible to 
conduct immune trypanolysis, an ELISA/T. evansi adjusted for high specificity by applying a high 
cut-off O.D. may be a good alternative (Verloo et al. 2000). It is clear that further research is 
necessary to increase the specificity of the test and to assess its diagnostic accuracy when applied 
on whole blood under field conditions. 
. 
  
General discussion 
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Animal African trypanosomosis, with an estimated annual loss of up to 4.5 billion USD is still 
one of the major parasitic disease constraints to animals’ productivity in sub-Sahara Africa, while 
human African trypanosomosis has reached the point where elimination is being discussed (Auty 
et al. 2015; Morrison et al. 2016; Holmes 2014; Holmes 2014; Shaw et al. 2014). The impact of 
AAT on local communities is the result of complex interactions between environmental, political, 
socio-cultural, entomological and livestock management factors (Bouyer et al. 2013). In 
recognition of the need for coordinated actions against AAT, the Pan-African Tsetse and 
Trypanosome Eradication Campaign (PATTEC), was established in 2000. However, many of the 
communities afflicted by AAT have insufficient resources available for its control and are not 
always reached by control programmes (Holt et al. 2016). Moreover, PATTEC has hitherto paid 
little attention to NTTATs, caused by T. evansi (and T. vivax), despite the serious economic losses 
due to surra in camel herding pastoral area of Africa. 
For example, in Somaliland, a country with a gross domestic product of 347 USD per citizen in 
2014, the annual loss of revenue due to surra in camels was estimated 223.1 million USD of 
which the majority was from decreased milk production and from body condition loss. The 
benefit of controlling T. evansi infection in camels was estimated 720 USD, and thus higher than 
the gross domestic product per citizen per year (Salah et al. 2015; World Bank 2014). For 
Indonesia, Peternakan estimated that the annual loss from morbidity and mortality in bovine and 
buffaly was 28 million USD (Payne et al. 1994b; Reid 2002). The estimated annual cost of T. 
evansi to the Pantanal region’s ranchers was about 2.4 million USD owing to mortality of 6462 
horses peryear (Seidl et al. 1998). These examples show that the global impact of surra may well 
be above the impact of TTAT that is confined to Africa.  
In Ethiopia, compared to TTAT, limited attention is given to control of NTTAT (Sinshaw et al. 
2006; Fikru et al. 2012). Studies on animal trypanosomosis in non-tsetse areas of Ethiopia, are 
limited, fragmented and mostly making use of poorly sensitive and specific diagnostic tests, thus 
inevitably underestimating or overestimating the impact of NTTAT on livestock production in the 
country. T. evansi strains from Ethiopia were typically lacking in the cryobank of the OIE 
Reference Centre for surra at ITM and elsewhere. Furthermore, there were no published reports 
on drug sensitivity profiles of T. evansi strains from Ethiopia. This PhD study was initiated 1° to 
conduct, for the first time, a large scale epidemiological survey on T. evansi and T. vivax in 
Northern Ethiopia using the most advanced parasitological, serological and molecular techniques, 
2° to isolate and characterise Ethiopian T. evansi strains and 3° to make improvements on the 
molecular and serological diagnosis of surra. 
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Epidemiology of NTTAT in Northern Ethiopia 
In the epidemiological study, we used the mHCT and CATT/T. evansi, respectively the OIE 
recommended parasitological and serological tests, for screening the animals (Figure 6.1) (OIE 
2012; OIE 2013b). Collected blood samples were subsequently processed in species- and type-
specific PCRs for T. vivax, T. evansi type A and T. evansi type B and in TL, the OIE recommended 
gold standard antibody detection test for serdiagnosis of surra (OIE 2012; Njiru et al. 2006; Claes 
et al. 2004; Fikru et al. 2014). 
Among the 754 camels, we observed parasites in 4% of the animals and T. evansi specific 
antibodies in 10.5%. Also the molecular diagnostics showed an important fraction of the animals 
infected with T. evansi type A (11.7%), T. evansi type B (0.5%) and even T. vivax (3.4%). These 
high prevalences of NTTAT in camel correspond with findings of other recent studies on Ethiopian 
camels conducted in Afar and Oromia (Fikru et al. 2015; Hagos et al. 2009). Interestingly, we 
confirmed the presence of T. evansi type B in Ethiopia, at least in Afar. Indirect evidence of non-
RoTat 1.2 expressing trypanosomes circulating in Ethiopian camels was provided in a previous 
study conducted in Oromia (Hagos et al. 2009). Our data, together with the indirect evidence of 
T. evansi type B circulating in Chad and in Sudan, indicate that T. evansi type B is probably 
present in more East African countries, beyond Kenya where it was first discovered (Ngaira et al. 
2005; Ngaira et al. 2004; Njiru et al. 2006; Sánchez et al. 2015; Boid 1988; Salim et al. 2011). 
Whether this parasite has reached Latin America or Asia remains unanswered. In a recent survey 
on camels in the Cholistan Desert of Pakistan T. evansi type B was not observed although T. 
evansi type A was highly prevalent (30%) (Tehseen et al. 2015). Our study revealed, for the first 
time, mixed infections with T. evansi type A and T. evansi type B. Whether both types cause 
differential pathology has not been studied so far. We noted an average PCV of 26% in T. evansi 
Figure 6.1: Field activities: registering of animals, blood sample collection, separation of 
blood components and mHCT.  
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type A infected camels and 22% in type B infected animals but the numbers are too small to draw 
firm conclusions on these data. So far, only camels have been shown to harbour type B despite 
epidemiological studies on equines, cattle and small ruminants in Kenya and Ethiopia (Njiru et al. 
2006; Birhanu et al. 2015a). Therefore, one may suggest that T. evansi type B may be restricted 
to camels. Experimental infections of various domestic animal species with T. evansi type B could 
give a better understanding on the host pathogen interaction of this parasite. The finding of 
camels infected with T. vivax in our study corresponds with the data presented by Fikru and 
colleagues (Fikru et al. 2015). Pathogenicity of T. vivax in camels has not been studied in detail. In 
our survey T. vivax infection was accompanied by a low PCV (24%). The mobility of camels either 
in search of food and water or for pack transport puts them at risk of attracting also tsetse-
transmitted trypanosomes and making them unintentional vehicles of these trypanosomes into 
non adjacent tsetse infested zones across tsetse free areas. Indeed, infection of camels with T. 
brucei and T. congolense has been documented in Kenya and Somalia but was not observed in 
our study (Dirie et al. 1989; Wilson et al. 1983). 
There is an encouraging trend of research in mechanically transmitted T. vivax in cattle from 
Ethiopia (Sinshaw et al. 2006; Fikru et al. 2012; Dagnachew et al. 2015a; Cherenet et al. 2006). In 
our survey, 493 cattle were included of which 7% were parasitologically positive and 37% were 
serologically positive in CATT/T. evansi. Presence of T. evansi and T. vivax was confirmed with 
RoTat 1.2 PCR (6%) and TvPRAC PCR (3%). However, among the parasitologically confirmed 
cattle, only three and one were positive in TvPRAC PCR and RoTat 1.2 PCRs respectively. Taking 
into account the low analytical sensitivity of TvPRAC PCR, caused by its single copy target 
sequence, the real prevalence of T. vivax in cattle may be higher (Fikru et al. 2014). Also for the 
RoTat 1.2 PCR it is known that its analytical sensitivity is lower than of a PCR targeting multicopy 
sequences, like ITS1 PCR. On the other hand, ITS1 PCR is poorly sensitive for T. vivax caused by 
the high GC content of its DNA. Also, ITS1 PCR is less specific and can generate many aspecific 
amplicons, particularly in bovine samples (Fikru et al. 2016). The ITS1 PCR results on the 
parasitologically positive cattle revealed 4 T. vivax that were not detected with TvPRAC PCR, 2 T. 
theileri, 8 negatives and 18 with amplicons of different lengths that could not be interpreted 
correctly. Due to the complexity of the aspecific amplicon profiles, we didn't undertake their 
sequencing. 
Among 445 small ruminants, we observed 0.4% parasitologically positive animals and 13% 
seropositives for antibodies against T. evansi type A. In PCR, about 3% were positive for T. evansi 
type A and for T. vivax. These prevalences are lower than in camels and cattle. Yet, the fact that 
they can be infected by all pathogenic trypanosomes, that they usually exhibit a mild or 
asymptomatic form of the disease and that they are rather neglected in trypanosomoses control 
projects make them potentially important reservoirs of NTTAT (Gutiérrez et al. 2006b; Ngeranwa 
et al. 1991; Ngeranwa et al. 1993). 
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A total of 119 equines (horses, mules and donkeys) were included in our survey. All were 
negative in the mHCT and antibodies against T. evansi type A were only detected in donkeys 
although PCR revealed T. evansi DNA in high proportions of the horses (28%), mules (10%) and 
donkeys (6%). Only donkeys were positive in T. vivax specific PCR (3.6%). Taken together, NTTAT 
is present in equines in Tigray and Afar although parasitaemia seems to remain under the 
detection limit of mHCT. Similar observations were made in a survey on horses in the Arsi Bale 
highlands antibodies were detected in 28%, 25% and 19% of 646 horses with respectively the 
CATT/T. evansi, LATEX/T. evansi and ELISA/T. evansi without any positive in Giemsa stained thick 
drop and in mHCT (Hagos et al. 2010a). The usual subclinical form of the disease and the 
transient and low parasitaemia, limiting the detection of circulating T. evansi parasites in blood 
has been reported by others (Berlin et al. 2009; Berlin et al. 2010; Pascucci et al. 2013). However, 
surra in horses can be a very serious diseases with up to 50% mortality as reported after an 
outbreak in the Pantanal in the Brazilian Mato Grosso state (Silva et al. 1995). A study conducted 
on 237 horses in the Arsi-Bale highlands of Ethiopia revealed parasites in 4.6% of the animals 
(with mHCT) and very high percentages of serologically (37% in CATT/T. evansi) and molecularly 
positive animals (up to 48% in 18S PCR) (Gari et al. 2010). Another study, conducted by Hagos 
and colleagues in 880 horses from Bale highlands in Oromia region also found a seroprevalence 
of 20% CATT/T. evansi (Hagos et al. 2010b). The differentiation in horses between infection with 
T. evansi and the sexually transmitted T. equiperdum remains challenging and is only possible on 
the basis of RoTat 1.2 specific antibodies and on the absence of maxicircles in the kDNA of T. 
evansi. T. equiperdum can be revealed by maxicircle specific PCR (Claes et al. 2003b; Claes et al. 
2004; OIE 2013a; Li et al. 2007a). Thus, together with the other studies on equine NTTAT, our 
survey indicates that surra is important in equines in Ethiopia. 
Due to the persistence of trypanosome-specific antibodies in cured animals and to reactions 
with antibodies against non-specific epitopes, a serological test like the CATT/T. evansi might 
overestimate the prevalence of T. evansi (Verloo et al. 2000; Büscher 2014; Urakawa et al. 2001; 
Hilali et al. 2004). In Ethiopia, where both T. evansi and T. vivax are endemic, cross reactivity in 
CATT/T. evansi is unavoidable but should not be problematic since current treatment for AAT is 
not species-specific (Büscher 2001; Uzcanga et al. 2002; Camargo et al. 2004). In Somaliland, 
biannual treatment of all seropositive camels was found the most efficient control strategy 
against surra (Salah et al. 2015). To discriminate between VSG-specific and non-specific reactions 
in CATT/T. evansi, sera or plasma can be tested in TL which is 100% VAT specific and 
recommended by OIE as the gold standard for serodiagnosis of surra due to T. evansi type A. The 
test is available only at the OIE Reference Laboratory for Surra at ITM. Due to sanitary and 
phytosanitary regulations, we could not bring animal plasma into Belgium. Hence, plasma 
samples collected during the survey were dried on Whatman 4 filter paper and the TL was 
performed on the antibodies eluted from the filter paper. Unexpectedly, only 34 animals were 
positive in TL resulting in poor agreement between CATT/T. evansi and TL. We have no firm 
explanation why TL was negative in all RoTat 1.2 PCR positive horses and cattle. A limited loss in 
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sensitivity of TL when performed on filter paper eluates compared to plasma has been 
documented (Holland et al. 2002). Recently, we have observed that drying 500 µl of plasma on 
the cotton plug of a Salivette, a device that is designed for the hygienic collection of saliva 
(Sarstedt, Germany), considerably improves the yield of antibodies that can be eluted, hence 
increasing the analytical sensitivity of TL on eluted antibodies (Figure 6.2).  
On the other hand, while TL detects exclusively variant specific antibodies, CATT/T. evansi 
detects also antibodies directed against non-variant epitopes of VSG RoTat 1.2 and other surface 
exposed antigens. Thus, infection with other trypanosomes, e.g. T. vivax, may lead to a positive 
result in CATT/T. evansi (Van Vlaenderen 1996; Uzcanga et al. 2004; Büscher 2001). This cross-
reactivity caused by T. vivax infection may explain why CATT/T. evansi positive cattle specimens 
remained negative in TL but had been in contact with T. vivax only. Parasitological and molecular 
tests are highly specific and provide conclusive evidence for ongoing infection, however their 
sensitivity is affected because of the often low number of circulating parasites. For diagnosis of 
AAT, parasite concentration techniques such as the mHCT that was used in this study are highly 
recommended (Büscher 2014).  
  
Figure 6.2: Salivette tube with push cap, inner tube, specimen absorbing 
plug and silica gel. 
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Isolation and genotypic characterization of T. evansi 
For the isolation of new trypanosome strains from Ethiopia, a total of 68 parasitologically 
positive buffy coat samples from cattle (36), dromedary camels (30), goat (1) and sheep (1) were 
inoculated in Swiss albino mice. In parallel, the buffy coat specimens were characterized by 
species specific PCRs. We achieved a high isolation success rate of 32% but only from camels and 
only T. evansi, confirming the appropriateness of mice to isolate T. evansi (Mekata et al. 2013). 
Most importantly, we isolated two Ethiopian T. evansi type B stocks, decades after its first 
isolation in Kenya. Not surprisingly, we were unable to isolate T. vivax. This species is notoriously 
difficult to adapt in laboratory rodents and so far, only one mouse-adapted Nigerian T. vivax 
strain is available for research (Guerreiro et al. 2005; Gardiner 1989). Isolation of T. vivax failed in 
immunosuppressed young zebu calves and in goats and only a short parasitaemic period was 
observed where after the parasites remained undetectable in the blood. Only in 
immunosuppressed Friesian Holstein calves, sufficiently high parasitaemia could be obtained to 
prepare cryostabilates and to purify the parasites for molecular characterization (Fikru 2015). In 
Brazil and Venezuela, local T. vivax strains from cattle were adapted to immunosuppressed sheep 
with subsequent purification of the parasites from the blood by Percoll gradient centrifugation 
(González et al. 2005; Greif et al. 2013). 
As expected, all 14 T. evansi stocks isolated in this study were negative for all four maxicircle 
genes (ND4, ND5, ND7, A6) (Borst et al. 1987; Dean et al. 2013; Domingo et al. 2003). All stocks 
that contain RoTat 1.2 VSG, except the akinetoplastic MCAM/ET/2013/MU/09, were positive in 
minicircle A PCR, both in their pellet DNA and buffy coat DNA (Njiru et al. 2006). The presence of 
a kinetoplast in the other 13 stocks was demonstrated using DAPI staining and fluorescence 
microscopy. The occurrence of naturally akinetoplastic T. evansi strains has been documented in 
Latin America and China (Stevens et al. 1989; Ventura et al. 2000; Ou et al. 1991; Lun & 
Vickerman 1991). We used the minisatellite locus MORF2-REP to confirm that the putative mixed 
T. evansi type A and B stocks were genuine mixed infections and not hybrids. From this analysis, 
it appeared that our Ethiopian T. evansi type A stocks are different from the classical T. evansi 
type A RoTat 1.2, isolated in 1980 from water buffalo in Indonesia. Also the two Ethiopian T. 
evansi type B stocks are different from the classical T. evansi type B KETRI 2479. These findings 
underline the interest of the minisatellite locus MORF2-REP to analyse diversity among T. evansi 
strains, even at type level (Biteau et al. 2000).  
During our study, we were confronted with the limited reliability of molecular tests for typing 
T. evansi strains. The RoTat 1.2 VSG gene is useful as a marker of T. evansi type A but the RoTat 
1.2 PCR developed by Claes and colleagues that generates a short amplicon (205 bp) 
unexpectedly was positive on DNA of T.b. gambiense LiTat 1.R, T.b. brucei AnTat 1.1 and T. evansi 
KETRI 2479 when high amount of target DNA is used in the PCR (Claes et al. 2004). Therefore, we 
recommend the use of the RoTat 1.2 PCR from Urakawa and colleagues that consistently 
generates a 488 bp fragment only in T. evansi type A (Urakawa et al. 2001). Despite previous 
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work that proposed the JN 2118Hu VSG gene as a specific marker for T. evansi type B (Ngaira et 
al. 2005), we cannot recommend its use. Indeed, we observed that the JN 2118Hu specific PCR 
cross reacts with T.b. brucei AnTat 1.1 and T.b. gambiense type II ABBA underlining the 
importance of including sufficiently diverse trypanosomes representing species, subspecies and 
type for the evaluation of new molecular typing markers. Based on the recent work of Carnes et 
al. who used SNPs in the gene of the F1-ATP synthase subunit for genotyping of 
dyskinetoplastic Trypanozoon (Carnes et al. 2015), we cloned and sequenced the full gene of F1-
ATP synthase subunit of several T. evansi and other closely related Trypanozoon strains. 
Interestingly, all Ethiopian T. evansi type A had a polymorphism corresponding to the classical 
type A group. The Ethiopian T. evansi type B had a similar profile as KETRI 2479 and mixed 
infections showed a mixed polymorphism profile. In this regard, we confirmed that 
polymorphism within the F1-ATP synthase subunit gene might become an interesting target for 
genotyping of T. evansi stocks, and is not related to a VSG repertoire that can change over time, 
nor to the presence of a kinetoplast that can be lost during evolution. We therefore recommend 
the development and evaluation of an allele specific F1-ATP synthase subunit PCR for reliable 
typing of T. evansi stocks during epidemiological surveys. 
In vitro adaptation and drug sensitivity profiling of Ethiopian T. evansi stocks 
The adaptation of the Ethiopian T. evansi stocks to in vitro culture with HMI-9 HS medium was 
successful in 5 of the 14 stocks. Unexpectedly, mixed type A and type B populations that could be 
propagated in vivo in mice became exclusively type B when adapted to in vitro culture 
underlining the possible selection bias of the method used for isolation of trypanosomes. This 
phenomenon necessitates regular checking of the T. evansi type during isolation and adaptation 
experiments. The in vitro drug sensitivity testing on some of the Ethiopian T. evansi stocks 
indicated no drug resistance against melarsomine dihydrochloride, suramin, isometamidium 
hydrochloride and diminazene diaceturate. However, in a parallel MSc study following the 
standard protocol of Eisler and coworkers, we observe that the same stocks are also sensitive to 
20 mg/kg diminazene diaceturate in vivo but appear resistant to 1 mg/kg isometamidium 
hydrochloride in vivo (Eisler et al. 2001). The discrepancy for sensitivity of T. evansi to 
isometamidium hydrochloride in vivo and in vitro has been documented and might be due to in 
vivo metabolisation of the drug to a less active form (Zhang et al. 1991). Although 
isometamidium hydrochloride is known to accumulate in the mitochondrion, in vivo testing with 
this drug in the akinetoplastic stock shows no trypanocidal activity in 100% of the infected mice 
thus corresponding with the recent finding that kinetoplast independent resistance of T. evansi 
type A to isometamidium hydrochloride is associated with the A281 deletion in the ATP F1  
subunit gene although other mechanisms may be involved as well (Gould & Schnaufer 2014; 
Dean et al. 2013; Baker et al. 2015). The in vivo assays further show that low doses of 
melarsomine dihydrochloride (0.125 mg/kg), as used by Gillingwater and coworkers, are not 
sufficient to cure mice from infections with the Ethiopian T. evansi stocks (Gillingwater et al. 
2010). Other studies report treatment failure with low doses of cymelarsan in buffaloes (0.25 
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mg/kg to 3 mg/kg), goats (0.3 mg/kg), mice (0.25 mg and 0.5 mg/kg) and cattle (0.5 mg/kg) (Lun 
et al. 1991; Payne et al. 1994a; Hagos et al. 2010c; Zweygarth et al. 1992; Syakalima et al. 1995). 
Therefore, the dosis in the in vivo experiment was increased to 2 mg/kg that showed 100% cure 
of mice infected with T. equiperdum (Hagos et al. 2010c). In the in vivo experiments in mice, the 
parasites are cleared in all mice at day 60 post treatment. All the in vitro adapted stocks (after 30 
and 60 days) remained infective to mice which is in agreement with observations of Baltz and 
colleagues up to three months in vitro propagation (Baltz et al. 1985). Another study reported 
loss of rodent infectivity after 14 months of in vitro propagation (Zweygarth et al. 1990). In in 
vitro culture, a progressive loss of kinetoplasts was observed. It has been suggested that either a 
selective enrichment of dyskinetoplastic cells from an initial trypanosome population containing 
a few dyskinetoplastic organisms is taking place during in vitro propagation or that the in vitro 
mutations lead to the loss of kinetoplasts (Zweygarth et al. 1990). 
Diagnostic accuracy of the Surra Sero K-SeT 
The strong humoral immune response resulting from an infection with trypanosomes is 
exploited for serodiagnosis (Büscher 2014). Next to ELISA, IFAT and TL, all bound to well-
equipped laboratories, the CATT/T. evansi is an OIE recommended antibody detecting serological 
test for serodiagnosis of surra (OIE 2012). The CATT/T. evansi can be performed in the field but is 
still dependent on electricity and equipment. In Human African Trypanosomosis (HAT), a similar 
test for mass screening in the field exists, the CATT/T.b. gambiense, produced as well at ITM, 
Antwerp but suffering from the same limitations as CATT/T. evansi. Together with Coris 
BioConcept, a Belgian diagnostic company, ITM has successfully developed the first real ASSURED 
RDT for HAT, the HAT Sero K-SeT (Büscher et al. 2013; Büscher et al. 2014). Following the success 
of the HAT Sero K-SeT, the Surra Sero K-SeT was developed by the same partners following the 
same principle, i.e. detection of VSG-specific antibodies in blood, plasma or serum. Our PhD study 
was the first to perform a large scale evaluation of the Surra Sero-K-SeT on sera from different 
domestic animal species. The overall sensitivity of Surra Sero K-SeT proved significantly higher 
but the specificity was significantly lower than that of CATT/T. evansi. This lower specificity was 
mainly due to an unexpected and hitherto unexplained low specificity of Surra Sero K-SeT in 
alpacas (Chapter 3, (Birhanu et al. 2015b)). High sensitivity of a serodiagnostic test for surra is of 
interest in situations where it is important to detect all infected animals, particularly when 
moving susceptible animals from an endemic to a non-endemic country or when disease control 
measures include the identification and treatment of reservoir hosts. Hence, the Surra Sero K-SeT 
may become an ASSURED alternative for the CATT/T. evansi for sensitive detection of antibodies 
against T. evansi in domestic animals except alpacas. On the other hand, since the Surra Sero K-
SeT is designed to detect RoTat 1.2-specific antibodies, it is not expected to react with the blood 
from camels infected with T. evansi type B. Since this type may be more widely distributed in 
Eastern Africa than previously recognized, it is of interest to adapt the Sero K-SeT to detect also 
antibodies against this type of T. evansi. In the absence of known T. evansi type B specific 
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antigens, incorporation of invariant antigens such as ISG75, ISG65 and GM6 that are common to 
all T. evansi types and all Trypanozoon taxa could be explored. Also in HAT, where some T.b. 
gambiense types do not express the two VSGs used as antigen in the HAT Sero K-SeT, efforts are 
going on to include ISG65 as an alternative antigen (Sullivan et al. 2013; Rooney et al. 2015). Of 
particular interest is the cytoskeleton tandem repeat protein GM6, that has been expressed in E. 
coli and incorporated in a prototype ICT with good diagnostic potential in water buffalo, sheep, 
goats and cattle (Müller et al. 1992; Nguyen et al. 2015; Nguyen et al. 2014; Nguyen et al. 2012). 
General conclusions and perspectives 
In conclusion, this doctoral study showed that NTTAT due to T. evansi type A, T. evansi type B 
and T. vivax is an important threat to the health of domestic animals in Tigray and Afar regions of 
Northern Ethiopia. Molecular diagnostic tests prove that not only camels and bovine are affected 
but also equines and small ruminants underlining the necessity of considering these domestic 
animals when developing NTTAT control strategies. With a prevalence of 12% in camels, an 
animal that becomes more and more important under the present climate change challenges, the 
negative impact of T. evansi on the living condition of pastoral communities can hardly be 
overestimated. Unfortunately, NTTAT in Ethiopia are rather neglected. Control interventions are 
not coordinated, access to trypanocidal drugs and veterinary care in remote areas is limited and 
animal health workers lack the necessary skills and tools for proper diagnosis. This negligence is 
not confined to Ethiopia but is a general aspect of NTTAT. As an example, the Global Alliance for 
Livestock Veterinary Medicine (GALVmed), that is the only international organization working on 
diagnostics, drug and vaccines against T. congolense and T. vivax, has not yet incorporated AAT 
due to T. evansi, T.b. brucei and T. equiperdum in its portfolio  
(http://www.galvmed.org/en/news/new-drugs-fight-nagana/). Having confirmed the presence of 
T. evansi type B in Ethiopia, we believe that our study will inspire other researchers to further 
investigate the epidemiology of T. evansi type B worldwide. We are convinced that only RDTs 
that are accurate and cheap can be useful for diagnosis of AAT in poor resource veterinary clinics 
and that the current Surra Sero K-SeT must be further improved to allow serodiagnosis of T. 
evansi type B and, if possible, other pathogenic trypanosomes like T. vivax. Access to RDTs for 
NTTAT may also facilitate field studies on co-infections of trypanosomes with viral and bacterial 
pathogens in diverse domestic host species.  
In view of further investigations on NTTAT, a number of limitations of this doctoral study has 
to be mentioned. For example, it was not possible to investigate all parameters that play a role in 
the epidemiology of NTTAT. We did not consider the effect of season, vector density, nutritional 
status of the animal and role of reservoir host. No detailed clinical examination of the study 
subjects, particularly camels infected with T. evansi type A and B was done. Comparison of the 
epidemiology of NTTAT between Tigray and Afar was not possible due to the significant 
differences in number of examined animal species per region and the number of sampled 
equines was too low to draw firm conclusions on NTTAT prevalence in these host species. Stained 
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blood smears, that could have allowed morphological distinction between Trypanozoon, T. vivax, 
T. congolense and T. theileri were not collected. Due to the sanitary and phytosanitary issues, 
importation of plasma samples to Belgium was not possible.  
Still, we believe that this doctoral study can be considered a contribution to our knowledge 
on NTTAT and to attract the attention of the international research community, funding agencies 
and policy makers like the Ethiopian Ministry of Livestock and Fisheries. To the latter, we wish to 
pass the message that NTTAT control can only be successful when the epidemiological situation 
of the disease is known, when appropriate diagnostic tools and drugs are available and when 
intervention activities are undertaken on a regional level well beyond the national borders of a 
country. 
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